Cyclin-dependent kinase 7 (CDK7) non-covalent inhibitors

Abstract

The present invention relates to a compound of formula (I) [Formula 1] TIFF2023542411000291.tif67170 and pharmaceutical compositions containing said compounds, processes for the preparation of said compounds and the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7) and in the treatment of diseases such as cancer.

Description

[Technical Field]

[0001] cross reference This application claims the benefit of European Patent Application Publication No. 20198367.3, filed September 25, 2020, which is incorporated herein by reference in its entirety.

[0002] The present invention relates to pharmaceutical compounds and pharmaceutical compositions containing said compounds, processes for the preparation of said compounds and their use as inhibitors of cyclin-dependent kinase 7 (CDK7) and in the treatment of diseases such as cancer. [Background technology]

[0003] Members of the cyclin-dependent kinase (CDK) family play important regulatory roles in proliferation. Unique among mammalian CDKs, CDK7 possesses indestructible kinase activity and regulates both the cell cycle and transcription. In the cytoplasm, CDK7 exists as a heterotrimeric complex and is thought to function as a CDK1 / 2-activating kinase (CAK). For full catalytic CDK activity and cell cycle progression, CDK7 phosphorylates conserved residues of CDK1 / 2. In the nucleus, CDK7 forms the kinase core of the RNA polymerase (RNAP) II general transcription factor complex and is responsible for phosphorylating the C-terminal domain (CTD) of RNAP II, an essential step in gene transcription initiation. Together, the two functions of CDK7, CAK and CTD phosphorylation, support key aspects of cell proliferation, cell cycle, and transcription.

[0004] Disruption of RNAP II CTD phosphorylation has been shown to preferentially affect short-lived proteins, including those of the anti-apoptotic BCL-2 family. Cancer cells have been shown to have the ability to evade pro-death signals by upregulating BCL-2 family members. Therefore, inhibition of human CDK7 kinase activity is thought to result in antiproliferative activity.

[0005] The discovery of selective inhibitors of CDK7 has been hindered by the high sequence and structural similarity of the kinase domains of CDK family members. Therefore, there is a need to discover and develop selective CDK7 inhibitors. Such CKD7 inhibitors are promising therapeutic agents for chronic lymphocytic leukemia and other cancers.

[0006] WO 2012 / 118850 A1 discloses amine and carbonyl substituted 5,8-dihydro-6H-pyrido[3,4-d]pyrimidines for use in the treatment of neoplastic diseases by inhibiting serine / threonine kinases; in particular, the compounds are disclosed as selective ERK inhibitors.

[0007] WO 2016 / 105528 A2 discloses carbonyl-substituted 4,6-dihydropyrrolo[3,4-c]pyrazoles for use in the treatment of proliferative diseases; in particular, the compounds are disclosed as inhibitors of the kinase CDK7. Summary of the Invention

[0008] The present invention relates to compounds of formula (I): including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof. [ka] (In the formula, A 1 is CR 1a R 1b or NR 2 and; A 2 is CR 3a R 3b or NR 4 and; A 3 and A 4 each independently represents CH or N; A 5 is -CH2- or -CH(CH3)-; m is 0 or 1; Each R 1a and R 1b are independently hydrogen, C 1~6 Alkyl or -N(C 1~4 alkyl)2; R 2 is hydrogen; haloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;C 3~6 Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C 1~6 Alkoxy, Cyano, C 3~6 C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 3a and R 3b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; Cyano C 1~6 Alkyl; Hydroxy C 1~6 Alkyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;-N(C 1~4 alkyl)2;C 3~6Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently represent one or more of halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 optionally substituted with alkyl; R 4 is C 1~6 Alkyl; or halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from alkyl; Each R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a may form a cyclopropyl group together with the carbon atom to which they are attached; provided that R 5a , R 5b , R 6a , R 6b , R 7a and R 7b is not hydrogen; R 8 is a direct bond, hydroxy, halo, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl, Cyano, Halo, HaloC 1~6 Alkyl, C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy, HaloC 1~6 Alkoxy, Hydroxyl, Hydroxy C 1~6 Alkyl, oxo, -SO2-C 1~4 Alkyl, -SO2-C 3~6 Cycloalkyl, -SO2-NH2, -SO2-NH(C 1~4 alkyl), -SO2-N(C 1~4 alkyl)2, -NH-C(=O)-C 2~6 Alkenyl, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl, -C(=O)-C 3~6 Cycloalkyl, -C(=O)-C 2~6 Alkenyl, C 3~6 Cycloalkyl, spiro-C 3~6 cycloalkyl, phenyl, a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5 The present invention relates to the compound

[0009] The compound has the formula (II): [ka] (In the formula, A 3 is CH or N; A 4 is CH or N; R 2 is hydrogen; haloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;C 3~6 Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C 1~6 Alkoxy, Cyano, C 3~6 C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 3a and R 3b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; Cyano C 1~6 Alkyl; Hydroxy C 1~6 Alkyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;-N(C 1~4 alkyl)2;C 3~6Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently represent one or more of halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 optionally substituted with alkyl; Each R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6amay form a cyclopropyl group together with the carbon atom to which they are attached; provided that R 5a , R 5b , R 6a , R 6b , R 7a and R 7b is not hydrogen; R 8 is a direct bond, hydroxy, halo, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl; Cyano; Halo; HaloC 1~6 Alkyl; C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy; HaloC 1~6 Alkoxy; Hydroxyl; HydroxyC 1~6 Alkyl;Oxo;-SO2-C 1~4 Alkyl;-SO2-C 3~6 Cycloalkyl; -SO2-NH2, -SO2-NH(C 1~4 alkyl);-SO2-N(C 1~4 alkyl)2;-NH-C(=O)-C 2~6 Alkenyl; -C(=O)-C 1~6 Alkyl; -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl; -C(=O)-C 3~6 Cycloalkyl; -C(=O)-C 2~6 Alkenyl; C 3~6Cycloalkyl;spiro-C 3~6 cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5 The compound may be:

[0010] In the compounds of formula (I) or (II), including any tautomers and stereochemical isomers, isotopically labeled derivatives or pharmaceutically acceptable salts or solvates thereof, preferably A 3 is CH; A 4 is CH or N; R 2 is hydrogen; or deuterium, hydroxyl, C 1~6 C optionally substituted with alkoxy or a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 3a and R 3b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 Alkyl;N(C 1~4 alkyl)2;C 3~6 cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl and heteroaryl each independently contain one or more of halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 optionally substituted with alkyl; Each R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are independently hydrogen or C 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a together with the carbon atom to which they are attached can form a cyclopropyl; R 8 is a direct bond, hydroxy, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl;Halo;HaloC 1~6 Alkyl; C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy; HaloC 1~6Alkoxy; Hydroxyl; HydroxyC 1~6 Alkyl;Oxo;-SO2-C 3~6 Cycloalkyl; -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl; -C(=O)-C 3~6 Cycloalkyl; C 3~6 Cycloalkyl;spiro-C 3~6 cycloalkyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3 or 4.

[0011] The present invention relates to compounds of formula (IIIa) or (IIIb), including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof: [ka] (In the formula, A 4 is CH or N; R 2 is hydrogen; haloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;C 3~6 Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C 1~6 Alkoxy, Cyano, C 3~6 C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; R 3a is C 1~6 Alkyl; HaloC1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; Cyano C 1~6 Alkyl; Hydroxy C 1~6 Alkyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;-N(C 1~4 alkyl)2;C 3~6 Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently represent one or more of halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 optionally substituted with alkyl; Each R 5a , R 5b , R 6a , R 6b , R 7a and R7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a together with the carbon atom to which they are attached can form a cyclopropyl; R 8 is a direct bond, hydroxy, halo, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl; Cyano; Halo; HaloC 1~6 Alkyl; C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy; HaloC 1~6 Alkoxy; Hydroxyl; HydroxyC 1~6 Alkyl;Oxo;-SO2-C 1~4 Alkyl;-SO2-C 3~6 Cycloalkyl; -SO2-NH2, -SO2-NH(C 1~4 alkyl);-SO2-N(C 1~4 alkyl)2;-NH-C(=O)-C 2~6Alkenyl; -C(=O)-C 1~6 Alkyl; -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl; -C(=O)-C 3~6 Cycloalkyl; -C(=O)-C 2~6 Alkenyl; C 3~6 Cycloalkyl;spiro-C 3~6 cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5 The present invention also relates to compounds of the formula:

[0012] The present invention relates to compounds of formula (IVa) or (IVb), including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof: [ka] (In the formula, A 4 , R 2 , R 5a , R 5b , R 6a , R 6b , R 7a , R 7b , R 8 , A, R 9 and each of n is independently as defined herein above; R 10 is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 is alkyl; and p is 0, 1, 2, 3, 4 or 5 The present invention also relates to compounds of the formula:

[0013] The present invention relates to compounds of formula (Va) or (Vb), including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof: [ka] (In the formula, R 2 is hydrogen; haloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; -C(=O)-NH2; -C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl)2;C 3~6 Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C 1~6 Alkoxy, Cyano, C 3~6 C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 5a , R 5b , R6a , R 6b , R 7a and R 7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a together with the carbon atom to which they are attached can form a cyclopropyl; R 8 is a direct bond, hydroxy, halo, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 3-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl; Cyano; Halo; HaloC 1~6 Alkyl; C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy; HaloC 1~6 Alkoxy; Hydroxyl; HydroxyC 1~6 Alkyl;Oxo;-SO2-C 1~4 Alkyl;-SO2-C 3~6 Cycloalkyl; -SO2-NH2, -SO2-NH(C 1~4 alkyl);-SO2-N(C1~4 alkyl)2;-NH-C(=O)-C 2~6 Alkenyl; -C(=O)-C 1~6 Alkyl; -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl; -C(=O)-C 3~6 Cycloalkyl; -C(=O)-C 2~6 Alkenyl; C 3~6 Cycloalkyl;spiro-C 3~6 cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; n is 0, 1, 2, 3, 4 or 5; R 10 is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 is alkyl; and p is 0, 1, 2, 3, 4 or 5 The present invention also relates to compounds of the formula:

[0014] In the compounds of formula (I) or (II), including any tautomers and stereochemical isomers, isotopically labeled derivatives or pharmaceutically acceptable salts or solvates thereof, preferably R 2 is hydrogen; or deuterium, hydroxyl, C 1~6 C optionally substituted with alkoxy or a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 5a , R 5b , R 6a , R 6b , R 7a and R 7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a together with the carbon atom to which they are attached can form a cyclopropyl; R 8 is a direct bond, hydroxy, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH2-C(=O)-;Spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl;Halo;HaloC 1~6Alkyl; C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy; HaloC 1~6 Alkoxy; Hydroxyl; HydroxyC 1~6 Alkyl;Oxo;-SO2-C 3~6 Cycloalkyl; -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl; -C(=O)-C 3~6 Cycloalkyl; C 3~6 Cycloalkyl;spiro-C 3~6 cycloalkyl; 4-7 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; n is 0, 1, 2, 3 or 4; R 10 is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 is alkyl; and p is 0, 1, 2 or 3.

[0015] In the compounds of the present invention, including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof, preferably A 1 is N, and R 2 is C optionally substituted with deuterium 1~6 It is alkyl.

[0016] In the compounds of the present invention, including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof, preferably R 5a is C 1~6 alkyl; or R 5a and R 5b may form a cyclopropyl group together with the carbon atom to which they are attached; or R 6a and R 6b may form a cyclopropyl group together with the carbon atom to which they are attached; or R 5b and R 6a together with the carbon atom to which they are attached can form a cyclopropyl.

[0017] In the compounds of the present invention, including any tautomers and stereochemical isomers, isotopically labeled derivatives or pharmaceutically acceptable salts or solvates thereof, preferably R 8 is C optionally substituted with hydroxy or deuterium 1~4 It is an alkanediyl; A is a 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R 9 is C 1~6 is alkyl; and n is 1.

[0018] The present invention relates to a compound selected from the following, including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof: [ka]

change

change

change

change

change

change

change

change

change

change

change

change

change

change

[0019] The present invention further relates to pharmaceutical compositions comprising the compounds disclosed herein and a pharmaceutically acceptable carrier.

[0020] The present invention further relates to the compounds disclosed herein for use in therapy.

[0021] The present invention further relates to the compounds disclosed herein for use in the prevention and / or treatment of disease states or conditions mediated by cyclin-dependent kinase 7 (CDK7).

[0022] The disease state or condition mediated by cyclin-dependent kinase 7 (CDK7) can be a proliferative disease.

[0023] The proliferative disorder can be cancer, leukemia, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, multiple myeloma, bone cancer, osteosarcoma, Ewing's sarcoma, triple-negative breast cancer (TNBC), brain tumor, neuroblastoma, lung cancer, small cell lung cancer (SCLC), large cell lung cancer, benign neoplasms, angiogenesis, inflammatory disorders, rheumatoid arthritis, autoinflammatory disorders, autoimmune disorders, or infectious disorders.

[0024] The present invention further relates to the use of a compound as defined herein for the manufacture of a medicament for the prevention or treatment of cancer; in particular for the treatment of cancer.

[0025] The present invention further relates to a method for the prevention or treatment of a disease state or condition mediated by CDK7, which method comprises administering to a subject in need thereof a compound as defined herein.

[0026] The subject can be a mammal.

[0027] The present invention further relates to an in vitro method of modulating CDK7 activity, comprising contacting a CDK7 protein or a portion thereof with a compound disclosed herein, or a pharmaceutically acceptable salt or solvate thereof. [Brief explanation of the drawings]

[0028] [Figure 1] Scheme 1. [Figure 2] This is Scheme 2. [Figure 3] Scheme 3. [Figure 4] This is Scheme 4. DETAILED DESCRIPTION OF THE INVENTION

[0029] Incorporation by Reference All publications, patents, patent applications, and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) mentioned in this specification are hereby incorporated by reference as if each individual publication, patent, patent application, or published nucleotide and amino acid sequence was specifically and individually indicated to be incorporated by reference.

[0030] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood to which the claimed subject matter pertains. When reference is made to a URL or other such identifier or address, it is understood that such identifiers may change and that particular information on the Internet may come and go, but that equivalent information may be found by searching the Internet. Reference thereto evidences the availability and general dissemination of such information.

[0031] It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed.

[0032] In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless specifically stated otherwise.

[0033] When values ​​are expressed as approximations, by use of the descriptor "about," it will be understood that the particular value forms another embodiment. As used herein, "about X" (where X is a numerical value) preferably means and includes ±10% of the referenced value. For example, the phrase "about 8" refers to and includes values ​​from 7.2 to 8.8; as another example, the phrase "about 8%" refers to and includes values ​​from 7.2% to 8.8%. Where present, all ranges are inclusive and combinable. For example, if a range of "1 to 5" is referenced, the referenced range should be interpreted as including ranges such as "1 to 4," "1 to 3," "1 to 2," "1 to 2 and 4 to 5," "1 to 3 and 5," etc. Furthermore, when a list of options is explicitly provided, such list may also include embodiments in which any of the options may be excluded. For example, when a range of "1 to 5" is stated, such a statement can support a situation in which any of 1, 2, 3, 4, or 5 is excluded, and therefore the statement "1 to 5" can support "1 and 3 to 5, but not 2" or simply "2 is not included here."

[0034] Some of the quantitative expressions set forth herein are not modified by the term "about." Whether or not the term "about" is explicitly used, it is understood that all quantities set forth herein are intended to refer to the actual given value, and also to refer to approximations of such given value that can be reasonably estimated based on ordinary skill in the art, including approximations due to experimental and / or measurement conditions and tolerances of such given value.

[0035] As used herein, the phrase "one or more" refers to at least one, for example 1, 2, 3, 4, 5 or more, where possible and depending on the context.

[0036] Furthermore, use of the term "including" and other forms such as "include," "includes," and "included" is not limiting.

[0037] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0038] Standard definitions of chemical terms are given in Carey and Sundberg, “Advanced Organic Chemistry 4 th Ed.” Vols. A(2000) and B(2001), Plenum Press, New York.

[0039] Unless otherwise defined, the nomenclature and laboratory procedures and techniques employed in analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those recognized in the art. Standard techniques may be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation, and delivery, and patient treatment. Standard techniques may be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques may be performed, for example, using kits according to manufacturer's specifications, or as commonly accomplished in the art, or as described herein. The foregoing techniques and procedures may generally be performed in a conventional manner and as described in the various general and more specific references cited and discussed throughout this specification.

[0040] It is understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein, as such may vary, and it is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods, compounds, and compositions described herein.

[0041] Above and below, the term "compounds of formula (I)" is intended to include the addition salts, solvates and stereoisomers thereof.

[0042] As used herein, "C x~y " (where x and y are integers) refers to the number of carbon atoms (excluding optional substituents) that make up the moiety it designates. Thus, C 1~6 The alkyl group contains 1 to 6 carbon atoms, and 3~6 Cycloalkyl groups contain 3 to 6 carbon atoms and are 1~4 An alkoxy group may contain 1 to 4 carbon atoms.

[0043] The term "halo" or alternatively "halogen" means fluoro, chloro, bromo and iodo.

[0044] An "alkyl" group can have 1 to 6 carbon atoms (whenever described herein, a numerical range such as "1 to 6" refers to each integer within the given range; for example, "1 to 6 carbon atoms" means that the alkyl group can consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to 6 carbon atoms, although this definition also covers descriptions of the term "alkyl" where no numerical range is specified). The alkyl groups of the compounds described herein are "C 1~6 The term "alkyl" may be used interchangeably with "alkyl" or similar designations.

[0045] For example, the term "C 1~4 Alkyl" or "C 1~6"Alkyl," as used herein as a group or part of a group, refers to a straight or branched chain saturated hydrocarbon group containing 1 to 4 or 1 to 6 carbon atoms. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, and the like.

[0046] The term "alkenyl" refers to a type of alkyl group in which at least two atoms of the alkyl group form a double bond that is not part of an aromatic group. Non-limiting examples of alkenyl groups include -CH=CH2, -C(CH3)=CH2, -CH=CH3, -CH=C(CH3)2, and -C(CH3)=CHCH3. The alkenyl moiety can be branched or straight-chained. Alkenyl groups can have 2 to 6 carbons. Alkenyl groups can be substituted or unsubstituted. Depending on the structure, alkenyl groups can be monoradicals or diradicals (i.e., alkenylene groups). Examples of "alkenyl" include "C 2~4 alkenyl" or "C 2~6 Alkenyl is also included.

[0047] The term "alkynyl" refers to a type of alkyl group in which at least two atoms of the alkyl group form a triple bond. Non-limiting examples of alkynyl groups include -C≡CH, -C≡CCH3, -C≡CCH2CH3, and -C≡CCH2CH2CH3. The alkynyl moiety can be branched or straight-chained. Alkynyl groups can have 2 to 6 carbons. Alkynyl groups can be substituted or unsubstituted. Depending on the structure, alkynyl groups can be monoradicals or diradicals (i.e., alkynylene groups). Examples of "alkynyl" include "C 2~4 alkynyl" or "C 2~6 "Alkynyl" is also included.

[0048] "Alkoxy" refers to the group "-O-alkyl", where alkyl is as defined herein.

[0049] The term “C 1~4 Alkoxy" or "C1~6 "Alkoxy" as used herein as a group or part of a group means -OC 1~4 Alkyl group or -OC 1~6 refers to an alkyl group, where C 1~4 Alkyl and C 1~6 Alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy and the like.

[0050] The term "hydroxy C 1~4 Alkyl" or "hydroxy C 1~6 "Alkyl," as used herein as a group or part of a group, refers to a C alkyl group, as defined herein, in which one or more hydrogen atoms have been replaced by a hydroxyl group. 1~4 Alkyl or C 1~6 It refers to an alkyl group. Hence, the term "hydroxy C 1~4 Alkyl" or "hydroxy C 1~6 "Alkyl" is a monohydroxy C 1~4 Alkyl, monohydroxy C 1~6 Alkyl and polyhydroxy C 1~4 Alkyl and Polyhydroxy C 1~6 One, two, three or more hydrogen atoms may be replaced by hydroxyl groups, so that hydroxy C 1~4 Alkyl or hydroxy C 1~6 Alkyl can have one, two, three or more hydroxyl groups. Examples of such groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and the like.

[0051] The term "haloalkyl" refers to an alkyl group, as defined herein, in which one or more hydrogen atoms are replaced with one or more halogens. Thus, the term "haloalkyl" includes "haloC 1~4 Alkyl, HaloC 1~6 Alkyl, Monohalo C 1~4 Alkyl, monohalo C 1~6 Alkyl, Polyhalo C 1~4 Alkyl and Polyhalo C 1~6The haloalkyl radicals include alkyl. One, two, three, or more hydrogen atoms can be replaced with halogen, and thus a haloC1-4 alkyl or haloC1-6 alkyl can have one, two, three, or more halogens. The halogens can be the same or they can be different. Non-limiting examples of haloalkyl radicals include -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, fluoroethyl, fluoromethyl, trifluoroethyl, and the like.

[0052] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal atoms are selected from atoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, silicon, or combinations thereof. The heteroatoms can be placed at any interior position of the heteroalkyl group. Examples include, but are not limited to, -CH2-O-CH3, -CH2-CH2-O-CH3, -CH2-NH-CH3, -CH2-CH2-NH-CH3, -CH2-N(CH3)-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)-CH3, -CH2-NH-OCH3, -CH2-O-Si(CH3)3, -CH2-CH=N-OCH3, and -CH=N(CH3)-CH3. Additionally, up to two heteroatoms can be consecutive, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. A "heteroalkyl" can have 1 to 6 carbon atoms, excluding the number of heteroatoms.

[0053] The term "Halo C 1~4 Alkoxy" or "HaloC 1~6 "Alkoxy," as used herein as a group or part of a group, refers to an -OC group, as defined herein, in which one or more hydrogen atoms are replaced by halogen. 1~4 Alkyl group or -OC 1~6 It refers to an alkyl group. Hence, the term "haloC" 1~4 Alkoxy" or "HaloC 1~6 "Alkoxy" is a monohalo C 1~4 Alkoxy, monohalo C 1~6Alkoxy and polyhalo C 1~4 Alkoxy and Polyhalo C 1~6 It includes alkoxy. One, two, three or more hydrogen atoms may be replaced by halogen, so haloC1-4alkoxy or haloC1-6alkoxy may have one, two, three or more halogens. Examples of such groups include fluoroethyloxy, difluoromethoxy or trifluoromethoxy and the like.

[0054] The terms "fluoroalkyl" and "fluoroalkoxy" include alkyl and alkoxy groups, respectively, that are substituted with one or more fluorine atoms. Non-limiting examples of fluoroalkyl include -CF, -CHF, -CHF, -CHCF, -CFCF, -CFCF, -CF(CH), and the like. Non-limiting examples of fluoroalkoxy groups include -OCF, -OCHF, -OCHF, -OCHCF, -OCFCF, -OCFCF, -OCF(CH), and the like.

[0055] The term cyano C 1~4 Alkyl or cyano C 1~6 Alkyl, as used herein, refers to a C alkyl group as defined herein. 1~4 Alkyl or C 1~-6 It refers to an alkyl group, which is substituted with one or two cyano groups (especially one cyano group).

[0056] "Amino" refers to the group -NH2.

[0057] The term "alkylamine" or "alkylamino" refers to an -N(alkyl) x H y "Dialkylamino" refers to the group -N(alkyl)2, where alkyl is as defined herein, and x and y are selected from the group x=1, y=1 and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen to which they are attached, can optionally form a cyclic ring system. "Dialkylamino" refers to the group -N(alkyl)2, where alkyl is as defined herein.

[0058] The term "carboxy" or "carboxyl" refers to -COH. In some embodiments, the carboxy moiety can be replaced by a "carboxylic acid bioisostere." This refers to a functional group or moiety that exhibits similar physical and / or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties as a carboxylic acid group. A compound having a carboxylic acid moiety can have the carboxylic acid moiety exchanged for a carboxylic acid bioisostere and have similar physical and / or biological properties compared to the carboxylic acid-containing compound. For example, in one embodiment, the carboxylic acid bioisostere will ionize to approximately the same extent as a carboxylic acid group at physiological pH. Examples of carboxylic acid bioisosteres include, but are not limited to: [ka] Examples include:

[0059] As used herein, the term "carbocyclyl," unless otherwise indicated, includes aromatic, non-aromatic, unsaturated, partially saturated, and fully saturated carbocyclic ring systems. Generally, unless the context indicates otherwise, such ring systems may be monocyclic or bicyclic or bridged and may contain, for example, 3 to 12 ring members or 4 to 10 ring members, or more usually 5 to 10 ring members. A reference to 3 to 6 ring members includes 3, 4, 5, or 6 atoms in the ring; a reference to 4 to 7 ring members includes 4, 5, 6, or 7 atoms in the ring; and a reference to 4 to 6 ring members includes 4, 5, or 6 atoms in the ring. Examples of monocyclic carbocyclyl ring systems are ring systems containing 3, 4, 5, 6, 7, and 8 ring members, more usually 3 to 7, preferably 4, 5, 6, or 7 ring members, and more preferably 5 or 6 ring members. Examples of bicyclic carbocyclyl ring systems are those containing 8, 9, 10, 11, and 12 ring members, more commonly 9 or 10 ring members. Where reference is made herein to a carbocyclyl ring system, the carbocyclyl ring may be optionally substituted (i.e., unsubstituted or substituted) with one or more substituents as discussed herein, unless the context indicates otherwise. Particular examples of 3- to 12-membered carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, phenyl, naphthyl, indenyl, tetrahydronaphthyl, azulenyl, norbornane (1,4-endo-methylene-cyclohexane), and adamantane ring systems.

[0060] "Aromatic" refers to a planar ring having a delocalized π-electron system containing 4n+2 π-electrons, where n is an integer. An aromatic ring can be formed from 5, 6, 7, 8, 9, or more than 9 atoms. An aromatic can be optionally substituted. The term "aromatic" includes both aryl groups (e.g., phenyl, naphthalenyl) and heteroaryl groups (e.g., pyridinyl, quinolinyl).

[0061] The term "non-aromatic group", unless otherwise indicated, includes unsaturated ring systems that do not contain aromatic character, partially saturated, and fully saturated heterocyclyl ring systems.

[0062] The terms "unsaturated" and "partially saturated" refer to rings whose ring structure contains atoms that share more than one valence bond, i.e., a ring containing at least one multiple bond (e.g., a C=C, C≡C, or N=C bond).

[0063] The term "fully saturated" refers to a ring in which there are no multiple bonds between ring atoms. Saturated heterocyclyl groups include piperidine, morpholine, thiomorpholine, and piperazine. Partially saturated heterocyclyl groups include pyrazolines (e.g., 2-pyrazoline and 3-pyrazoline).

[0064] The carbocyclyl ring system may be an aryl ring system.

[0065] The term "aryl" as used herein refers to a carbocyclyl aromatic group and includes polycyclic (e.g., bicyclic) ring systems, where at least one ring is aromatic and one or more rings are non-aromatic. In such polycyclic systems, the ring system can be connected to the remainder of the compound by an aromatic ring or a non-aromatic ring. The term "aryl" includes phenyl, naphthyl or naphthalenyl, indenyl, and tetrahydronaphthyl groups. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group).

[0066] The term "cycloalkyl" refers to a monocyclic or polycyclic non-aromatic group in which each of the atoms forming the ring (i.e., the skeletal atoms) is a carbon atom. A cycloalkyl can be saturated or partially unsaturated. Examples of "cycloalkyl" include "C 3~6 Cycloalkyl groups include "cycloalkyl." Cycloalkyls can be fused to an aromatic ring (in which case the cycloalkyl is attached via a non-aromatic ring carbon atom). Cycloalkyl groups include groups having 3 to 10 ring atoms. Examples of cycloalkyl groups include, but are not limited to, the following moieties: [ka] Examples include:

[0067] The term "heterocyclyl," "heterocycloalkyl," or "heteroalicyclic" group refers to a carbocyclyl, as defined herein, containing at least one heteroatom, typically selected from nitrogen, oxygen, or sulfur, in particular up to five, up to four, up to three, up to two, or a single heteroatom. Where reference is made herein to a heterocyclyl ring system, the heterocyclyl ring may be optionally substituted (i.e., unsubstituted or substituted) with one or more substituents as discussed herein, unless the context indicates otherwise. The group may be fused to an aryl or heteroaryl. Examples of heterocycloalkyl groups, also referred to as non-aromatic heterocyclyls, include: [ka] Examples include:

[0068] The term heteroalicyclic also includes all cyclic forms of carbohydrates, including, but not limited to, monosaccharides, disaccharides, and oligosaccharides. Unless otherwise specified, heterocycloalkyls have 2 to 10 carbons in the ring. When referring to the number of carbon atoms in a heterocycloalkyl, it is understood that the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including heteroatoms) that make up the heterocycloalkyl (i.e., the skeletal atoms of the heterocycloalkyl ring).

[0069] Heterocyclyl ring systems can be heteroaryl ring systems having from 5 to 12 ring members, more usually from 5 to 10 ring members.

[0070] The term "heteroaryl" is used herein to refer to a heterocyclyl ring system having aromatic character. The term "heteroaryl" encompasses polycyclic (e.g., bicyclic) ring systems in which at least one ring is aromatic and one or more rings are non-aromatic. In such polycyclic systems, the ring system can be attached to the remainder of the compound by an aromatic ring or a non-aromatic ring.

[0071] Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, more typically 5 to 10 ring members. Heteroaryl groups can be, for example, fused 5- and 6-membered rings, or two fused 6-membered rings, or 5- or 6-membered monocyclic or bicyclic structures formed from two fused 5-membered rings. Heteroaryl ring systems typically contain up to about five heteroatoms selected from nitrogen, oxygen, and sulfur. Typically, heteroaryl rings contain up to four heteroatoms, more typically up to three heteroatoms, and more typically up to two, e.g., a single heteroatom. In one embodiment, a heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in a heteroaryl ring can be basic, as in the case of imidazole or pyridine, or essentially non-basic, as in the case of indole or pyrrole nitrogens. Generally, the number of basic nitrogen atoms present in a heteroaryl group, including any ring amino group substituents, is less than five.

[0072] Examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, oxadiazolyl, oxatriazole, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl groups. Particularly, examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyrazolyl, and triazolyl groups.

[0073] Examples of 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.

[0074] Bicyclic heteroaryl groups include, for example, a benzene ring fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 0, 1, 2, or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 0, 1, or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 0, 1, 2, or 3 ring heteroatoms; a pyrazole ring fused to a 5- or 6-membered ring containing 0, 1, or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 0, 1, or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 0, 1, or 2 ring heteroatoms; The ring may be a group selected from an isoxazole ring fused to a 5- or 6-membered ring containing two ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing zero, one, or two ring heteroatoms; an isothiazole ring fused to a 5- or 6-membered ring containing zero, one, or two ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing zero, one, two, or three ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing zero, one, two, or three ring heteroatoms; a cyclohexyl ring fused to a 5- or 6-membered aromatic ring containing one, two, or three ring heteroatoms; and a cyclopentyl ring fused to a 5- or 6-membered aromatic ring containing one, two, or three ring heteroatoms.

[0075] Particular examples of bicyclic heteroaryl groups containing a 5-membered ring fused to another 5-membered ring include, but are not limited to, imidazothiazolyl (e.g., imidazo[2,1-b]thiazole) and imidazoimidazolyl (e.g., imidazo[1,2-a]imidazole).

[0076] Particular examples of bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring include, but are not limited to, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, isobenzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl, indazolyl, pyrazolopyrimidinyl (e.g., pyrazolo[1,5-a]pyrimidine), triazolopyrimidinyl (e.g., [1,2,4]triazolo[1,5-a]pyrimidine), benzodioxolyl, imidazopyrazinyl, imidazopyridazinyl, imidazopyridinyl, and pyrazolopyridinyl (e.g., pyrazolo[1,5-a]pyridine) groups.

[0077] Particular examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolidinyl, quinolinyl, isoquinolinyl, cinnolinyl, chromanyl, isochromanyl, thiochromanyl, benzopyranyl, benzodioxanyl, benzoxazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.

[0078] Particular examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolidinyl, quinolinyl, isoquinolinyl, benzopyranyl, benzodioxanyl, benzoxazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.

[0079] Examples of polycyclic heteroaryl groups containing an aromatic ring and a non-aromatic ring include tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydrobenzothienyl, dihydrobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 4,5,6,7-tetrahydrobenzofuranyl, tetrahydrotriazolopyrazinyl (e.g., 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl), and indolinyl.

[0080] Nitrogen-containing heteroaryl rings must contain at least one ring nitrogen atom. In addition, each ring may contain up to about four other heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, heteroaryl rings contain up to three heteroatoms, for example, one, two, or three, more commonly up to two nitrogen atoms, for example, a single nitrogen. The nitrogen atoms in the heteroaryl ring may be basic, as in the case of imidazole or pyridine, or essentially non-basic, as in the case of indole or pyrrole nitrogen. Generally, the number of basic nitrogen atoms present in the heteroaryl group, including any ring amino group substituents, is less than 5.

[0081] Examples of nitrogen-containing heteroaryl groups include, but are not limited to, pyridyl, pyrrolyl, imidazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl and benzisothiazole, indolyl, 3H-indolyl, isoindolyl, indolizinyl, isoindolinyl, purinyl, indazolyl, quinolizinyl, benzoxazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl and pteridinyl.

[0082] Examples of nitrogen-containing polycyclic heteroaryl groups containing aromatic and non-aromatic rings include tetrahydroisoquinolinyl, tetrahydroquinolinyl, and indolinyl.

[0083] Examples of non-aromatic heterocyclyl groups are those having 3 to 12 ring members, more usually 5 to 10 ring members. Such groups can be monocyclic or bicyclic and, for example, can typically have 1 to 5 heteroatom ring members (more usually 1, 2, 3, or 4 heteroatom ring members), usually selected from nitrogen, oxygen, and sulfur. Heterocyclyl groups can include, for example, cyclic ether moieties (e.g., in tetrahydrofuran and dioxane), cyclic thioether moieties (e.g., in tetrahydrothiophene and dithiane), cyclic amine moieties (e.g., in pyrrolidine), and combinations thereof (e.g., thiomorpholine).

[0084] Particular examples include morpholinyl, thiomorpholinyl, piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, and 3-pyrrolidinyl), azetidinyl, pyranyl (2H-pyranyl or 4H-pyranyl), dihydrothiophenyl, dihydropyranyl, dihydrofuranyl, dihydrothiazolyl, tetrahydrofuranyl, tetrahydrothiophenyl, dioxanyl, dioxolanyl, tetrahydropyranyl, imidazolinyl, oxazolinyl, oxazolidinyl, oxetanyl, thiazolinyl, 2-pyrazolinyl, pyrazolidinyl, and piperazinyl. In general, preferred non-aromatic heterocyclyl groups include saturated groups such as piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, and piperazinyl. In general, preferred non-aromatic heterocyclyl groups include saturated groups such as piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, and piperazinyl.

[0085] In a nitrogen-containing non-aromatic heterocyclyl ring, the ring must contain at least one ring nitrogen atom.

[0086] Particular examples of nitrogen-containing non-aromatic heterocyclyl groups include aziridinyl, morpholinyl, thiomorpholinyl, piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), dihydrothiazolyl, imidazolinyl, oxazolinyl, thiazolinyl, 2-pyrazolinyl, 3-pyrazolinyl, pyrazolidinyl and piperazinyl.

[0087] Particular examples of 3- to 6-membered monocyclic saturated heterocyclyls include morpholinyl, thiomorpholinyl, dioxanyl, piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), piperazinyl, pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl (e.g., 4-tetrahydropyranyl), dithianyl, trioxanyl, trithianyl, aziridinyl, oxiranyl, thiiranyl, diaziridinyl, dioxalinyl, oxetanyl, azetidinyl, thietanyl and dioxetanyl ring systems.

[0088] Examples of the 3- to 6-membered monocyclic heterocyclyl include morpholinyl, thiomorpholinyl, piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, and 3-pyrrolidinyl), imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, piperazinyl, tetrahydrofuranyl, tetrahydrothiophenyl, dioxanyl, and tetrahydropyranyl (e.g., 4-tetrahydropyranyl). Examples include trihydropyranyl), dithianyl, trioxanyl, trithianyl, aziridinyl, oxiranyl, thiiranyl, diaziridinyl, dioxalinyl, oxetanyl, azetidinyl, thietanyl, dioxetanyl, azirinyl, azetyl, 1,2-dithiethyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, dithiazolyl, pyridinyl, pyranyl, thiopyranyl, pyrimidinyl, thiazinyl, oxazinyl, and triazinyl ring systems.

[0089] Specific examples of 3- to 12-membered heterocycles include morpholinyl, thiomorpholinyl, piperidinyl (e.g., 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, and 4-piperidinyl), pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, and 3-pyrrolidinyl), imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, piperazinyl, tetrahydrofuranyl, tetrahydrothiophenyl, and the like. dioxanyl, tetrahydropyranyl (e.g., 4-tetrahydropyranyl), dithianyl, trioxanyl, trithianyl, aziridinyl, oxiranyl, thiiranyl, diaziridinyl, dioxalinyl, oxetanyl, azetidinyl, thietanyl, dioxetanyl, azirinyl, azetyl, 1,2-dithiethyl, pyrrolyl, furanyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, dithi azolyl, pyridinyl, pyranyl, thiopyranyl, pyrimidinyl, thiazinyl, oxazinyl, triazinyl, azepanyl, oxepanyl, thiepanyl, 1,2-diazepanyl, 1,4-diazepanyl, diazepinyl, thiazepinyl, azocanyl, azocinyl, imidazothiazolyl (e.g., imidazo[2,1-b]thiazolyl), imidazoimidazolyl (e.g., imidazo[1,2-a]imidazolyl), benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, Isobenzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl, indazolyl, pyrazolopyrimidinyl (e.g., pyrazolo[1,5-a]pyrimidinyl), triazolopyrimidinyl (e.g., [1,2,4]triazolo[1,5-a]pyrimidinyl), benzodioxolyl, imidazopyridinyl and pyrazolopyridinyl (e.g., pyrazolo[1,5-a]pyridinyl), quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, dihydrobenzothienyl, dihydrobenzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1 ,3]dioxolyl, 4,5,6,7-tetrahydrobenzofuranyl, tetrahydrotriazolopyrazinyl (e.g., 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl), 8-oxa-3-azabicyclo[3.2.1]octanyl, 2-oxa-5-azabicyclo[2.2.1]heptanyl, 3-oxa-8-azabicyclo[3.2.1]octanyl, and 3,6-diazabicyclo[3.1.1]heptanyl ring systems.

[0090] Specific examples of 5- to 6-membered aromatic heterocycles include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl ring systems.

[0091] Heterocyclyl and carbocyclyl rings also include bridged ring systems, such as bridged cycloalkanes, such as norbornane (1,4-endo-methylene-cyclohexane), adamantane, and oxa-adamantane; bridged morpholine rings, such as 8-oxa-3-azabicyclo[3.2.1]octane, 2-oxa-5-azabicyclo[2.2.1]heptane, and 3-oxa-8-azabicyclo[3.2.1]octane; bridged piperazine rings, such as 3,6-diazabicyclo[3.1.1]heptane; and bridged piperidine rings, such as 1,4-ethylenepiperidine. For a discussion of the difference between fused and bridged ring systems, see Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages 131-133, 1992.

[0092] Lines drawn in ring systems indicate that the bond may be attached to any suitable and available ring atom.

[0093] The term "optional" or "optionally" means that the event described after it may or may not occur. The term encompasses cases where the event may or may not occur.

[0094] In the compounds of the present disclosure, * A carbon atom marked with "(R * )" means that it is a pure enantiomer, but it is not known whether it is the R or S enantiomer. Similarly, when a carbon atom is denoted by "(S * )" means that it is a pure enantiomer, but it is not clear whether it is the R or S enantiomer.

[0095] The term "bond" or "single bond" refers to a chemical bond between two atoms or a chemical linking of two moieties when the atoms joined by the bond are considered part of a larger substructure.

[0096] The term "moiety" refers to a specific segment or functional group of a molecule. A chemical moiety is often a recognized chemical entity embedded in or appended to a molecule.

[0097] As used herein, the substituent "R" appearing alone and without a number designation refers to a substituent selected from among alkyl, haloalkyl, heteroalkyl, alkenyl, cycloalkyl, aryl, heteroaryl (bonded via a ring carbon), and heterocycloalkyl.

[0098] The terms "optionally substituted" or "substituted," unless expressly defined, mean that the group to which it refers is alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, -OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, -CN, alkynyl, C 1~6 This means that they may be substituted with one or more additional groups individually and independently selected from alkylalkynyl, halo, acyl, acyloxy, -COH, -CO-alkyl, nitro, haloalkyl, fluoroalkyl, and amino, including mono- and di-substituted amino groups (e.g., -NH, -NHR, -N(R)), and protected derivatives thereof. In some embodiments, the optional substituents are independently selected from halogen, -CN, -NH, -NH(CH), -N(CH), -OH, -COH, -COalkyl, -C(=O)NH, -C(=O)NH(alkyl), -C(=O)N(alkyl), -S(=O)NH, -S(=O)NH(alkyl), -S(=O)N(alkyl), alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone. In some embodiments, the optional substituents are independently selected from halogen, -CN, -NH, -OH, -NH(CH), -N(CH), -CH, -CHCH, -CF, -OCH, and -OCF. In some embodiments, a substituent is substituted with one or two of the above groups. In some embodiments, an optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atom, excluding aromatic carbon atoms) includes oxo (=O).

[0099] As used herein, the term "therapeutically effective amount" refers to an amount of an active compound or pharmaceutical agent that, when administered to a mammal in need thereof, is effective to at least partially ameliorate or at least partially prevent a disease, disorder or condition described herein.

[0100] As used herein, the term "composition" is intended to encompass a product containing the specified ingredients in the specified amounts and any product resulting directly or indirectly from combining the specified ingredients in the specified amounts.

[0101] As used herein, the term "expression" includes the process by which a polynucleotide is transcribed into mRNA and translated into a peptide, polypeptide, or protein.

[0102] The term "activator" is used herein to refer to any molecular species that results in activation of the indicated receptor, regardless of whether the species itself binds to the receptor or a metabolite of the species binds to the receptor. Thus, an activator can be a ligand of the receptor, or it can be an activator that is metabolized to a ligand of the receptor, i.e., a metabolite formed in the tissue that becomes the actual ligand.

[0103] As used herein, the term "antagonist" refers to a small molecule agent that binds to a receptor and subsequently reduces agonist-induced transcriptional activity of the receptor.

[0104] As used herein, the term "agonist" refers to a small molecule agent that binds to a receptor and subsequently increases the transcriptional activity of the receptor in the absence of a known agonist.

[0105] As used herein, the term "inverse agonist" refers to a small molecule drug that binds to a receptor and subsequently reduces the basal level of receptor transcriptional activity that exists in the absence of a known agonist.

[0106] The term "modulate," as used herein, means to interact with a target either directly or indirectly so as to alter the activity of the target, such as, by way of example only, enhancing the activity of the target, inhibiting the activity of the target, limiting the activity of the target, or prolonging the activity of the target.

[0107] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees, and other ape and monkey species; domestic animals such as cows, horses, sheep, goats, and pigs; domestic animals such as rabbits, dogs, and cats; and laboratory animals including rodents such as rats, mice, and guinea pigs. In one embodiment, the mammal is a human. Those skilled in the art will recognize that a therapy that reduces the severity of a condition in one species of mammal is predictive of the effectiveness of the therapy in another species of mammal.

[0108] As used herein, the terms "treat", "treating" or "treatment" include alleviating, reducing or ameliorating at least one symptom of a disease or condition, preventing additional symptoms, inhibiting a disease or condition, e.g., halting the progression of a disease or condition, relieving a disease or condition, causing regression of a disease or condition, alleviating conditions caused by a disease or condition, or halting the symptoms of a disease or condition prophylactically and / or therapeutically.

[0109] "Proliferative disease" refers to a disease resulting from abnormal growth or elongation due to cell proliferation. Proliferative diseases may be associated with 1) pathological proliferation of normally quiescent cells; 2) pathological migration of cells from normal locations (e.g., metastasis of neoplastic cells); 3) pathological expression of proteolytic enzymes such as matrix metalloproteinases (e.g., collagenase, gelatinase, and elastase); or 4) pathological angiogenesis in proliferative retinopathies and tumor metastasis. Exemplary proliferative diseases include cancer (i.e., "malignant neoplasms"), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases.

[0110] The terms "neoplasm" and "tumor" are used interchangeably herein and refer to an abnormal mass of tissue whose growth exceeds and is discordant with that of normal tissue. Neoplasms or tumors can be "benign" or "malignant" depending on the following characteristics: degree of cellular differentiation (including morphology and functionality), growth rate, local invasion, and metastasis. "Benign neoplasms" are generally well differentiated, characteristically have a slower growth rate than malignant neoplasms, and remain localized to the site of origin. Furthermore, benign neoplasms lack the ability to infiltrate, invade, or metastasize to distant sites. Exemplary benign neoplasms include, but are not limited to, lipomas, chondromas, adenomas, acrochordons, senile hemangiomas, seborrheic keratoses, lentigines, and sebaceous gland hyperplasia. In some cases, certain "benign" tumors can subsequently give rise to malignant neoplasms, which can result from additional genetic alterations in a subpopulation of the tumor's neoplastic cells; these tumors are referred to as "premalignant neoplasms." An exemplary premalignant neoplasm is a teratoma. "Malignant neoplasms," on the other hand, are generally poorly differentiated (anaplastic) and characteristically have rapid growth accompanied by progressive infiltration, invasion, and destruction of surrounding tissue. Furthermore, malignant neoplasms generally have the ability to metastasize to distant sites.

[0111] As used herein, the term "cancer" refers to a malignant neoplasm. Exemplary cancers include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal carcinoma, anal carcinoma, angiosarcoma (e.g., lymphangiosarcoma, lymphangioendocortical sarcoma, angiosarcoma), appendix cancer, benign monoclonal gammopathies, biliary tract cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g., breast adenocarcinoma, papillary breast carcinoma, adenocarcinoma, medullary breast carcinoma), brain cancer (e.g., meningioma, glioblastoma, glioma (e.g., astrocytoma, oligodendroglioma), medulloblastoma), bronchial carcinoma, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma, and colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma). ;Connective tissue cancer;Epithelial carcinoma;Ependymoma;Endothelial sarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma);Endometrial cancer (e.g., uterine carcinoma, uterine sarcoma);Esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma);Ewing's sarcoma;Eye cancer (e.g., intraocular melanoma, retinoblastoma);Familial eosinophilia;Gallbladder cancer;Gastric cancer (e.g., gastric adenocarcinoma);Gastrointestinal stromal tumor (GIST);Germ cell carcinoma;Head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer));Hematopoietic cancer (e.g., acute lymphoblastic leukemia, Leukemias such as acute myeloid leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL); Hodgkin's lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin's lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma) , follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., Waldenström's macroglobulinemia), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-lymphocytic lymphoma, and primary central nervous system (CNS) lymphoma;and lymphomas such as precursor T-lymphocytic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sézary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enterocolitis-type T-cell lymphoma, subcutaneous pancreatic leukemia-like T-cell lymphoma, and anaplastic large cell lymphoma); mixed leukemia / lymphomas of one or more of the above; and multiple myeloma (MM)), heavy chain diseases (e.g., alpha chain disease, gamma chain disease, mu chain disease); hemangioblastoma; Pharyngeal cancer; inflammatory myofibroblastic tumor; immune cell amyloidosis; kidney cancer (e.g., nephroblastoma, also known as Wilms' tumor, renal cell carcinoma); liver cancer (hepatocellular carcinoma (HCC), malignant hepatocellular carcinoma); lung cancer (bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorders (MPDs) (e.g., polycythemia vera (PV), essential thrombocytopenia (ET), myelodysplasia myeloma (AMM) aka myelofibrosis) myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilia (HES)); neuroblastoma; neurofibromas (e.g., neurofibromatosis (NF) type 1 or 2, schwannomatosis); neuroendocrine carcinomas (e.g., gastroenteropancreatic neuroendocrine tumors (GEP-NETs), carcinoid tumors); osteosarcomas (e.g., bone cancer); ovarian cancers (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancers (e.g., pancreatic adenocarcinoma, intrapapillary mucinous neoplasm (IPMN), pancreatic islet cell tumors); penile cancers (e.g., penile and Paget's disease of the scrotum; pinealoma; primitive neuroectodermal tumor (PNT); plasma cell neoplasm; paraneoplastic syndromes; intraepithelial neoplasia; prostate cancer (e.g., prostatic adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small intestine cancer (e.g., appendix cancer); soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small intestine cancer; sweat gland carcinoma; synovium;These include testicular cancer (e.g., seminoma, testicular embryonal carcinoma), thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma), urethral cancer, vaginal cancer, and vulvar cancer (e.g., Paget's disease of the vulva);

[0112] The term "angiogenesis" refers to the formation and growth of new blood vessels. Normal angiogenesis occurs in a subject's healthy body for wound healing and the restoration of blood flow to tissues after injury. A healthy body controls angiogenesis through many means, for example, growth factors that stimulate angiogenesis and angiogenesis inhibitors. Many disease states, such as cancer, diabetic blindness, age-related macular degeneration, rheumatoid arthritis, and psoriasis, are characterized by abnormal (i.e., increased or excessive) angiogenesis. Abnormal angiogenesis refers to angiogenesis that is greater than that in the normal body, particularly in adults that is unrelated to normal angiogenesis (e.g., menstruation or wound healing). Abnormal angiogenesis can provide new blood vessels to supply diseased tissue and / or destroy normal tissue; in cancer, the new blood vessels allow tumor cells to escape into the circulation and locate in other organs (tumor metastasis).

[0113] As used herein, "inflammatory disease" refers to a disease caused by, resulting from, or resulting in inflammation. The term "inflammatory disease" can also refer to a dysregulated inflammatory response that causes an overreaction by macrophages, granulocytes, and / or T lymphocytes, resulting in abnormal tissue damage and / or cell death. Inflammatory diseases are acute or chronic inflammatory conditions and can result from infectious or non-infectious causes.Inflammatory diseases include, but are not limited to, atherosclerosis, arteriosclerosis, autoimmune diseases, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendonitis, bursitis, psoriasis, cystic fibrosis, arthritis, rheumatoid arthritis, inflammatory arthritis, Sjogren's syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., type 1), myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, and the like. Coryne's disease, Goodpasture's disease, mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pernicious anemia, inflammatory dermatoses, unintentional interstitial pneumonia (UIP), asbestosis, silicosis, bronchiectasis, beryllium disease, tarcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphocytic interstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener's granulomatosis and related forms of vasculitis (temporal arteritis and polyarteritis nodosa), inflammatory dermatoses, hepatitis, delayed-onset Hypersensitivity reactions (e.g., poison ivy), pneumonia, airway inflammation, adult respiratory distress syndrome (ARDS), encephalitis, immediate hypersensitivity reactions, asthma, hay fever, allergy, acute anaphylaxis, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host-versus-graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioalveolitis, conjunctivitis, dacryoadenitis, dermatomyositis, endocarditis, endocarditis, enteritis, enterococcitis, upper extremity inflammation inflammation, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, pharyngitis, pleuritis, phlebitis, pneumonia, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, orchitis, tonsillitis, urethritis, cystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, vasculitis, chronic bronchitis, osteomyelitis, optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis.

[0114] As used herein, "autoimmune disease" refers to a disease caused by an inappropriate immune response of a subject's body against substances and tissues normally present in the body. That is, the immune system mistakes any part of the body for a pathogen and attacks the body's own cells. This may be limited to a specific organ (e.g., autoimmune thyroiditis) or may involve specific tissues in different locations (e.g., Goodpasture's disease, which can affect the basement membrane of both the lungs and kidneys). Treatment of autoimmune diseases is usually with immunosuppressants, e.g., drugs that reduce the immune response. Exemplary autoimmune diseases include, but are not limited to, glomerulonephritis, Goodpasture's syndrome, necrotizing vasculitis, lymphadenitis, periarteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, arthritis, psoriatic arthritis, systemic lupus erythematosus, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, antiphospholipid syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener's granulomatosis, microscopic polyangiitis), uveitis, Sjogren's syndrome, Crohn's disease, Reiter's syndrome, ankylosing spondylitis, Lyme arthritis, Guillain-Barré syndrome, Hashimoto's thyroiditis, and cardiomyopathy.

[0115] The term "autoinflammatory disease" refers to a category of diseases similar to but distinct from autoimmune diseases. Autoinflammatory and autoimmune diseases share a common characteristic in that both groups of diseases result from the immune system attacking a subject's own tissues, resulting in increased inflammation. In autoinflammatory diseases, the subject's innate immune system triggers inflammation for unknown reasons. The innate immune system responds despite never having encountered the subject's autoantibodies or antigens. Autoinflammatory diseases are characterized by severe inflammatory episodes resulting in symptoms such as fever, rash, or swollen joints. These diseases also carry the risk of amyloidosis, which can lead to the potentially fatal accumulation of blood proteins in vital organs. Autoinflammatory diseases include, but are not limited to, familial Mediterranean fever (FMF), neonatal-onset multisystem inflammatory disease (NOMID), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), interleukin-1 receptor antagonist deficiency (DIRA), and Behçet's disease.

[0116] The term "biological sample" refers to any sample, including tissue samples (such as tissue sections and tissue needle biopsies); cell samples (e.g., cytological smears (such as Pap or blood smears) or samples of cells obtained by microdissection); whole organism samples (such as yeast or bacterial samples); or cell fractions, fragments, or organelles (such as those obtained by lysing cells and separating their components by centrifugation or other means). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical or needle biopsy), nipple aspirate, milk, vaginal fluid, saliva, swabs (such as oral swabs), or any biomolecule-containing material obtained from a first biological sample. Biological samples also include biological samples that are transgenic, such as transgenic eggs, sperm cells, blastocysts, embryos, fetuses, donor cells, or cell nuclei.

[0117] Isomers, salts, N-oxides, solvates, polymorphs, prodrugs, isotopically labeled derivatives Above and below, any reference to "compounds of Formula (I), (II), (IIIa), (IIIb), (IVa), (IVb), (Va), (Vb)", "compounds of the disclosure or invention", "compounds presented herein" or similar terms is meant to include addition salts, solvates and stereoisomers thereof.

[0118] In certain embodiments, the compounds presented herein contain one or more stereocenters, each of which independently exists in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, atropisomeric, and epimeric forms, as well as appropriate mixtures thereof. Stereoisomers can be obtained, if desired, by methods such as stereoselective synthesis and / or separation of stereoisomers by chiral chromatographic columns. In some embodiments, the compounds of the present disclosure are used as single enantiomers. In some embodiments, the compounds of the present disclosure are used as racemic mixtures. In some embodiments, the compounds of the present disclosure have rotational hindrance about a single bond, resulting in an atropisomer.

[0119] In some situations, compounds may exist as tautomers, and all tautomers are included within the scope of the compounds presented herein.

[0120] For the avoidance of doubt, compounds may exist in one of several geometric isomeric or tautomeric forms, and where only one is specifically described or shown, all others are nevertheless included. Examples of tautomeric forms include keto, enol, and enolate forms, such as, for example, the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / enediamine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro. [ka]

[0121] It is intended that such forms, insofar as they may exist, are included within the scope of the compounds presented herein, and it follows that a single compound may exist in both stereoisomeric and tautomeric forms.

[0122] Where a compound described herein contains one or more chiral centers and can exist in two or more optically isomeric forms, a reference to the compound described herein includes all optically isomeric forms thereof (e.g., enantiomers, epimers, and diastereoisomers), either as individual optical isomers or as mixtures of two or more optical isomers (e.g., racemic mixtures), unless the context requires otherwise. Where a compound has multiple chiral centers and one chiral center is designated as having an absolute configuration, the other chiral centers include all optical isomers thereof, either as individual optical isomers or as mixtures of two or more optical isomers thereof (e.g., racemic mixtures), unless the context requires otherwise. Optical isomers can be characterized and identified by their optical activity (i.e., as + and - isomers or d and l isomers depending on the direction they rotate plane-polarized light), or they can be characterized in terms of their absolute stereochemistry using the "R and S" nomenclature developed by Cahn, Ingold and Prelog, Advanced Organic Chemistry, by Jerry March, 4 th Edition, John Wiley & Sons, New York, 1992, pages 109-114; see also Cahn, Ingold & Prelog (1966) Angew. Chem. Int. Ed. Engl., 5, 385-415. For example, resolved enantiomers of unknown absolute configuration can be designated (+) or (-) depending on the direction they rotate plane-polarized light.

[0123] Optical isomers can be separated by several techniques, including chiral chromatography (chromatography on a chiral support), and such techniques are well known to those skilled in the art. As an alternative to chiral chromatography, optical isomers can be separated by forming diastereoisomeric salts with chiral acids such as (+)-tartaric acid, (-)-pyroglutamic acid, (-)-di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (-)-camphorsulfonic acid, separating the diastereoisomers by preferential crystallization, and then dissociating the salts to give the individual enantiomers of the free base.

[0124] When a compound exists in more than one isomeric form, one isomeric form, e.g., one enantiomer of a pair of enantiomers, may exhibit advantages over the other isomeric form, e.g., over the other enantiomer, e.g., in terms of biological activity. Thus, in certain situations, it may be desirable to use only one of the pair of enantiomers or only one of several diastereoisomers as a therapeutic agent.

[0125] When a particular stereoisomer is identified, this means that said stereoisomer is substantially free of other isomers, i.e., associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, particularly less than 2%, and most preferably less than 1% of other isomers. Thus, for example, when a compound described herein is identified as (S), this means that the compound is substantially free of the (R) isomer; when a compound described herein is identified as, for example, E, this means that the compound is substantially free of the Z isomer; and when a compound described herein is identified as, for example, cis, this means that the compound is substantially free of the trans isomer.

[0126] As used herein, any chemical formula in which bonds are shown only as solid lines, rather than as solid wedge bonds or dashed wedge bonds, or any chemical formula that is not otherwise shown as having a particular configuration (e.g., R, S) about one or more atoms, contemplates each possible stereoisomer or mixture of two or more stereoisomers.

[0127] The terms "stereoisomer", "stereoisomeric form" or "stereochemically isomeric form" are used interchangeably above and below.

[0128] Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.

[0129] Atropisomers (or atropoisomers) are stereoisomers with specific spatial configurations resulting from restricted rotation about a single bond due to significant steric hindrance. All atropisomeric forms of the compounds described herein are intended to be included within the scope of the present invention.

[0130] Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e., not mirror-image related. When a compound contains a double bond, the substituent can be in the E or Z configuration. Substituents on a divalent cyclic (partially) saturated group can have the cis or trans configuration; for example, if a compound contains a disubstituted cycloalkyl group, the substituent can be in the cis or trans configuration. Thus, the present disclosure includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers, and mixtures thereof, whenever chemically possible.

[0131] The meanings of all these terms, i.e. enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, are known to those skilled in the art.

[0132] The methods and formulations described herein include the use of N-oxides (where appropriate), crystalline forms (also known as polymorphs), solvates and hydrates (also known as pseudopolymorphs), pharmaceutically acceptable salts and combinations thereof of compounds having the structures presented herein, as well as active metabolites of these compounds having the same type of activity.

[0133] In some embodiments, the compounds described herein are in various forms, including, but not limited to, amorphous, pulverized, and nanoparticulate forms. Furthermore, the compounds described herein include crystalline forms known as polymorphs. Polymorphs include different crystal packing arrangements of compounds with the same elemental composition. Polymorphs typically have different X-ray diffraction patterns, melting points, densities, hardnesses, crystal shapes, optical properties, stability, and solubility. Various factors, such as recrystallization solvents, crystallization rates, and storage temperatures, can result in a single crystalline form predominating.

[0134] In certain embodiments, the compounds described herein exist in a solvated form with pharmaceutically acceptable solvents such as water, ethanol, etc. In other embodiments, the compounds described herein exist in an unsolvated form.

[0135] In some embodiments, the compounds described herein include their solvent addition forms or crystalline forms, particularly solvates or polymorphs. As used herein, the term "solvate" means that a compound of the present invention is physically associated with one or more solvent molecules and their pharmaceutically acceptable addition salts. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid, the solvate may be isolated. The term "solvate" is intended to encompass both solution-phase and isolatable solvates. Solvates contain stoichiometric or non-stoichiometric amounts of solvent and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, isopropanol, methanol, DMSO, ethyl acetate, acetic acid, ethanolamine, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. The compounds described herein may exert their biological effects in solution.

[0136] Salt forms of the compounds presented herein are typically pharmaceutically acceptable salts, and examples of pharmaceutically acceptable salts are discussed in Berge et al. (1977) "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19. However, pharmaceutically unacceptable salts may also be prepared as intermediate forms that can then be converted to pharmaceutically acceptable salts. Such pharmaceutically unacceptable salt forms may be useful, for example, in the purification or separation of the compounds of the invention and also form part of the invention.

[0137] Pharmaceutically acceptable salts include pharmaceutically acceptable acid and base addition salts and are intended to include the therapeutically active non-toxic acid and base addition salt forms that the compounds described herein are able to form.

[0138] The salts of the present disclosure can be synthesized from a parent compound containing a basic or acidic moiety by conventional chemical methods, such as those described in "Pharmaceutical Salts: Properties, Selection, and Use," P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. Generally, such salts can be prepared by reacting the free acid or free base form of the compound with the appropriate base or acid in water or an organic solvent, or a mixture of the two (generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used). The compounds of the present invention can exist as mono- or di-salts, depending on the pKa of the acid from which the salt is formed.

[0139] Pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form in its anionic form with such suitable inorganic acids (hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.) or organic acids (acetic acid, methanesulfonic acid, maleic acid, tartaric acid, citric acid, etc.).

[0140] Suitable anions include, for example, acetate, 2,2-dichloroacetate, adipate, alginate, ascorbate (e.g., L-ascorbate), L-aspartate, benzenesulfonate, benzoate, 4-acetamidobenzoate, butanoate, bicarbonate, bitartrate, bromide, (+) camphorate, camphor-sulfonate, (+)-(1S)-camphor-10-sulfonate, calcium edetate, camsylate, caprate, caproate, caprylate, carbonate, chloride, cinnamate, citrate, cyclamate, dihydrochloride, dodecyl sulfate, edetate, estolate, esylate, ethane-1,2-disulfonate, ethanesulfonate, formate, fumarate, galactarate, gentisate, glucoheptonate, gluceptate. , gluconate, D-gluconate, glucuronate (e.g., D-glucuronate), glutamate (e.g., L-glutamate), α-oxoglutarate, glycolate, glycolyl arsanilate, hexylresorcinate, hippurate, hydrabamine, hydrobromide, hydrochloride, hydriodate, 2-hydroxyethane-sulfonate, hydroxynaphthoate, iodide, isethionate ester, lactate (e.g., (+)-L-lactate, (±)-DL-lactate), lactobionate, malate, (-)-L-malate, maleate, malonate, mandelate, (±)-DL-mandelate, mesylate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucate, naphthalene-sulfonate (e.g., naphthalene-2 ​​sulfonate), naphthalene-1,These salt forms include 5-disulfonate, 1-hydroxy-2-naphthoate, napsylate, nicotinate, nitrate, oleate, orotate, oxalate, palmidate, pamoate (embonate), pantothenate, phosphate / diphosphate, propionate, polygalacturonate, L-pyroglutamimate, pyruvate, salicylate, 4-aminosalicylate, sebacate, stearate, subacetate, succinate, sulfate, tannate, tartrate, (+)-L-tartrate, thioclate, toluenesulfonate (e.g., p-toluenesulfonate), tosylate, triethiodide, undecylenate, valerate, and acylated amino acids and cation exchange resins. Conversely, the salt forms can be converted to the free base form by treatment with an appropriate base.

[0141] Compounds of the present disclosure containing acidic protons can also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases in cationic form. Suitable base salts include those formed with organic cations such as arginine, benzathine, benzylamine, butylamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, diethanolamine, diethylamine, ethanolamine, ethylamine, ethylenediamine, lysine, meglumine, phenylbenzylamine, piperazine, procaine, triethylamine, tromethamine, and the like; ammonium ions (i.e., NH + ), quaternary ammonium ion N(CH3)4 + and substituted ammonium ions (e.g., NHR + , NH2R2 + , NHR3 + , NR4 +) as well as those formed with metal cations such as aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and the like. The compounds described herein, when they contain an amine functionality, may form quaternary ammonium salts, for example, by reaction with an alkylating agent according to methods well known to those skilled in the art. Such quaternary ammonium compounds are within the scope of the compounds presented herein.

[0142] Conversely, said salt forms can be converted into the free forms by treatment with an appropriate acid.

[0143] Screening and characterization of pharmaceutically acceptable salts, polymorphs, and / or solvates can be accomplished using a variety of techniques, including, but not limited to, thermal analysis, X-ray diffraction, spectroscopy, vapor sorption, and microscopy. Thermal analysis methods address thermochemical decomposition or thermophysical processes, including, but not limited to, polymorphic transformations. Such methods are used to analyze relationships between polymorphs, determine weight loss, determine glass transition temperatures, or for excipient compatibility studies. Such methods include, but are not limited to, differential scanning calorimetry (DSC), modulated differential scanning calorimetry (MDCS), thermogravimetric analysis (TGA), and thermogravimetric-infrared analysis (TG / IR). X-ray diffraction methods include, but are not limited to, single crystal and powder diffractometers and synchrotron radiation sources. Various spectroscopic techniques used include, but are not limited to, Raman, FTIR, UV-VIS, and NMR (liquid and solid). Solid-state NMR (SS-NMR) is also known as Magic Angle Spinning NMR or MAS-NMR. Various microscopy techniques include, but are not limited to, polarized light microscopy, scanning electron microscopy (SEM) with energy dispersive X-ray analysis (EDX), environmental scanning electron microscopy (in a gas or water vapor atmosphere) with EDX, IR microscopy, and Raman microscopy.

[0144] In some embodiments, the compounds described herein are prepared as prodrugs. A "prodrug" refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. For example, they may be orally bioavailable, whereas the parent drug is not. A prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. In some embodiments, the prodrug design increases its effective water solubility. In certain embodiments, upon in vivo administration, a prodrug is chemically converted into the biologically, pharmaceutically, or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to produce the biologically, pharmaceutically, or therapeutically active form of the compound.

[0145] Prodrugs of the compounds described herein include, but are not limited to, esters, ethers, carbonates, thiocarbonates, N-acyl derivatives, N-acyloxyalkyl derivatives, quaternary derivatives of tertiary amines, N-Mannich bases, Schiff bases, amino acid conjugates, phosphate esters, and sulfonate esters. See, for example, Vivekkumar K. and Bari S., "Prodrug Design," Academic Press, 2016; Rautio, J., and Laine, K., "Prodrugs in Drug Design and Development," in "Textbook of Drug Design and Development," Stromgaard, Krogsgaard-Larsen, and Madsen, Eds. 5, 2017, Chapter 10; and Di and Kerns, "Prodrugs," in "Drug-Like Properties," 2016, 2 nd.Ed. 471-485, each of which is incorporated herein by reference. In some embodiments, hydroxyl groups in the compounds disclosed herein are used to form prodrugs, wherein the hydroxyl groups are incorporated into acyloxyalkyl esters, alkoxycarbonyloxyalkyl esters, alkyl esters, aryl esters, phosphate esters, sugar esters, ethers, and the like.

[0146] Prodrug forms of the compounds described herein, where the prodrug is metabolized in vivo to produce a compound of the present disclosure described herein, are included within the scope of the claims. In some cases, some of the compounds described herein may be prodrugs of another derivative or active compound.

[0147] In some embodiments, sites on the compounds disclosed herein are susceptible to various metabolic reactions. Therefore, incorporating appropriate substituents at metabolic sites reduces, minimizes, or eliminates metabolic pathways. In certain embodiments, suitable substituents for reducing or eliminating the susceptibility of aromatic rings to metabolic reactions include, by way of example only, halogen, deuterium, or alkyl groups.

[0148] The compounds of the present disclosure include isotopically labeled compounds, i.e., compounds with one or more isotopic substitutions.These compounds are identical to those described in the various formulas and structures presented herein, but due to the fact that one or more atoms are replaced with atoms having atomic masses or mass numbers different from the atomic masses or mass numbers usually found in nature.A reference to a specific element includes within the scope of this compound all isotopes of that element, whether naturally occurring or synthetically produced, whether naturally abundant or isotopically enriched form.For example, a reference to hydrogen includes within its scope all isotopes of that element, whether naturally occurring or synthetically produced, whether naturally abundant or isotopically enriched form. 1 H, 2 H(D) and 3 Similarly, references to carbon and oxygen include within their scope, respectively. 12 C. 13C and 14 C and 16 O and 18 The radiolabeled compounds described herein include 0. The isotopes may be radioactive or non-radioactive. In one embodiment of the present invention, the compounds do not contain radioactive isotopes. In another embodiment, the compounds may contain one or more radioisotopes. Compounds containing such radioisotopes may also be useful from a diagnostic perspective. Radiolabeled compounds described herein include: 2 H, 3 H, 11 C. 18 F, 122 I, 123 I, 125 I, 131 I, 75 Br, 76 Br, 77 Br and 82 Preferably, the radioisotope is selected from the group consisting of: 2 H, 3 H, 11 C and 18 F. More preferably, the radioisotope is selected from the group 2 H. Specifically, deuterated compounds are intended to be included within the scope of the present invention. In some embodiments, metabolic sites on the compounds described herein are deuterated.

[0149] Throughout the specification, groups and substituents may be chosen to provide stable moieties and compounds.

[0150] Compound synthesis In this section, as in all other sections, unless the context dictates otherwise, references to formula (I) also include all other subgroups and examples thereof defined herein.

[0151] Synthesis of the compounds described herein may be accomplished using procedures described in the chemical literature, using the methods described herein, or by a combination thereof. Furthermore, solvents, temperatures, and other reaction conditions presented herein may be varied. Art-recognized techniques and materials are readily available, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989); March, Advanced Organic Chemistry 4 th Ed.,(Wiley 1992);Carey and Sundberg,Advanced Organic Chemistry 4 th Ed., Vols. A and B (Plenum 2000, 2001) and Green and Wuts, Protective Groups in Organic Synthesis 3 rd Ed., (Wiley 1999), all of which are incorporated by reference for such disclosure. General methods for the preparation of compounds as disclosed herein are derived from reactions which can be modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the formulae as provided herein.

[0152] The starting materials and reagents used in the synthesis of the compounds described herein can be synthesized or obtained from commercial sources such as, but not limited to, Sigma-Aldrich, Fischer Scientific (Fischer Chemicals), and AcrosOrganics.

[0153] In the reactions described herein, if a reactive functional group, such as a hydroxy, amino, imino, thio, or carboxy group, is desired in the final product, it may be necessary to protect the reactive functional group to prevent its undesired participation in the reaction. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protecting group is removed. Each protecting group is preferably removable by a different means. Protecting groups that are cleaved under completely different reaction conditions fulfill different removal requirements.

[0154] Protecting groups can be removed by acid, base, reducing conditions (e.g., hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and t-butyldimethylsilyl are acid labile and can be used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected by Cbz groups, which are removable by hydrogenolysis, and base-labile Fmoc groups. Carboxylic acid and hydroxy reactive moieties can be blocked with base-labile groups, such as, but not limited to, methyl, ethyl, and acetyl, in the presence of amines blocked with acid-labile groups, such as t-butyl carbamate or carbamates, both of which are acid- and base-stable but removable by hydrolysis.

[0155] Carboxylic acid and hydroxy reactive moieties can be blocked with hydrolytically removable protecting groups such as benzyl groups, while amine groups capable of hydrogen bonding with acids can be blocked with base labile groups such as acetyl, trifluoroacetyl, t-butoxycarbonyl (Boc), benzyloxycarbonyl (CBz), and 9-fluorenylmethyleneoxycarbonyl (Fmoc). Carboxylic acid reactive moieties can be protected by conversion to simple ester compounds as exemplified herein, including conversion to alkyl esters, or they can be blocked with oxidatively removable protecting groups such as 2,4-dimethoxybenzyl, while coexisting amino groups can be blocked with fluoride labile silyl carbamates.

[0156] Allyl blocking groups are useful in the presence of acid and base protecting groups, the former being stable and subsequently removable by metal or pi-acid catalysts. For example, allyl-blocked carboxylic acids can be removed by Pd cleavage in the presence of acid-labile t-butyl carbamate or base-labile acetate amine protecting groups. 0 It can be deprotected by a catalytic reaction. Yet another form of protecting group is a resin to which a compound or intermediate can be attached. As long as the residue is attached to the resin, the functional group is blocked and cannot react. Once released from the resin, the functional group becomes reactive.

[0157] Typical blocking / protecting groups may be selected from the following: [ka]

[0158] Detailed descriptions of other protecting groups and techniques applicable to the creation of protecting groups and their removal are provided in T.W. Greene and P.G.M. Butts, Protective Groups in Organic Synthesis, 4th ed., Wiley, Hoboken, New Jersey, 2007, the disclosure of which is incorporated herein by reference.

[0159] Synthesis scheme Compounds of formula (I) and intermediates thereof (wherein all variables are as defined in this disclosure) can be prepared according to the reaction schemes shown in the figures, where LG represents a leaving group, e.g., an ester, acyl chloride, etc.; and PG represents a suitable protecting group, as exemplified above.

[0160] In Scheme 1 (see Figure 1), the following definitions apply: A 4 represents nitrogen.

[0161] The conditions for each reaction shown in Scheme 1 may be as follows:

[0162] Reaction 1: The intermediate of formula (X) can be reacted with Bredereck's reagent in a suitable solvent such as toluene. The resulting compound can be cyclized in a suitable solvent such as EtOH in the presence of a suitable base such as 2-methyl-2-thiopseudourea hemisulfate, e.g., sodium ethoxide. The resulting compound can be oxidized in the presence of metachloroperbenzoic acid in a suitable solvent such as DCM to give a compound of formula (XI).

[0163] Reaction 2: The intermediate of formula (XI) may be deprotected in the presence of trifluoroacetic acid in a suitable solvent such as DCM to give a compound of formula (XII).

[0164] Reaction 3: The intermediate of formula (XII) may be reacted with an intermediate of formula (XIII) in the presence of a suitable base, such as triethylamine, and a suitable solvent, such as DCM, to provide a compound of formula (XV).

[0165] Reaction 4: The intermediate of formula (XII) may be reacted with diphosgene in the presence of a suitable base, such as triethylamine, and a suitable solvent, such as DCM. The resulting intermediate may be reacted with an intermediate of formula (XIV) in the presence of a suitable base, such as triethylamine, and a suitable solvent, such as DCM, to give a compound of formula (XV).

[0166] Reaction 5: The intermediate of formula (XV) may be reacted with an intermediate of formula (XVI), thereby providing a compound of formula (I).

[0167] Reaction 6: An intermediate of formula (XI) may be reacted with an intermediate of formula (XVI), followed by deprotection in the presence of trifluoroacetic acid in a suitable solvent such as DCM, to give a compound of formula (XVIII).

[0168] Reaction 7: The intermediate of formula (X) may be reacted with Bredereck's reagent in a suitable solvent such as toluene. The resulting compound may be cyclized with an intermediate of formula (XVI) in the presence of a suitable base such as sodium ethoxide and a suitable solvent such as EtOH to give a compound of formula (XVII).

[0169] Reaction 8: The intermediate of formula (XVII) may be converted to the intermediate of formula (XVIII) in the presence of HCl 4M and a suitable solvent or mixture of solvents such as, for example, Dioxane and MeOH.

[0170] Reaction 9: The intermediate of formula (XVIII) may be reacted with an intermediate of formula (XIX) in the presence of HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), a suitable base such as diisopropylethylamine and a suitable solvent such as DMF, to give a compound of formula (I).

[0171] Reaction 10: The intermediate of formula (XVIII) may be reacted with an intermediate of formula (XIII) in the presence of a suitable base such as triethylamine and a suitable solvent such as DCM to give a compound of formula (I).

[0172] In Scheme 2 (see Figure 2), the following definitions apply: A 4 represents nitrogen.

[0173] The conditions for each reaction shown in Scheme 2 may be as follows:

[0174] Reaction 11: The intermediate of formula (XX) can be reacted with urea in the presence of a suitable base such as sodium methoxide and a suitable solvent such as MeOH. The resulting compound can be finally converted to the intermediate of formula (XXI) by reaction with POCl in the presence of activated zinc, ammonia, NH (28% in HO) and a suitable solvent such as EtOH.

[0175] Reaction 12: The intermediate of formula (XXI) can be reacted with the intermediate of formula (XVI) in the presence of a suitable catalyst, such as RuPhos Pd G3, a suitable base, such as sodium tert-butoxide, and a suitable solvent, such as toluene. The resulting compound can be deprotected in the presence of hydrogen and 10% Pd / C in a suitable solvent, such as MeOH, to give the compound of formula (XVIII).

[0176] In Scheme 3 (see Figure 3), the following definitions apply: A 4 represents CH.

[0177] The conditions for each reaction shown in Scheme 3 may be as follows:

[0178] Reaction 13: The intermediate of formula (XXII) may be reacted with propylene, for example PdCl2(TPP)2, in the presence of a suitable catalyst such as copper iodide, a suitable base such as triethylamine, and a suitable solvent such as DMF. The resulting intermediate may be reacted with tert-butylamine in a suitable solvent such as water. The resulting intermediate may be cyclized with copper iodide in a suitable solvent such as DMF. The resulting intermediate may be alkylated with benzyl bromide in a suitable solvent such as CH3CN. The resulting intermediate may be reduced with sodium borohydride in a suitable solvent such as MeOH, thereby providing a compound of formula (XXIII).

[0179] Reaction 14: The intermediate of formula (XXIII) may be deprotected with 1-chloroethyl chloroformate in a suitable base such as potassium carbonate in a suitable solvent such as dichloroethane to give a compound of formula (XXIV).

[0180] Reaction 15: The intermediate of formula (XXIV) may be reacted with an intermediate of formula (XIX) in the presence of HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), a suitable base such as diisopropylethylamine and a suitable solvent such as DMF, to give a compound of formula (XXV).

[0181] Reaction 16: An intermediate of formula (XXV) may be reacted with an intermediate of formula (XVI) in the presence of a suitable catalyst, such as RuPhos Pd G3, a suitable base, such as sodium tert-butoxide, and a suitable solvent, such as toluene, to give a compound of formula (I).

[0182] In Scheme 4 (see Figure 4), the following definitions apply: A 1 =NR 2 , A 2 =CR 3a R 3b , A 3 =CH.

[0183] The conditions for each reaction shown in Scheme 4 may be as follows: [ka]

[0184] Reaction 17: The intermediate of formula (XXVI) may be converted to the intermediate of formula (XXVII) in the presence of trifluoromethanesulfonic anhydride, a suitable base such as diisopropylethylamine and a suitable solvent such as toluene.

[0185] Reaction 18: The intermediate of formula (XXVII) may be reacted with bis(pinacolato)diboron, a suitable catalyst such as Pd(dppf)Cl.CHCl, a suitable base such as potassium acetate, and a suitable solvent such as dioxane to provide a compound of formula (XXVIII).

[0186] Reaction 19: The intermediate of formula (XXVIII) can be reacted with an aryl bromide in the presence of a suitable catalyst, such as bis(triphenylphosphine)palladium(II) dichloride, a suitable base, such as 1M sodium carbonate, and a suitable solvent, such as dioxane. The resulting intermediate can be converted to the intermediate of formula (XIX) in the presence of 6M HCl and water.

[0187] Reaction 20: The intermediate of formula (XXVII) can be reacted with an arylboronic acid, a pinacol ester, a suitable catalyst such as bis(triphenylphosphine)palladium(II) dichloride, a suitable base such as 1M sodium carbonate, and a suitable solvent such as dioxane. The resulting intermediate can be converted to the intermediate of formula (XIX) in the presence of 6M HCl and water.

[0188] Reaction 21: 4-Pyridinecarboxylic acid, 2-chloro-5-(trifluoromethyl)-, ethyl ester can be hydrogenated with 37% HCl and 10% Pd / C in a suitable solvent such as MeOH. The resulting intermediate can be reacted with aqueous formaldehyde 37% and sodium triacetoxyborohydride in a suitable solvent such as THF to give a compound of formula (XIX).

[0189] Reaction 22: 4-Pyridinecarboxylic acid, 3-methyl-, ethyl ester can be hydrogenated with 37% HCl and 10% Pd / C in a suitable solvent such as MeOH. The resulting intermediate can be reacted with aqueous formaldehyde 37% and sodium triacetoxyborohydride in a suitable solvent such as THF to give a compound of formula (XIX).

[0190] Those skilled in the art will recognize that the chemical reactions shown in the following schemes may be performed in an alternate order to provide the desired compounds of formula (I).

[0191] Those skilled in the art will appreciate that the intermediates and final compounds shown in the schemes below can be further functionalized according to methods well known to those skilled in the art.

[0192] Compounds of formula (I) may also be interconverted via reactions or functional group transformations known in the art, for example, -C(=O)-OC 1~6 Alkyl or C 1~6 Substituents such as alkyl-OC(=O)- can be converted to HOOC-C in the presence of lithium hydroxide and a suitable solvent such as tetrahydrofuran or an alcohol, e.g., methanol, by the reaction 1~6 It can be converted to alkyl or carboxyl.

[0193] Those skilled in the art will appreciate that in some cases it may be desirable or necessary to carry out the reactions depicted in the schemes under an inert atmosphere, such as, for example, under an atmosphere of N2 gas.

[0194] It will be apparent to one skilled in the art that it may be necessary to cool the reaction mixture before reaction work-up (which refers to the series of operations required to isolate and purify the products of a chemical reaction, such as, for example, quenching, column chromatography, extraction, etc.).

[0195] Those skilled in the art will appreciate that heating the reaction mixture under stirring may improve the reaction outcome. In some reactions, microwave heating may be used in place of conventional heating to shorten the overall reaction time.

[0196] The compounds of the present invention prepared by the methods described herein may be synthesized in the form of a mixture of enantiomers, particularly a racemic mixture of enantiomers, which can be separated from one another using art-known resolution procedures. Racemic compounds of formula (I) containing a basic nitrogen atom can be converted to the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. The diastereomeric salt forms are then separated, for example, by selective or fractional crystallization, followed by liberation of the enantiomers with alkali. Alternative methods for separating the enantiomeric forms of the compound of formula (I) and its pharmaceutically acceptable addition salts and solvates include liquid chromatography using a chiral stationary phase, for example, rather than supercritical fluid chromatography. The pure stereochemically isomeric forms can also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, the compound will be synthesized using a stereospecific preparation method. These methods advantageously employ enantiomerically pure starting materials.

[0197] In all of these preparations, the reaction product may be isolated from the reaction medium and, if necessary, further purified by methods generally known in the art, such as extraction, crystallization, trituration, chromatography, etc. The purity of the reaction product may be determined according to methodologies generally known in the art, such as LC-MS, TLC, HPLC, etc.

[0198] Treatment methods and medical uses, pharmaceutical compositions and combinations thereof The present invention also provides methods for treating or preventing a proliferative disease (e.g., cancer, benign neoplasm, angiogenesis, inflammatory, autoinflammatory, or autoimmune disease) or an infectious disease (e.g., viral disease) in a subject. Such methods comprise the step of administering to a subject in need thereof an effective amount of a compound of the present disclosure, or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, stereoisomer, or isotopically labeled derivative thereof, or a pharmaceutical composition thereof.

[0199] The subject to be treated is a mammal. The subject may be a human. The subject may be a domestic animal, such as a dog, cat, cow, pig, horse, sheep, or goat. The subject may be a companion animal, such as a dog or cat. The subject may be a livestock animal, such as a cow, pig, horse, sheep, or goat. The subject may be a zoo animal. The subject may be a research animal, such as a rodent, dog, or non-human primate. The subject may be a non-human transgenic animal, such as a transgenic mouse or a transgenic pig.

[0200] Proliferative disorders treated or prevented using compounds of Formula (I) or Formula (II) will typically be associated with abnormal CDK7 activity. The abnormal CDK7 activity can be elevated and / or inappropriate (e.g., abnormal) activity of CDK7. In certain embodiments, CDK7 is not overexpressed and CDK7 activity is elevated and / or inappropriate. In certain other embodiments, CDK7 is overexpressed and CDK7 activity is elevated and / or inappropriate. The disclosed compounds and pharmaceutically acceptable salts, solvates, hydrates, tautomers, isotopically labeled derivatives, and compositions thereof may be useful for inhibiting CDK7 activity and treating and / or preventing proliferative disorders.

[0201] Proliferative disorders may also be associated with the inhibition of cellular apoptosis in a biological sample or subject. All types of biological samples described herein or known in the art are considered to be within the scope of the present invention. Inhibition of CDK7 activity is expected to cause cytotoxicity through the induction of apoptosis. The compounds of the present disclosure, as well as their pharmaceutically acceptable salts, solvates, hydrates, tautomers, isotope-labeled derivatives, and compositions, may induce apoptosis and thus be useful for the treatment and / or prevention of proliferative disorders.

[0202] In certain embodiments, the proliferative disease treated or prevented using the compounds of the present disclosure is cancer. All types of cancer disclosed herein or known in the art are contemplated as being within the scope of the present invention.

[0203] The compounds of the invention are useful in treating carcinomas including, but not limited to, those of the breast, liver, lung, colon, kidney, bladder (including small cell lung cancer, non-small cell lung cancer), head and neck, thyroid, esophagus, stomach, pancreas, ovary, gallbladder, cervix, prostate, and skin (including tonsillar cell carcinoma); leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, myeloma, mantle cell lymphoma, and Burkett's lymphoma. myeloid hematopoietic malignancies, including acute and chronic myeloid leukemia, myelodysplastic syndromes, and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannoma; and other tumors, including seminoma, melanoma, osteosarcoma, teratocarcinoma, keratopantomas, pigmentary disorders, follicular thyroid carcinoma, and Kaposi's sarcoma.

[0204] The proliferative disorder can be a cancer associated with a dependency on BCL-2 anti-apoptotic proteins (e.g., MCL-1 and / or XIAP). The proliferative disorder can be a cancer associated with overexpression of MYC (a gene encoding a transcription factor). The proliferative disorder can be a hematological malignancy. The proliferative disorder can be a blood cancer. The proliferative disorder can be a leukemia. The proliferative disorder can be chronic lymphocytic leukemia (CLL). The proliferative disorder can be acute lymphoblastic leukemia (ALL). The proliferative disorder can be T-cell acute lymphoblastic leukemia (T-ALL). The proliferative disorder can be chronic myeloid leukemia (CML). The proliferative disorder can be acute myeloid leukemia (AML). The proliferative disorder can be a lymphoma. The proliferative disorder can be melanoma. The proliferative disorder can be multiple myeloma. The proliferative disorder can be bone cancer. The proliferative disorder can be osteosarcoma. The proliferative disorder may be Ewing's sarcoma. The proliferative disorder may be triple-negative breast cancer (TNBC). The proliferative disorder may be brain tumor. The proliferative disorder may be neuroblastoma. The proliferative disorder may be lung cancer, small cell lung cancer (SCLC), or large cell lung cancer. The proliferative disorder may be a benign neoplasm. All types of benign neoplasms disclosed herein or known in the art are considered to be within the scope of the present invention.

[0205] The proliferative disorder may be associated with angiogenesis. All types of angiogenesis disclosed herein or known in the art are considered to be within the scope of the present invention.

[0206] The proliferative disease may be an inflammatory disease. All types of inflammatory diseases disclosed herein or known in the art are considered to be within the scope of the present invention. The inflammatory disease may be rheumatoid arthritis. The proliferative disease may be an autoinflammatory disease. All types of autoinflammatory diseases disclosed herein or known in the art are considered to be within the scope of the present invention. The proliferative disease may be an autoimmune disease. All types of autoimmune diseases disclosed herein or known in the art are considered to be within the scope of the present invention.

[0207] The cells described herein can be diseased cells. The cells can be in vitro or in vivo. The cells can be proliferating cells. The cells can be blood cells. The cells can be lymphocytes. The cells can be cancer cells. The cells can be leukemia cells. The cells can be CLL cells. The cells can be melanoma cells. The cells can be multiple myeloma cells. The cells can be benign neoplastic cells. The cells can be endothelial cells. The cells can be immune cells.

[0208] In another aspect, the present invention provides a method of downregulating expression of CDK7 in a biological sample or a subject.

[0209] In yet another aspect, the present invention provides compounds of the present disclosure, as well as pharmaceutically acceptable salts, solvates, hydrates, tautomers, isotopically labeled derivatives, and compositions thereof, for use in treating a proliferative disease in a subject. The compounds described herein, as well as pharmaceutically acceptable salts and compositions thereof, can be used to inhibit cell proliferation. The compounds described herein, as well as pharmaceutically acceptable salts and compositions thereof, can be used to induce apoptosis in cells. The compounds described herein, as well as pharmaceutically acceptable salts and compositions thereof, can be used to inhibit transcription.

[0210] Those skilled in the art will recognize that a therapeutically effective amount of a compound of the invention is an amount that has sufficient therapeutic activity, and that this amount will vary depending, inter alia, on the type of disease, the concentration of the compound in the therapeutic formulation, and the condition of the patient. Generally, the amount of a compound of the invention to be administered as a therapeutic agent to treat the disorders mentioned herein will be determined on an individual basis by the attending physician.

[0211] Those skilled in the art of treating such diseases can determine an effective therapeutic daily dose from the test results provided below. The effective therapeutic daily dose can be from about 0.005 mg / kg to 50 mg / kg. The amount of a compound according to the present invention, also referred to herein as the active ingredient, required to achieve a therapeutic effect will vary individually, depending, for example, on the specific compound, the route of administration, the age and condition of the recipient, and the specific disorder or disease being treated. Treatment methods may also include administering the active ingredient in a regimen of one to four doses per day. In these treatment methods, the compounds according to the present invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using known and readily available ingredients.

[0212] While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition. Accordingly, the present invention further provides pharmaceutical compositions comprising a compound of the present invention together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

[0213] The pharmaceutical compositions of the present invention can be prepared by any method known in the art of pharmacy, for example, by the methods described in Gennaro et al., Remington's Pharmaceutical Sciences (18 thed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical preparations and their Manufacture). A therapeutically effective amount of the specific compound, in base or addition salt form, as the active ingredient is combined with a pharmaceutically acceptable carrier to form a homogeneous mixture, which may take a variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are preferably in unit dosage forms suitable for systemic administration, such as oral, transdermal, or parenteral administration, or for local administration by inhalation or nasal spray. For example, in preparing compositions in oral dosage form, any of the usual pharmaceutical media can be used, such as water, glycols, oils, and alcohols for oral liquid preparations such as suspensions, syrups, elixirs, and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, and disintegrants for powders, pills, capsules, and tablets. Tablets and capsules are the most advantageous oral dosage unit forms due to their ease of administration, in which case solid pharmaceutical carriers are naturally used. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, although other ingredients, for example, to aid solubility, may be included. For example, injectable solutions may be prepared in which the carrier comprises saline, glucose solution, or a mixture of saline and glucose solution. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be used. In compositions suitable for transdermal administration, the carrier may optionally comprise a penetration enhancer and / or a suitable wetting agent, optionally in combination with minor amounts of suitable additives of any nature that do not cause significant adverse effects on the skin. Such additives may facilitate application to the skin and / or aid in the formulation of the desired composition. These compositions may be administered in a variety of ways, for example, as a transdermal patch, spot-on, or ointment.

[0214] It is particularly advantageous to formulate the aforementioned pharmaceutical compositions into unit dosage forms for ease of administration and uniformity of dosage. Unit dosage form, as used in the present specification and claims, refers to a physically discrete unit suitable as a unit dose, each unit containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect together with the necessary pharmaceutical carrier. Examples of such unit dosage forms include tablets (including scored tablets or coated tablets), capsules, pills, sachet powders, cachets, injection solutions or suspensions, teaspoons and tablespoons, and their divided combinations.

[0215] The exact dosage and frequency of administration will vary, as known to those skilled in the art, depending on the particular compound used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disability and general health of the particular patient, and other medications that the individual may be taking. Furthermore, it will be apparent that the effective daily amounts set forth above may be reduced or increased depending on the response of the treated subject and / or depending on the evaluation of the physician prescribing the compounds of the present invention.

[0216] The methods described herein may include the additional step of administering one or more additional pharmaceutical agents in combination with a compound of the present invention, a pharmaceutically acceptable salt thereof, or a composition comprising such a compound or pharmaceutically acceptable salt. Such additional pharmaceutical agents include, but are not limited to, antiproliferative agents, anticancer agents, antidiabetic agents, anti-inflammatory agents, immunosuppressants, and analgesics. The additional pharmaceutical agents may synergistically enhance the inhibition of CDK7 or CDK12 and / or CDK13 induced by a compound or composition of the present invention in a biological sample or subject. Thus, the combination of a compound or composition of the present invention with an additional pharmaceutical agent may be useful for treating proliferative diseases that are resistant to treatment with an additional pharmaceutical agent without a compound or composition of the present invention.

[0217] The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical formulation containing the compounds of the present invention and one or more additional therapeutic agents, as well as administration of the compounds of the present invention and each additional therapeutic agent in separate pharmaceutical formulations. For example, the compounds of the present invention and the therapeutic agents can be administered to a patient together in a single oral dosage composition such as a tablet or capsule, or each agent can be administered in a separate oral dosage formulation.

[0218] For the treatment of the above-mentioned conditions, the compounds of the present invention may be advantageously used in combination with one or more other drugs, more particularly with other anti-cancer drugs or adjuvants in cancer therapy. Examples of anti-cancer drugs or adjuvants (auxiliary drugs in treatment) include, but are not limited to: - platinum coordination compounds, such as cisplatin, optionally in combination with amifostine, carboplatin or oxaliplatin; - taxane compounds, such as paclitaxel, paclitaxel protein-bound particles (Abraxane™) or docetaxel; - topoisomerase I inhibitors such as camptothecin compounds, for example, irinotecan, SN-38, topotecan, topotecan hcl; topoisomerase II inhibitors, such as antitumor epipodophyllotoxins or podophyllotoxin derivatives, for example etoposide, etoposide phosphate or teniposide; - antitumor vinca alkaloids, such as vinblastine, vincristine or vinorelbine; - antitumor nucleoside derivatives, such as 5-fluorouracil, leucovorin, gemcitabine, gemcitabine hcl, capecitabine, cladribine, fludarabine, nelarabine; - alkylating agents such as nitrogen mustards or nitrosoureas, for example cyclophosphamide, chlorambucil, carmustine, thiotepa, mephalan (melphalan), lomustine, altretamine, busulfan, dacarbazine, estramustine, ifosfamide, optionally in combination with mesna, pipobroman, procarbazine, streptozocin, temozolomide, uracil; - antitumor anthracycline derivatives, such as daunorubicin, doxorubicin, optionally in combination with dexrazoxane, doxil, idarubicin, mitoxantrone, epirubicin, epirubicin hcl, valrubicin; - Molecules that target the IGF-1 receptor, such as picropodophyllin; - Tetrocarcin derivatives, such as tetrocarcin A; - glucocorticoids, such as prednisone or prednisolone; - antibodies, such as trastuzumab (HER2 antibody), rituximab (CD20 antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab, pertuzumab, bevacizumab, alemtuzumab, eculizumab, ibritumomab tiuxetan, nofetumomab, panitumumab, tositumomab, CNTO328; - estrogen receptor antagonists or selective estrogen receptor modulators or inhibitors of estrogen synthesis, such as tamoxifen, fulvestrant, toremifene, droloxifene, faslodex, raloxifene or letrozole; - Aromatase inhibitors such as exemestane, anastrozole, letrazole, testolactone and vorozole; - differentiation agents such as retinoids, vitamin D or retinoic acid and retinoic acid metabolism blockers (RAMBA), for example Accutane; - DNA methyltransferase inhibitors, such as azacitidine or decitabine; - Antifolates, e.g. pemetrexed disodium; - antibiotics, such as antinomycin D, bleomycin, mitomycin C, dactinomycin, carminomycin, daunomycin, levamisole, plicamycin, mithramycin; - antimetabolites, such as clofarabine, aminopterin, cytosine arabinoside or methotrexate, azacitidine, cytarabine, floxuridine, pentostatin, thioguanine; - apoptosis inducers such as Bcl-2 inhibitors and antiangiogenic agents, for example YC137, BH312, venetoclax, ABT737, gossypol, HA14-1, TW37 or decanoic acid; - tubulin-binding agents, such as combrestatin, colchicine or nocodazole; - Kinase inhibitors (e.g. EGFR (epidermal growth factor receptor) inhibitors, MTKI (multi-targeted kinase inhibitors), mTOR inhibitors), such as flaboperidol, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, lapatinib ditosylate, sorafenib, sunitinib, sunitinib malate, temsirolimus; - Farnesyltransferase inhibitors, e.g. tipifarnib; - histone deacetylase (HDAC) inhibitors, such as sodium butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide (FR901228), NVP-LAQ824, R306465, quisinostat, trichostantin A, vorinostat; - inhibitors of the ubiquitin-proteasome pathway, such as PS-341, Velcade (MLN-341) or bortezomib; - Yondelis; - telomerase inhibitors, such as telomestatin; - matrix metalloproteinase inhibitors, such as batimastat, marimastat, prinostat or metastat; - recombinant interleukins, such as aldesleukin, denileukin diftitox, interferon alfa-2a, interferon alfa-2b, pegylated interferon alfa-2b; - MAPK inhibitors; - Retinoids, such as aletretinoin, bexarotene, tretinoin; - arsenic trioxide; - Asparaginase; - steroids, such as dromostanolone propionate, megastrol acetate, nandrolone (decanoate, fenpropionate), dexamethasone; - gonadotropin-releasing hormone agonists or antagonists, such as abarelix, goserelin acetate, histrelin acetate, leuprolide acetate; - thalidomide, lenalidomide; - mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase, rasburicase; - BH3 mimetics, e.g. ABT-199; - MEK inhibitors, e.g. PD98059, AZD6244, CI-1040; - Colony-stimulating factor analogues, such as filgrastim, pegfilgrastim, sargramostim; erythropoietin or its analogues (e.g., darbepoetin alfa); interleukin-11; oprelvekin; zoledronate, zoledronic acid; fentanyl; bisphosphonates; palifermin; - steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitors (CYP17), for example, abiraterone, abiraterone acetate; - mTOR inhibitors and mTOR kinase inhibitors such as rapamycin and rapalogs; - PI3K inhibitors, dual mTOR / PI3K inhibitors, PI3K delta inhibitors, such as idelalisib and duvelisib; - BTK inhibitors, e.g., ibrutinib, ONO-4059, ACP-196; - R-CHOP (Rituxan added to CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisolone); - Daratumumab.

[0219] Thus, one embodiment of the present invention relates to a product comprising a compound according to the invention as a first active ingredient and one or more anti-cancer agents as further active ingredients as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.

[0220] One or more other drugs and the compound of the present invention can be administered simultaneously (e.g., in separate compositions or a unitary composition) or sequentially in any order. In the latter case, the two or more compounds are administered within a period, in amounts, and in a manner sufficient to ensure a beneficial or synergistic effect. It will be understood that the preferred method and order of administration, as well as the respective dosages and administration regimens of each combined component, will vary depending on the specific other drug and compound of the present invention administered, their administration routes, the specific tumor being treated, and the specific host being treated. Those skilled in the art can easily determine the optimal method and order of administration, as well as the dosages and administration regimens, using conventional methods and in light of the information provided herein.

[0221] When administered in combination, one skilled in the art can determine the weight ratio of the compound of the present invention to one or more other anticancer agents. This ratio, as well as the exact dosage and frequency of administration, will depend, as is well known to those skilled in the art, on the specific compound of the present invention and other anticancer agents used, the specific condition being treated, the severity of the condition being treated, the age, weight, sex, diet, time of administration, and general health of the particular patient, the mode of administration, and other pharmaceutical agents the individual may be taking. Furthermore, it will be apparent that the effective daily dose may be decreased or increased depending on the response of the treated subject and / or the evaluation of the physician prescribing the compound of the present invention. Specific weight ratios of the compound of Formula (I) to another anticancer agent may range from 1 / 10 to 10 / 1, more particularly from 1 / 5 to 5 / 1, and even more particularly from 1 / 3 to 3 / 1. [Example]

[0222] The following examples are provided for illustrative purposes and are not intended to limit the scope of the claims provided herein. All literature citations in these examples and throughout this specification are incorporated herein by reference for all legal purposes served thereby. The starting materials and reagents used in the synthesis of the compounds described herein can be synthesized or obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Acros Organics, Fluka, and Fischer Scientific.

[0223] When a stereocenter is designated "RS," this means that a racemic mixture was obtained.

[0224] For intermediates that can be used as crude or partially purified intermediates in the next reaction step, the theoretical molar amounts are given in the reaction protocols described below.

[0225] In the following, "DCM" and "CH2Cl2" mean dichloromethane, "rt" means room temperature, "Boc" means tert-butoxycarbonyl, "CH3CN" and "ACN" mean acetonitrile, "MeOH" means methanol, "EtOH" means ethanol, "iPrOH" means isopropanol, "DMF" means dimethylformamide, "iPrNH2" means isopropylamine, "SOCl2" means thionyl chloride, "Et3N" means triethylamine, "NH4OAc" means ammonium acetate, "NH4OH" means ammonium hydroxide, "NH4Cl" means ammonium chloride, "NaBH(OAc)3" means sodium triacetoxyborohydride, "POCl3" means phosphorus oxychloride, "RuPhos Pd "G3" means (2-dicyclohexylphosphino-2,6-diisopropoxy-1,1-biphenyl)(2-(2'-amino-1,1-biphenyl))palladium(II) methanesulfonate, "Na2CO3" means sodium carbonate, "KHSO4" means potassium hydrogen sulfate, "HBTU" means 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, "EA" means ethylamine, and "NH4HCO3" means ammonium bicarbonate. "TFA" means trifluoroacetic acid, "THF" means tetrahydrofuran, "h" means time, "RM" means reaction mixture, "SFC" means supercritical fluid chromatography, "Bredereck's reagent" means tert-butoxybis(dimethylamino)methane, "AcOEt" means acetate, "K2CO3" means potassium carbonate, "MgSO4" means magnesium sulfate, and "Boc2O" means di-tert-butyldecanoate.

[0226] Example A: Preparation and characterization of intermediate and final compounds Synthesis of intermediate 1: [ka] To a solution of 1-boc-2-methyl-piperidin-5-one (37 g, 0.173 mol) in toluene (370 mL) was slowly added Bredereck's reagent (43 mL, 0.208 mol) at room temperature. The reaction was stirred for 15 hours. The mixture was evaporated to dryness, and the residue was used for the next step without purification.

[0227] Synthesis of intermediate 2: [ka] To a mixture of intermediate 1 (46.6 g, 173.6 mmol) and 2-methyl-2-thiopseudourea hemisulfate (48.3 g, 347.3 mmol) in EtOH (340 mL) at room temperature, sodium ethoxide (150 mL, 382.6 mmol) was added slowly. The reaction was heated at 90 °C for 8 h. The reaction mixture was cooled to room temperature, poured into HO and NaCl, and extracted with AcOEt. The organic layer was dried over MgSO, filtered, and evaporated to dryness. The residue was purified by flash chromatography (dry load: DCM / MeOH gradient from 100:0 to 98:2). Pure fractions were collected and evaporated to give intermediate 2 (18.1 g, 35%).

[0228] Synthesis of intermediates 3a and 3b: [ka] Metachloroperbenzoic acid (17.5 g, 71 mmol) was added portionwise to a solution of Intermediate 2 (7.1 g, 24 mmol) in DCM (120 mL) at 5 °C. The reaction was stirred for 2 h. HO was added, the mixture was basified with KCO, and after stirring for 1 h, the organic layer was extracted, dried over MgSO, filtered, evaporated, and the residue purified by flash chromatography (DCM / MeOH / NHOH gradient from 100:0:0 to 95:5:0:2). Pure fractions were collected and evaporated to give 5.68 g (72%) of both enantiomers.

[0229] Both enantiomers were separated by chiral SFC (stationary phase: Chiralpak IG 5 μm 250*20 mm, mobile phase: 70% CO2, 30% EtOH / iPrOH 50 / 50 v / v mixture) to give intermediate 3b (2.48 g, 31%, enantiomer (S), [α] d : -70.2°C (589 nm, c 0.32 w / v%, DMF, 20°C) and intermediate 3a (2.72 g, 34%, enantiomer (R), [α] d : +77.3° (589 nm, c 0.22 w / v%, DMF, 20°C).

[0230] Synthesis of intermediate 4: [ka] (1-Methyl-1H-pyrazol-3-yl)methylamine (5 g, 45 mmol) in a sealed tube was heated to 100 °C, then Intermediate 3a (1.8 g, 5.5 mmol) was added and the mixture was heated at 110 °C for 5 h. The residue was purified by flash chromatography (DCM / MeOH / NH4OH gradient from 100:0:0 to 95:5:0.2) without workup to give Intermediate 4 (1.87 g, 83%).

[0231] Synthesis of intermediate 5: [ka] To a solution of intermediate 4 (7.18 g, 20 mmol) in dichloromethane (110 mL) at room temperature was slowly added trifluoroacetic acid (15 mL, 0.196 mol). The reaction was stirred for 15 hours. H2O was added and the mixture was basified with K2CO3. The organic layer was extracted, dried over MgSO4, filtered, and evaporated to dryness to give intermediate 5 (5.2 g, 100%).

[0232] Synthesis of intermediate 6: [ka] NaH (16.3 g, 407.2 mmol) was slowly added to MeOH (300 mL) at room temperature under N. The mixture was stirred at room temperature for 10 minutes. Then, 4-piperidinecarboxylic acid, 1-methyl-3-phenyl-methyl ester (95 g, 407.2 mmol) in MeOH (500 mL) was added, and the mixture was stirred at 80 °C under a nitrogen atmosphere for 16 hours. MeOH was removed in vacuo. Aqueous KCO was added, the mixture was extracted with DCM, and the organic layer was dried over MgSO, filtered, and evaporated to dryness to give intermediate 6 (88 g, 93%).

[0233] Synthesis of intermediates 7a and 7b: [ka] Intermediate 6 (74.7 g, 320.3 mmol) was purified by chiral SFC (stationary phase: CHIRALPAK IC 5 μm 250*30 mm, mobile phase: 94% CO , 6% iPOH (0.6% iPrNH )) to give Intermediate 7b (36.3 g, 48.5%) and Intermediate 7a (32.1 g, 42.9%).

[0234] Synthesis of intermediate 8: [ka] Intermediate 7a (32 g, 0.137 mol) in HCl 6M (470 ml) was heated at 100° C. in a sealed tube overnight. The reaction mixture was evaporated, taken up in toluene three times, dried and gave intermediate 8 (30 g, 100%, [α] d : +56° (589 nm, c 0.55 w / v%, DMF, 20°C).

[0235] Synthesis of intermediate 9: [ka] HCl 4M in dioxane (38 mL, 152 mmol) was added dropwise to a solution of intermediate 3a (5 g, 15.3 mmol) in dioxane (50 mL) at room temperature. The reaction mixture was stirred for 8 h. The mixture was evaporated to dryness. The residue was taken up in HO, KCO and DCM. The organic layer was extracted, dried over MgSO, filtered and evaporated to dryness to give intermediate 9 (3.4 g, 98%).

[0236] Synthesis of intermediate 10: [ka] Intermediate 8 (5.4 g, 21.1 mmol) in SOCl (108 mL, 1.64 g / mL, 1489 mmol) was stirred at 80 °C for 3 h and cooled to room temperature. The solvent was removed and the compound was placed under a N atmosphere and used without further purification.

[0237] Synthesis of intermediate 11: [ka] Intermediate 10 (5.7 g, 21.12 mmol) in DCM (45 mL) was added dropwise at rt to a stirred solution of intermediate 9 (4 g, 17.6 mmol) and EtN (9 mL, 65.12 mmol) in DCM (92 mL). The reaction mixture was stirred at rt for 2 h, water was added, and the organic layer was extracted with DCM (2 times), dried over MgSO, filtered, and evaporated to dryness. The residue was purified by flash chromatography (100:0:0 to 88:12:0.2 DCM / MeOH / NHOH gradient). Pure fractions were collected and evaporated. The residue was purified by flash chromatography (60:40 to 70:30 heptane / AcOEt gradient). Pure fractions were collected and evaporated to give intermediate compound 10 (5 g, 66%).

[0238] Synthesis of intermediate 12: [ka] To a solution of pentanoic acid, 4-[[(1R)-1-phenylethyl]amino]-, ethyl ester (70 g, 0.28 mol) and NaBH(OAc) (116.2 g, 0.83 mol) in DCM (1 L) was added ethyl glyoxylate 50% in toluene (116 mL, 0.55 mol) at rt. The resulting mixture was stirred at rt for 24 h. Ethyl glyoxylate 50% in toluene (59 mL, 0.28 mol) and then NaBH(OAc) (60 g, 0.283 mol) were added again, and the reaction mixture was stirred for 20 h and 2 days. The mixture was poured into a saturated aqueous solution of NaHCO. The organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. The residue was purified by flash chromatography (90:10 to 60:40 heptane / AcOEt gradient) to give intermediate 12 (59.2 g, 62%).

[0239] Synthesis of intermediate 13: [ka] The reaction was carried out in two batches in parallel.

[0240] To a solution of intermediate 12 (29.6 g; 0.088 mol) in toluene (300 mL) at room temperature was added potassium tert-butylate (22.5 g; 0.2 mol) in several portions. The reaction was stirred for 8 h, poured into HO + NH4Cl, and extracted with AcOEt. The organic layer was dried over MgSO4, filtered, and evaporated. The residue was purified by flash chromatography (100:0 to 95:5 heptane / AcOEt gradient). Collected fractions were evaporated to dryness to give intermediate 13 (23.1 g, 45%) and a mixture of two diastereoisomers (3.6 g, 22:78 (R,R):(R,S)).

[0241] Synthesis of intermediate 14: [ka] To a solution of intermediate 13 (23 g, 79.5 mmol), urea (19 g, 316 mmol) in MeOH at room temperature, sodium methoxide (29.5 mL, 160 mmol) was added slowly. The reaction was stirred and refluxed for 23 h, then heated again at 120 °C for 2 h. MeOH was evaporated, and the residue was taken up with a minimum volume of HO. The pH was adjusted to around 8 with HCl 3 M, then 1 M. The precipitate was filtered, washed with HO, and dried to give intermediate 14 (19.4 g, 85%).

[0242] Synthesis of intermediate 15: [ka] A mixture of intermediate 14 (17.4 g, 61 mmol) in POCl3 (200 mL) was heated to 100 °C for 15 h and then cooled to room temperature. POCl3 was evaporated to dryness, and the crude mixture was taken up in DCM and poured into ice and water under stirring (temperature control below 40 °C). The organic layer was decanted, dried over MgSO4, filtered, and the solvent was evaporated to dryness. This mixture was purified by flash chromatography (DCM / MeOH gradient from 100:0 to 90:10). The fractions were collected and evaporated to dryness to give intermediate 15 (21.9 g, 100%).

[0243] Synthesis of intermediate 16: [ka] Intermediate 15 (21 g, 65.2 mmol), activated Zn (34.3 g, 0.524 mol), and NH (28% in HO) (21 mL, 0.333 mol) were stirred in a round flask in EtOH (400 mL). The mixture was heated to reflux for 15 h, cooled to room temperature, and filtered. The insoluble material was washed with DCM, and the filtrate was evaporated to dryness, poured into NH Cl + HO, and extracted with DCM. The organic layer was dried over MgSO, filtered, and evaporated to dryness. The residue was purified by flash chromatography (100:0 to 95:5 DCM / MeOH gradient). The fractions were collected and evaporated to give Intermediate 16 (11.1 g, 59%).

[0244] Synthesis of intermediate 17: [ka] In a sealed vessel under N2, 1-methyl-1H-pyrazol-4-amine (1.2 g, 12.4 mmol) was added to a mixture of Intermediate 16 (2.5 g, 8.7 mmol), RuPhos Pd G3 (371 mg, 0.44 mmol), and sodium tert-butoxide (2.1 g, 21.9 mmol) in toluene (110 mL). The reaction was degassed under N2 for 5 minutes. The reaction mixture was stirred at 120 °C for 2 hours. The mixture was poured into water and EtOAc, and the organic layer was separated, dried over MgSO4, filtered, and evaporated. Purification was carried out by flash chromatography (100:0:0 to 95:5:0.2 DCM / MeOH / NH4OH gradient) to give Intermediate 17 (2.54 g, 84%).

[0245] Synthesis of intermediate 18: [ka] Intermediate 17 (2.54 g, 7.3 mmol) was hydrogenated in MeOH (110 mL) at room temperature using Pd / C (2 g, 1.9 mmol) as a catalyst for 18 hours at atmospheric pressure. The catalyst was filtered off through a pad of Celite®. The Celite® was washed twice with MeOH. The filtrate was evaporated to give Intermediate 18 (1.73 g, 97%), which was used directly in the next step.

[0246] Synthesis of intermediate 19: [ka] Trifluoromethanesulfonic anhydride (13.6 mL, 81.1 mmol) was added to a solution of ethyl 1-Boc-3-oxypiperidine-4-carboxylate (20 g, 73.7 mmol) and diisopropylethylamine (19.3 mL, 110.6 mmol) in 180 mL of toluene at 0° C. The mixture was stirred at 0° C. for 16 h. Water was added and the mixture was extracted with AcOEt. The organic layer was separated, dried over MgSO4, filtered and evaporated to give intermediate 19 (32.8 g, 81.3 mmol, >100%), which was used without further purification.

[0247] Synthesis of intermediate 20: [ka] Intermediate 19 (4.4 g, 9.9 mmol), bis(triphenylphosphine)palladium(II) dichloride (696 mg, 1 mmol), 4-fluorophenylboronic acid, pinacol ester (3.3 g, 14.9 mmol), and 1M sodium carbonate (19.8 mL, 19.8 mmol) were added to dioxane (100 mL). N was bubbled through the mixture for 15 min, and then it was heated at 80 °C for 2 h. The mixture was filtered through a short pad of Celite. HO and AcOEt were added, and the organic layer was washed with brine, dried over MgSO, and evaporated. The crude product was purified by flash column chromatography (silica gel, AcOEt / heptane, 0 / 100 to 40 / 60). The desired fractions were collected, evaporated in vacuo, and dried under high vacuum to give Intermediate 20 (3 g, 87%) as a yellow oil.

[0248] Synthesis of intermediate 21: [ka] Intermediate 20 (3.1 g, 8.4 mmol) was added to MeOH. 10% Pd / C (540 mg, 5 mmol) was added, and the reaction vessel was connected to a hydrogen-filled balloon. The mixture was stirred under a hydrogen atmosphere at room temperature overnight. The mixture was filtered through a Celite pad, and the cake was washed with MeOH (5 × 10 mL) and concentrated to dryness to give Intermediate 21 (3 g, 93%). This product was used directly in the next step.

[0249] Synthesis of intermediate 22: [ka] To a solution of intermediate 21 in 60 mL of EtOH under a N2 atmosphere was added sodium ethylate (3.4 mL, 9 mmol). The reaction mixture was heated under reflux for 3 h. The reaction mixture was poured into aqueous ammonium chloride solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography on silica gel using the eluent heptane / AcOEt (0:100 to 50:50) to give intermediate 22 (2 g, 59%).

[0250] Synthesis of intermediate 23: [ka] Trifluoroacetic acid (4.3 mL, 56 mmol) was added to a solution of intermediate 22 (2 g, 5.6 mmol) in DCM (60 mL). The mixture was stirred overnight and concentrated to dryness. The crude mixture was washed twice with toluene and concentrated to dryness. 1 M Na2CO3 (15 mL) and DCM (75 mL) were added. The organic layer was separated and the aqueous phase was extracted once more with DCM. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. Intermediate 23 was used directly in the next step (1.3 g, 95%).

[0251] Synthesis of intermediate 24: [ka] Intermediate 23 was dissolved in THF (15 mL) and treated with 37% aqueous formaldehyde (0.3 mL, 4 mmol) at room temperature. Sodium triacetoxyborohydride (0.8 g, 4 mmol) was then added after 15 min. The reaction mixture was stirred overnight. Na2CO3 was added, and the mixture was extracted with DCM (2 x 50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated. The crude mixture was purified by chromatography on silica gel (25 g column, gradient of MeOH in DCM 100:0 to 0:100) to give Intermediate 24 (0.42 g, 80%).

[0252] Synthesis of intermediate 25: [ka] Intermediate 24, HCl 6M (0.7 mL, 1.6 mmol) and HO (2 mL) were stirred under reflux overnight. The mixture was dried under high vacuum at room temperature and used directly in the next synthetic step (438 mg, 1.6 mmol, 100%).

[0253] Synthesis of intermediates 26a and 26b: [ka] 1-(Tetrahydro-2H-pyran-4-yl)guanidine (22 g, 153.6 mmol) and Intermediate 1 (31.4 g, 117 mmol) were added to EtOH (500 mL). Sodium ethoxide (100 mL, 255.7 mmol) was added, and the resulting mixture was heated at 50° C. for 5.5 h. The solution was partially evaporated, and the residue was poured into HO+DCM. The organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. The residue was purified by preparative LC (SiOH 35-40 μm Buchi, gradient from 100% DCM to 90% DCM, 10% CHOH). The fractions were collected and evaporated to dryness, yielding 30.6 g. Purification was carried out by chiral SFC (stationary phase: CHIRALPAK AD-H 5 μm 250*30 mm, mobile phase: 65% CO2, 35% EtOH) to obtain intermediate 26a (13 g, 32%, [α] d : +99.3° (589 nm, c 0.45 w / v%, DMF, 20°C)) and intermediate 26b (13.1 g, 32%, [α] d : -101.6° (589 nm, c 0.43 w / v%, DMF, 20°C)).

[0254] Synthesis of intermediate 27: [ka] HCl 4M in dioxane (91 mL, 364 mmol) was added to a solution of intermediate 26a (13 g, 37.3 mmol) in dioxane (145 mL) and MeOH (45 mL) at room temperature. The reaction was stirred for 15 h. The solvent was evaporated to dryness and the residue was taken up in DCM + HO + KCO. The organic layer was extracted, dried over MgSO, filtered and evaporated. The residue was purified by preparative LC (80 g SiOH 35-40 μm Buchi, gradient from 100% DCM to 80% DCM 20% CHOH 0.2% NHOH). The fractions were collected and evaporated to dryness to give intermediate 27 (8.2 g, 88%).

[0255] Synthesis of intermediate 28: [ka] Intermediate 28 was prepared by the same procedure as intermediate 22, substituting 3-fluoro-4-chlorophenylboronic acid, pinacol ester for 4-fluorophenylboronic acid, pinacol ester.

[0256] Synthesis of intermediate 29: [ka] To a solution of intermediate 28 (3.8 g, 9.8 mmol) in MeOH (50 mL) was added 1 M sodium hydroxide (19.5 mL, 19.5 mmol). The mixture was stirred overnight at room temperature for 24 hours. The pH was adjusted to 2-3 with 1 M KHSO, and the mixture was concentrated to dryness. The product (solid) was used directly in the next step (1.6 g, 47%).

[0257] Synthesis of intermediate 30: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.9 g, 2.4 mmol) was added to a solution of Intermediate 29 (0.9 g, 2.6 mmol), Intermediate 27 (0.5 g, 2 mmol), and diisopropylethylamine (0.7 mL, 4 mmol) in DMF (20 mL). The reaction was stirred overnight at room temperature for 8 hours. Na2CO3 (50 mL, 1 M) was added, and the reaction was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered, and concentrated to give the crude product. Chromatography on silica gel (DCM / MeOH 100:0 to 0:100) gave Intermediate 30 (1.2 g, 98%).

[0258] Synthesis of intermediate 31: [ka] Trifluoroacetic acid (4.7 mL, 61.6 mmol) was added to a solution of intermediate 30 (1.2 g, 1.9 mmol) in DCM (20 mL) at room temperature. The mixture was stirred for 4 h. The solvent was then evaporated in vacuo. The crude mixture was added to DCM (20 mL) and the solution was washed with 1 M Na2CO3 (30 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude mixture was purified by chromatography on silica gel (DCM / MeOH / NH4OH, 9.0 / 0.9 / 0.1, v / v / v gradient 0 to 100% in DCM) to give intermediate 31 (0.6 g, 67%) as a colorless oil.

[0259] Synthesis of intermediates 32a and 32b: [ka] The same procedure as for intermediate 22 was used, substituting 3-fluorophenylboronic acid, pinacol ester for 4-fluorophenylboronic acid, pinacol ester. Both trans enantiomers were purified by chiral SFC (stationary phase: CHIRACEL OJ-H 5 μm 250*30 mm, mobile phase: 88% CO , 12% MeOH) to give intermediate 32a (0.59 g, 21%, [α] d : +9° (589 nm, c 0.468 w / v%, DMF, 20 ° C) and intermediate 32b (0.61 g, 22%, [α] d :-8° (589 nm, c 0.98 w / v%, DMF, 20°C) was obtained.

[0260] Synthesis of intermediate 33: [ka] Intermediate 32b (613 mg, 1.8 mmol) and lithium hydroxide monohydrate (404 mg, 9.6 mmol) in THF / HO (50 / 50) (10 mL) were stirred at rt over the weekend. HCl 3M (3.2 mL, 9.6 mmol) was added and the reaction mixture was extracted. The organic layer was separated, dried over MgSO, filtered, and evaporated to give Intermediate 33 (423 mg, 72%).

[0261] Synthesis of intermediate 34: [ka] Intermediate 27 (200 mg, 0.8 mmol), Intermediate 33 (434 mg, 1.2 mmol), HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (610 mg, 1.6 mmol), and diisopropylamine (0.8 mL, 4.8 mmol) in DMF (15 mL) were stirred overnight at rt. HO and DCM were added, the reaction mixture was extracted, and the organic layer was separated, dried over MgSO, filtered, and evaporated. Purification was carried out by preparative LC (stationary phase: irregular SiOH 40 μm 25 g, mobile phase: 98 / 2 to 90 / 10 / 0.1 DCM / MeOH / NHOH) to give 450 mg (100%) of Intermediate 34.

[0262] Synthesis of intermediate 35: [ka] Intermediate 34 (380 mg, 0.81 mmol) and trifluoroacetic acid (0.93 mL, 12.2 mmol) were stirred in DCM (10 mL) at rt for 8 h. Trifluoroacetic acid was evaporated. H2O, DCM, and K2CO3 were added, the reaction mixture was extracted, and the organic layer was separated, dried over MgSO4, filtered, and evaporated to give Intermediate 35 (0.5 g, 95%).

[0263] Synthesis of intermediate 36: [ka] Intermediate 36 (3.49 g, 89%) was prepared in a similar manner to Intermediate 29.

[0264] Synthesis of intermediates 37a and 37b: [ka] A mixture of Intermediate 36 (1.54 g, 4.8 mmol), Intermediate 27 (1 g, 4 mmol), and diisopropylethylamine (1.37 mL, 8.05 mmol) was added to DMF (40 mL). HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.8 g, 4.8 mmol) was added at room temperature. The reaction mixture was stirred overnight. AcOEt (200 mL) and 1 M Na2CO3 (100 mL) were added. The aqueous phase was extracted once more with AcOEt (50 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered, and evaporated to dryness. The crude mixture was purified by silica gel chromatography (0-5% MeOH in DCM gradient) to give an amorphous solid. Separation of the diastereoisomers was achieved by reverse phase: Method MMP5-AC-ACN: 28-64% gradient of ACN in 65 mM NH4OAc in water / ACN 9 / 1. The two diastereoisomers were collected separately. The pH of both fractions was raised to 8 with 1 M Na2CO3. Intermediates 37a and 37b were extracted with DCM (3 times). The organic layer was dried over MgSO4, filtered, and concentrated to a white amorphous solid; intermediate 37a (1.02 g, 46%) and intermediate 37b (0.65 g, 29%) were obtained.

[0265] Synthesis of intermediate 38: [ka] TFA (3.04 g, 39.4 mmol) was added to a solution of intermediate 37b (652 mg, 1.2 mmol) in DCM (20 mL) at room temperature. The mixture was stirred for 4 h. The reaction mixture was concentrated to dryness. The crude mixture was taken up in DCM (100 mL) and a solution of 1 M Na2CO3 (50 mL) was added. The organic layer was dried over MgSO4, filtered, and concentrated to a crude sticky solid. Flash chromatography on silica gel (DCM / MeOH / NH4OH, 9.0 / 0.9 / 0.1 gradient 0-100% in DCM) afforded intermediate 38 (552 mg, 94%) as an amorphous white solid.

[0266] Synthesis of intermediate 39: [ka] Intermediate 19 (10 g, 25 mmol), bis(pinacolato)diboron (9.5 g, 37.5 mmol), Pd(dppf)Cl2·CHCl2 (0.6 g, 0.75 mmol), and potassium acetate (7.3 g, 75 mmol) were suspended in dioxane (100 mL). The mixture was degassed by bubbling nitrogen through it for 15 minutes and heated at 90 °C for 5 hours. The reaction mixture was allowed to cool to room temperature. Water (50 mL) and AcOEt (50 mL) were added. The organic layer was separated. The aqueous phase was extracted once more with AcOEt (25 mL). The combined organic layers were washed with saturated NaCl (25 mL), dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica gel; AcOEt in heptane 0 / 100 to 50 / 50) to give an oil (7.5 g, 79%) which was used directly in the next step.

[0267] Synthesis of intermediate 40: [ka] Intermediate 39 (7.5 g, 16.7 mmol), 3-bromophenyl isopropyl ether (2 mL, 12.4 mmol), bis(triphenylphosphine)palladium(II) dichloride (0.4 g, 0.6 mmol), and 1M sodium carbonate (18.5 mL, 18.5 mmol) were taken up in dioxane (50 mL). The mixture was bubbled with N for 15 min and heated at 100 °C for 2 h. The mixture was filtered through a short pad of Celite. HO and AcOEt were added, and the organic layer was washed with brine, dried over MgSO, and evaporated. The residue was purified by flash column chromatography (silica gel; eluent: AcOEt in heptane 0 / 100 to 25 / 75). The product was obtained as an oil (3.9 g, 71%).

[0268] Synthesis of intermediate 41: [ka] Intermediate 40 (7.9 g, 20.2 mmol) was taken up in MeOH (80 mL) and cooled in an ice bath under a stream of nitrogen. 10% Pd / C (0.9 g, 8.3 mmol) was added and the reaction vessel was connected to a balloon filled with H. The mixture was stirred overnight at room temperature under an atmosphere of H. The mixture was filtered through a pad of Celite, and the cake was washed with MeOH (5 x 30 mL) and concentrated to dryness. Intermediate 41 (oil) was used directly in the next step (7.2 g, 91%).

[0269] Synthesis of intermediate 42: [ka] To a solution of intermediate 41 (7.2 g, 18.5 mmol) in EtOH (25 mL) under N2 atmosphere was added sodium ethylate (7.2 mL, 19.4 mmol). The reaction mixture was heated to reflux overnight. HO and DCM were added, and the organic layer was separated, dried over MgSO4, filtered, and concentrated to dryness. The aqueous layer was acidified with 1 M KHSO4 to pH = 5-6. AcOEt was added, and the organic layer was separated, dried over MgSO4, filtered, and concentrated to dryness to give intermediate 42 (0.9 g, 13%).

[0270] Synthesis of intermediate 43: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.7 g, 1.9 mmol) was added to a solution of intermediate 42 (0.7 g, 1.9 mmol), intermediate 5 (0.4 g, 1.6 mmol), and diisopropylethylamine (0.8 mL, 4.8 mmol) in DMF (20 mL). The reaction was stirred at room temperature for 2 days. 1 M Na2CO3 (20 mL) and AcOEt (50 mL) were added. The layers were separated. The combined organic layer was dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica gel; eluent: DCM / MeOH (9:1) 0 / 100 to 100 / 0). The desired fractions were collected and concentrated in vacuo to give intermediate 43 (0.3 g, 33%).

[0271] Synthesis of intermediate 44: [ka] Trifluoroacetic acid (0.4 mL, 5.4 mmol) was added to a solution of intermediate 43 (0.3 g, 0.5 mmol) in DCM (15 mL). The mixture was stirred overnight and concentrated to dryness. The crude mixture was washed twice with toluene and concentrated to dryness; neutralized with 1 M Na2CO3. The mixture was extracted with DCM, and the organic layer was dried over MgSO4, filtered, and concentrated to dryness. Intermediate 44 was used directly in the next step (0.2 g, 88%).

[0272] Synthesis of intermediate 45: [ka] A solution of 4-pyridinecarboxylic acid, 2-chloro-5-(trifluoromethyl)-, ethyl ester (9.6 g, 37.8 mmol) in MeOH (150 mL) was treated with 37% HCl (0.3 mL, 3.8 mmol). To this mixture was added 10% Pd / C (4 g, 3.7 mmol), and the resulting suspension was stirred under 100 psi of hydrogen at 50° C. for 20 hours. The catalyst was filtered through a pad of Celite. The filtrate was concentrated to give Intermediate 45 as a white solid (9.6 g, 100%).

[0273] Synthesis of intermediate 46: [ka] Intermediate 45 (4.4 g, 19.6 mmol) was taken up in THF (50 mL) and treated with aqueous formaldehyde 37% (2.2 mL, 29.4 mmol) at room temperature. After 15 min, sodium triacetoxyborohydride (6.2 g, 29.4 mmol) was added. The reaction was continued for 2 h. The reaction mixture was diluted with DCM (150 mL) and washed with 1 M Na2CO3 (150 mL). The aqueous phase was extracted once more with DCM (100 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated. Chromatography on silica gel (80 g column, 0-100 gradient of AcOEt in heptane) gave Intermediate 46 (2.9 g, 62%).

[0274] Synthesis of intermediate 47: [ka] To a solution of intermediate 46 (2.2 g, 9.4 mmol) in 100 mL of EtOH under a N atmosphere was added sodium ethylate (3.7 g, 9.8 mmol). The reaction mixture was heated to reflux overnight. Water was added, and the organic layer was separated, dried over MgSO, filtered, and concentrated to dryness to give intermediate 47 (1.4 g, 63%). This product was used directly in the next step.

[0275] Synthesis of intermediate 48: [ka] HCl 6M (3 mL, 6.7 mmol) was added to a solution of intermediate 47 (0.8 g, 3.3 mmol) and water (2 mL). The mixture was stirred at 110° C. overnight and concentrated to dryness. The product was used directly in the next step.

[0276] Synthesis of intermediates 49a and 49b: [ka] 1,2-Piperidinedicarboxylic acid, 5-hydroxy-, 1-(1,1-dimethylethyl) 2-ethyl ester (2.2 g, 8.3 mmol) and triethylamine (2.9 mL, 20.8 mmol) were dissolved in DCM (25 mL) and cooled to 0 °C under a nitrogen atmosphere. Methanesulfonyl chloride (0.7 mL, 8.7 mmol) was added. The reaction mixture was allowed to warm to room temperature and stirred for an additional 1.5 h. The reaction mixture was diluted with DCM (20 mL) and washed with water (10 mL). The phases were separated, and the aqueous layer was extracted once more with DCM (10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica gel; eluent: AcOEt in heptane 0 / 100 to 100 / 0). Product fractions containing 49a and 49b were collected and concentrated in vacuo. Intermediate 49a was obtained purely by reverse-phase chromatography [start (70% HO-30% CHCN-CHOH)-finish (27% HO-73% CHCN-CHOH)]-[HO:25 mM NHHCO] (1.61 g, 55%). Intermediate 49b was obtained purely by reverse-phase chromatography [start (70% HO-30% CHCN-CHOH)-finish (27% HO-73% CHCN-CHOH)]-[HO:25 mM NHHCO] (0.35 g, 12%).

[0277] Synthesis of intermediate 50: [ka] Intermediate 49a (1.6 g, 4.1 mmol) and DMF (4 mL) were added to a sealed tube. Dimethylamine solution (8.5 mL, 62.2 mmol) was added. The mixture was heated at 70 °C for 60 h. After concentration in vacuo, the residue was purified by flash column chromatography (silica gel; CHCl / CHOH, 9 / 1, v / v 0 / 100 to 100 / 0 in CHCl). The desired fractions were collected and concentrated in vacuo. Intermediate 50 was obtained pure (0.4 g, 31%) by reverse-phase chromatography [start (95% HO - 5% CHCN-CHOH) - end (63% HO - 37% CHCN-CHOH)] - [HO: 0.1% HCOOH].

[0278] Synthesis of intermediate 51: [ka] Intermediate 50 (0.4 g, 1.3 mmol) and HO (2.7 mL) were added to a sealed tube. HCl 12 M (0.9 mL, 3.8 mmol) was added. The mixture was refluxed overnight. The mixture was concentrated to dryness and co-evaporated with diethyl ether (2 × 5 mL). Crude intermediate 51 was dried under high vacuum at 50 °C and used directly in the next step (0.3 g, 100%).

[0279] Synthesis of intermediate 52: [ka] Intermediate 51 (0.3 g, 1.3 mmol) and DMF (3.8 mL) were added to a sealed tube and bubbled with nitrogen for approximately 15 minutes. Next, cesium carbonate (0.8 g, 2.6 mmol), iodobenzene (0.15 mL, 1.3 mmol), and copper iodide (0.03 g, 0.15 mmol) were added, and the resulting mixture was heated at 140 °C overnight under a nitrogen atmosphere. The reaction was allowed to cool to room temperature. Water (5 mL) and AcOEt (10 mL) were added. The phases were separated, and the organic layer was discarded. The aqueous layer was brought to pH 6 by the addition of 1 M HCl and then concentrated in vacuo. The residue was washed several times with CHCl / CHOH 9 / 1, v / v, and the washings were filtered through a syringe filter (0.45 μm). The solvent was evaporated in vacuo and the residue was purified by reverse phase chromatography [start (95% H2O-5% CH3CN-CH3OH)-end (63% H2O-37% CH3CN-CH3OH)]-[H2O:25 mM NH4HCO3] to give intermediate 52 (0.14 g, 43%).

[0280] Synthesis of intermediate 53: [ka] 4-Piperidinecarboxylic acid, 2-methyl-5-oxo-1-(1-phenylethyl)-, ethyl ester (2 g, 6.5 mmol) was added to EtOH (50 mL) and cooled in an ice bath under a stream of nitrogen. H2 and di-tert-butyl dicarbonate (4.5 mL, 19.7 mmol) were added, and the reaction vessel was connected to a balloon filled with H2. The mixture was stirred overnight at room temperature under an atmosphere of H2. The mixture was filtered through a pad of Celite, the cake was washed with MeOH (5 × 10 mL), and the filtrate was concentrated to dryness. The residue was purified by flash column chromatography (silica gel; heptane / AcOEt, 5 / 1, v / v 0 / 100 to 100 / 0 in heptane). The desired fractions were collected and concentrated in vacuo to give 1.8 g (99%) of intermediate 53.

[0281] Synthesis of intermediate 54: [ka] To a solution of intermediate 53 (1.9 g, 6.5 mmol) and diisopropylethylamine (1.7 mL, 9.8 mmol) in 30 mL of toluene was added trifluoromethanesulfonic anhydride (1.3 mL, 7.9 mmol) at 0 °C. The mixture was stirred at 0 °C for 16 h. Water was added, and the mixture was extracted with AcOEt. The organic layer was separated, dried over MgSO4, filtered, and evaporated. The residue was purified by flash column chromatography (silica gel; AcOEt in heptane 0 / 100 to 100 / 0). The desired fractions were collected and concentrated in vacuo to give intermediate 54, 1.3 g (47%), as a red gum.

[0282] Synthesis of intermediate 55: [ka] Intermediate 54 (3.5 g, 8.4 mmol), bis(triphenylphosphine)palladium(II) dichloride (587 mg, 0.8 mmol), phenylboronic acid (1.5 g, 12.5 mmol), and 1M sodium carbonate (16.7 mL, 16.7 mmol) were added to dioxane (100 mL), and the mixture was bubbled with nitrogen for 15 min. It was then heated at 80 °C overnight. The mixture was filtered through a short pad of Celite. Water and AcOEt were added, and the organic layer was washed with brine, dried over MgSO4, and evaporated. The crude mixture was purified by flash column chromatography (silica gel, AcOEt / heptane, 0 / 100 to 40 / 60). The desired fractions were collected, evaporated in vacuo, and dried under high vacuum to give Intermediate 55 (2.9 g, 100%).

[0283] Synthesis of intermediate 56: [ka] Intermediate 55 (2.9 g, 8.4 mmol) was added to MeOH (70 mL) and cooled in an ice bath under a stream of nitrogen. 10% Pd / C (0.5 g, 4.9 mmol) was added, and the reaction vessel was connected to a balloon filled with H. The mixture was stirred at room temperature under an atmosphere of H overnight. The mixture was filtered through a pad of Celite, and the cake was washed with MeOH (5 × 10 mL) and concentrated to dryness. Intermediate 56 was used directly in the next step (2.8 g, 95%).

[0284] Synthesis of intermediate 57: [ka] To a solution of intermediate 56 in 60 mL of EtOH under a N2 atmosphere, sodium ethylate (3.1 mL, 8.4 mmol) was added. The reaction mixture was heated to reflux for 3 h. The reaction mixture was poured into aqueous ammonium chloride solution, and the resulting product was extracted with ethyl acetate. The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography on silica gel using heptane / AcOEt (0:100 to 50:50) as the eluent. Purification by reverse-phase chromatography [start (47% HO - 53% ACN:MeOH 1:1) - end (18% HO - 82% ACN:MeOH 1:1)] - [65 mM NHOAc + ACN (90:10)] gave intermediate 57 (1.8 g, 71%).

[0285] Synthesis of intermediate 58: [ka] Intermediate 57 (0.2 g, 0.86 mmol), Intermediate 27 (0.3 g, 0.9 mmol), and diisopropylethylamine (0.4 mL, 2.6 mmol) were added to DMF (15 mL) at room temperature. HBTU (0.4 g, 1 mmol) was added, and the mixture was stirred for 20 min. 1 M Na2CO3 (10 mL) and CHCl2 (35 mL) were added. The organic layer was separated, and the aqueous phase was extracted once more with CHCl2 (30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel; CHCl2 / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in CHCl2). The desired fractions were collected and concentrated in vacuo to give Intermediate 58 (0.3 g, 64%).

[0286] Synthesis of intermediate 59: [ka] Trifluoroacetic acid (0.4 mL, 5.5 mmol) was added to a solution of intermediate 58 (0.3 g, 0.5 mmol) in DCM (40 mL). The mixture was stirred overnight. The mixture was concentrated to dryness. The crude mixture was washed twice with toluene and concentrated to dryness. 1 M Na2CO3 (35 mL) and CHCl2 (150 mL) were added. The organic layer was separated and the aqueous phase was extracted once more with CHCl2 (30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The crude intermediate 59 was used directly in the next step (0.24 g, 96%).

[0287] Synthesis of intermediate 60: [ka] Propylene (2.7 g, 67.4 mmol) was bubbled into DMF (75 mL) at −10 / −15 °C. 5-Bromo-2-chloro-4-pyridinecarboxaldehyde (12.4 g, 56.2 mmol), PdCl(TPP) (1.5 g, 2.2 mmol), CuI (321 mg, 1.7 mmol), and triethylamine (23.5 mL, 168.5 mmol) were added, and the reaction vessel was sealed. The mixture was stirred at room temperature for 2.5 h. The reaction mixture was then poured onto ice water (200 mL) / saturated NHCl (20 mL). The organics were extracted with AcOEt (250 mL and 150 mL). The combined organic layers were washed with saturated NaHCO (100 mL). The aqueous phase was back-extracted with AcOEt (50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated. Chromatography on silica gel (0-35% gradient of AcOEt in heptane) gave yellowish solid intermediate 60 (5.1 g, 50%).

[0288] Synthesis of intermediate 61: [ka] To a suspension of intermediate 60 (9 g, 50.3 mmol) in water (100 mL) was added tert-butylamine (25 mL, 238 mmol). The reaction was stirred at room temperature for 48 hours. Excess tert-butylamine was removed by rotary evaporation. The resulting residue was partitioned between AcOEt (200 mL) and water (100 mL). The organic layer was washed with brine (50 mL), dried over MgSO4, filtered, and concentrated to give crude intermediate 61 (11.9 g, 100%), which was used in the next step without further purification.

[0289] Synthesis of intermediate 62: [ka] Intermediate 61 (2.7 g, 11.4 mmol) was added to DMF (150 mL) and degassed by bubbling nitrogen through for 15 minutes. Catalyst copper iodide (0.2 g, 1.1 mmol) was added, and the resulting mixture was heated at 100 °C for 2 hours. The mixture was cooled to room temperature and quenched with water (10 mL). Most of the solvent was removed under vacuum. The residue was added to AcOEt (200 mL), washed with saturated NH4Cl (70 mL), dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0-30% gradient of AcOEt in heptane) gave Intermediate 62 (1.7 g, 81%).

[0290] Synthesis of intermediate 63: [ka] Intermediate 62 (1.5 g, 8.4 mmol) and benzyl bromide (1.6 mL, 13.6 mmol) were added to a sealed tube in acetonitrile (30 mL). The mixture was stirred at 80 °C for 48 h. The mixture was cooled to room temperature and poured onto diethyl ether (200 mL). The precipitate was filtered through a sintered funnel and washed with diethyl ether (2 × 15 mL). Intermediate 63 was collected and dried under high vacuum (2.3 g, 75%).

[0291] Synthesis of intermediate 64: [ka] Sodium borohydride (1.2 g, 32.6 mmol) was added portionwise over 30 min to a solution of Intermediate 63 (2.3 g, 6.5 mmol) in MeOH (60 mL). The mixture was then stirred for an additional 2 h. The reaction mixture was quenched with water (150 mL) and 1 M NaOH (50 mL). The organics were extracted with DCM (3 × 100 mL), dried over MgSO, filtered, and concentrated to dryness. Chromatography on silica gel (0–5% MeOH in DCM gradient) afforded Intermediate 64 (1.5 g, 82%).

[0292] Synthesis of intermediate 65: [ka] Intermediate 64 (1.5 g, 5.5 mmol), 4-aminotetrahydropyran (1.1 mL, 11 mmol), RuPhosPdG3 (230 mg, 0.3 mmol), and sodium tert-butoxide (1 g, 11 mmol) were added to toluene (50 mL) in a reaction tube while bubbling nitrogen. Degassing was continued for 5 min, and the reaction vessel was sealed with a screw cap. The mixture was heated at 120 °C for 2 h. The mixture was cooled to room temperature, diluted with AcOEt (100 mL), and washed once with water (100 mL). The organic layer was dried over MgSO4, filtered, and concentrated. Chromatography on silica gel (0–5% MeOH in DCM gradient) gave Intermediate 65 (1.6 g, 82%).

[0293] Synthesis of intermediate 66: [ka] Hydrogenolysis of the benzyl group of intermediate 65 (1.6 g, 4.7 mmol) was carried out over Pd / C 10% (569 mg, 0.5 mmol) under atmospheric pressure of hydrogen for 2.5 h. The catalyst was filtered through a pad of Celite and washed with additional MeOH (3 × 20 mL). The filtrate was concentrated. Flash chromatography on silica gel (mixture DCM / MeOH / NH4OH, 9.0 / 0.9 / 0.1, v / v / v, gradient 0 to 50% in DCM) gave intermediate 66 (843 mg, 70%).

[0294] Synthesis of intermediates 67a and 67b: [ka] Both enantiomers of intermediate 64 (3.5 g, 9.9 mmol) were separated using Chiral SFC 20% 2-propanol, 80% CO2, Column Lux-Amylose-1 to give intermediate 67a (1.2 g, 45%) and intermediate 67b (1.2 g, 45%).

[0295] Synthesis of intermediate 68: [ka] To a suspension of intermediate 67b (1.2 g, 4.5 mmol) and potassium bicarbonate (5 g, 49.6 mmol) in dichloroethane (40 mL) was added 1-chloroethyl chloroformate (1.5 mL, 13.5 mmol) dropwise. The mixture was refluxed for 3 h. The mixture was filtered through a sintered funnel, and the filtrate was concentrated to dryness. The residue was added to MeOH (50 mL) and refluxed for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was triturated with diethyl ether (50 mL). The resulting powdery solid was filtered through a sintered funnel and washed with diethyl ether (2 × 15 mL) to give intermediate 68 as the hydrochloride salt (1 g, 84%).

[0296] Synthesis of intermediate 69: [ka] HBTU (1.9 g, 5.2 mmol) was added to a solution of intermediate 68 (1 g, 1.7 mmol), intermediate 8 (1.1 g, 5.2 mmol), and diisopropylethylamine (3.2 mL, 18.8 mmol) in DMF (25 mL) at room temperature. The reaction was continued for 20 h. The mixture was concentrated to dryness. The residue was added to AcOEt (200 mL) and washed with 1 M Na2CO3 (150 mL). The aqueous phase was extracted with AcOEt (100 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1, v / v / v) gradient 0-50% in DCM) gave intermediate 69 (760 mg, 38%).

[0297] Synthesis of intermediate 70: [ka] Intermediate 67b (331 mg, 1.2 mmol), 1-methyl-1H-pyrazol-4-amine hydrochloride (0.24 g, 1.8 mmol), RuPhosPdG3 (51 mg, 0.06 mmol), and potassium carbonate (0.4 g, 3 mmol) were added to tBuOH (25 mL) in a reaction tube with nitrogen bubbling. Degassing was continued for 5 min, and the reaction vessel was sealed with a screw cap. The mixture was heated at 120 °C for 12 h. The mixture was cooled to room temperature, diluted with AcOEt (80 mL), and washed once with water (20 mL). The organic layer was dried over MgSO4, filtered, and concentrated. Chromatography on silica gel (0–5% MeOH in DCM gradient) afforded Intermediate 70 (268 mg, 52%).

[0298] Synthesis of intermediate 71: [ka] Intermediate 70 (268 mg, 0.8 mmol) was added to MeOH (30 mL) and cooled in an ice bath under a stream of nitrogen. Pd / C 10% (22 mg, 0.2 mmol) was added and the reaction vessel was connected to a hydrogen-filled balloon. The mixture was stirred overnight at room temperature under an atmosphere of hydrogen. The mixture was filtered through a pad of Celite, and the cake was washed with MeOH (5 × 10 mL) and concentrated to dryness. Intermediate 71 (0.209 g, >100%) was used directly in the next step.

[0299] Synthesis of intermediate 72: [ka] HBTU (2.2 g, 5.9 mmol) was added to a solution of Intermediate 68 (0.9 g, 4.9 mmol), Intermediate 36 (1.8 g, 5.6 mmol), and diisopropylethylamine (2.5 mL, 14.8 mmol) in DMF (40 mL). The reaction was stirred at room temperature for 2 days. 1 M Na2CO3 (20 mL) and CHCl2 (150 mL) were added. The phases were separated. The aqueous layer was extracted with CHCl2 (5 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica gel; AcOEt in heptane 0 / 100 to 15 / 85). The desired fractions were collected and concentrated in vacuo to give Intermediate 72 (2.1 g, 84%).

[0300] Synthesis of intermediate 73: [ka] Intermediate 72 (712 mg, 1.4 mmol), trans-4-methoxycyclohexylamine (0.4 g, 2.7 mmol), RuPhosPdG3 (58 mg, 0.07 mmol), and sodium tert-butoxide (0.2 g, 2.1 mmol) were added to a reaction tube in toluene (20 mL) with nitrogen bubbling. Degassing was continued for 5 min, and the reaction vessel was sealed with a screw cap. The mixture was heated at 100 °C for 20 h. The mixture was cooled to room temperature, diluted with ethyl acetate (50 mL), and washed once with water (20 mL). The organic layer was dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (DCM / MeOH (9.0 / 1.0, v / v) gradient 0 to 80% in DCM) gave Intermediate 73 (663 mg, 81%).

[0301] Synthesis of intermediate 74: [ka] To a solution of intermediate 73 (663 mg, 1.1 mmol) in DCM (15 mL) was added trifluoroacetic acid (0.9 mL, 11.5 mmol). The mixture was stirred overnight. The mixture was concentrated to dryness. The crude mixture was washed twice with toluene and concentrated to dryness. The crude material was treated with Amberlyst A26 hydroxide until pH = 7. The resin was filtered through a sintered funnel, washed successively with MeOH (40 mL) and then DCM (40 mL), and concentrated to dryness. The residue was purified by flash column chromatography (silica gel; CHCl / CHOH / NH, 9 / 0.9 / 0.1, v / v 0 / 100 to 100 / 0 in CHCl) to give intermediate 74 as an oil (492 mg, 88%).

[0302] Synthesis of intermediate 75: [ka] D-Alanine methyl ester hydrochloride (2 g, 14.3 mmol) and triethylamine (4.4 mL, 31.5 mmol) were added to DCM (30 mL) with stirring. Next, 2-nitrobenzenesulfonyl chloride (3.5 g, 15.7 mmol) in DCM (20 mL) was slowly added to the mixture at RT, and the mixture was stirred for 3 h. Water (60 mL) was added to the mixture. The organics were extracted with DCM (10 mL). The organic layer was dried over MgSO4, filtered, and concentrated to give the crude product. Chromatography on silica gel (0-60% gradient of AcOEt in heptane) afforded Intermediate 75 (3.7 g, 88%) as a solid.

[0303] Synthesis of intermediate 76: [ka] Cesium carbonate (5.1 g, 15.8 mmol) was added to a mixture of intermediate 75 (3.8 g, 13.2 mmol) and butanoic acid, 4-iodo-3-methyl-, ethyl ester (4 g, 15.8 mmol) in DMF (50 mL). The reaction mixture was stirred at room temperature for 1 h and then at 50 °C overnight. HO and AcOEt were added, the organics were separated, and the organic layer was dried over MgSO, filtered, and concentrated to dryness. The residue was purified by flash column chromatography (silica gel; heptane in AcOEt, 100 / 0 to 40 / 60) to give 4.6 g of a mixture of intermediates 76 and 75, which was used directly in the next step.

[0304] Synthesis of intermediate 77: [ka] Thiophenol (0.8 mL, 8.3 mmol) was added to a mixture of intermediates 76 and 75 (4.6 g) and cesium carbonate (4.9 g, 15.1 mmol) in DMF (30 mL). The reaction was stirred at rt for 3 h. The mixture was diluted with diethyl ether (50 mL) and water (50 mL). The organic layer was separated and washed once more with water (30 mL) and brine (30 mL). Drying over MgSO4, filtration, and removal of the solvent gave the crude product, which was purified by chromatography on silica gel (0-100% gradient of AcOEt in heptane) to give intermediate 77 (1.6 g, 86%).

[0305] Synthesis of intermediate 78: [ka] Intermediate 77 (1.6 g, 6.5 mmol) and di-tert-butyl decarbonate (1.7 mL, 11 mmol) in DCM (20 mL) were stirred at room temperature overnight. The mixture was partitioned between water (25 mM) and DCM (50 mL). The aqueous layer was extracted again with DCM (30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. The residue was chromatographed on silica gel (AcOEt / heptane, 0 / 100 to 35 / 65). Intermediate 78 was obtained as an oil (1.9 g, 91%).

[0306] Synthesis of intermediates 79a and 79b: [ka] Intermediate 78 (1.9 g, 6 mmol) was stirred in THF (50 mL) for 10 min. Potassium tert-butoxide (1 g, 9 mmol) was added, and the reaction mixture was stirred for 2 h. Water was added, and the mixture was extracted with AcOEt. The organic layer was separated, dried over MgSO4, filtered, and evaporated to dryness. Chromatography (silica gel, AcOEt / heptane, 0 / 100 to 50 / 50) gave a mixture of 79a and 79b (1.3 g).

[0307] Synthesis of intermediate 80: [ka] Intermediate 79a and 79b (1.3 g) and sodium chloride (0.26 g, 4.4 mmol) were stirred overnight at 140 °C in a mixture of DMSO (10 mL) and HO (5 mL). The mixture was cooled to room temperature and diluted with water (25 mL). The organics were extracted with AcOEt (2 × 40 mL), washed with brine, dried over MgSO, filtered, and concentrated. The residue was purified by flash column chromatography (silica gel; AcOEt in heptane 0 / 100 to 100 / 0). Intermediate 80 was obtained as an oil (0.5 g, 90%).

[0308] Synthesis of intermediate 81: [ka] Tert-butoxybis(dimethylamino)methane (2.2 mL, 10.9 mmol) was added to a solution of intermediate 80 (495 mg, 2.2 mmol) in toluene (10 mL) at room temperature. The mixture was stirred overnight. Two more equivalents of tert-butoxybis(dimethylamino)methane were added, and the reaction mixture was stirred at 80° C. for 5 hours. The reaction mixture was concentrated to dryness. The crude residue was dried under high vacuum at room temperature and finally used directly in the next step.

[0309] Synthesis of intermediate 82: [ka] To a mixture of intermediate 81 (0.61 g, 2.2 mmol) and 1-(tetrahydro-2H-pyran-4-yl)guanidine (11 g, 7.4 mmol) in EtOH (20 mL) was added sodium ethylate (1.6 mL, 4.3 mmol). The resulting mixture was heated to 90 °C over a weekend. The mixture was cooled to room temperature, quenched with water (20 mL), and extracted with DCM (60 mL). The organic layer was dried over MgSO, filtered, and concentrated. Chromatography on silica gel (0-100% gradient of AcOEt in heptane) gave intermediate 82 (0.6 g, 71%).

[0310] Synthesis of intermediate 83: [ka] Trifluoroacetic acid (1.2 mL, 15.9 mmol) was added to a solution of intermediate 82 (578 mg, 1.6 mmol) in DCM (10 mL). The reaction mixture was stirred overnight. The mixture was concentrated to dryness, washed twice with toluene, and concentrated to dryness. The crude mixture was treated with Amberlyst A26 hydroxide until pH = 7. The resin was filtered through a sintered funnel, washed successively with MeOH (40 mL) and then DCM (40 mL), and the mixture was concentrated to dryness. Compound 83 (0.42 g, 98%) was obtained as an oil and used directly in the next step.

[0311] Synthesis of intermediates 84a and 84b: [ka] Intermediate 83 (732 mg, 2.8 mmol) was purified by reverse-phase chromatography [start (95% HO-5% ACN-MeOH)-finish (63% HO-37% ACN-MeOH)-[0.1% TFA]. The solution was neutralized with solid NaCO, extracted with DCM, dried over MgSO, filtered, and concentrated to dryness to give 84a (315 mg, 42%) and 84b (133 mg, 18%).

[0312] Synthesis of intermediate 85: [ka] tert-Butyl 4-amino-4-methylpentanoate (19.4 g, 104 mmol) was added to DCE (200 mL) and treated with ethyl 2-oxoacetate (30.8 mL, 156 mmol) at RT, and the mixture was stirred for 45 min. Triacetoxyborohydride (33 g, 156 mmol) was then added portionwise over 15 min, and the reaction was allowed to stir overnight. The reaction was quenched with 1 M Na2CO3 (150 mL), and the organics were extracted with DCE (2 × 60 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0–40% MeOH in DCM gradient) afforded intermediate 85 (11.2 g, 39%).

[0313] Synthesis of intermediate 86: [ka] Benzyl chloroformate (23.4 mL, 164 mmol) was added to a solution of intermediate 85 (11.2 g, 41 mmol) in a saturated solution of NaHCO (70 mL) and DCM (100 mL) at 0 °C. The mixture was allowed to reach RT and stirred overnight. The mixture was diluted with DCM (100 mL) and 25% NH OH (30 mL) was added with stirring. After 15 min, the organic layer was separated, dried over MgSO , filtered, and concentrated. Chromatography on silica gel (0-30% gradient of AcOEt in heptane) gave intermediate 86 (3.8 g, 82%).

[0314] Synthesis of intermediate 87: [ka] To a solution of intermediate 86 (13.8 g, 33.8 mmol) in THF (120 mL) was added potassium tert-butoxide (5.7 g, 50.7 mmol), and the mixture was allowed to stir at RT for 1 h. The reaction was diluted with DCM (250 mL) and HO (50 mL). 1M KHSO (30 mL) was added with stirring. The organic layer was separated, and the aqueous phase was extracted once with additional DCM (50 mL). The combined organic layers were dried over MgSO, filtered, and concentrated to give a crude oil. Chromatography on silica gel (0-20% gradient of AcOEt in heptane) gave intermediate 87 (9.5 g, 78%).

[0315] Synthesis of intermediate 88: [ka] Sodium ethoxide (29.6 mL, 79.3 mmol) in EtOH was added to a mixture of Intermediate 87 (9.5 g, 26.4 mmol) and S-methylisothiourea (11 g, 79.3 mmol) in EtOH (120 mL). The resulting mixture was heated to 90 °C and stirred overnight. The mixture was cooled to room temperature and diluted with AcOEt (100 mL) and HO (40 mL). The pH was adjusted to 2-3 with 1 M HCl. The organic layer was separated (brine was added to separate the phases), dried over MgSO, filtered, and concentrated under vacuum. Acetonitrile was added to remove impurities, and the solution was filtered under vacuum. Intermediate 88 was dried to give 828 mg (9%) of a white solid. The filtered solution was concentrated in vacuo and purified by flash chromatography on silica gel (0-40% gradient of AcOEt in heptane) to give intermediate 88 (5.3 g, 49%) as a yellow solid.

[0316] Synthesis of intermediate 89: [ka] Intermediate 88 (5.3 g, 14.8 mmol) in POCl3 (44 mL) was heated at 80 °C for 1 h. The reaction mixture was poured onto crushed ice (200 g). H2O (100 mL) and DCM (100 mL) were added with stirring. Na2CO3 was added slowly to bring the pH to 7-8. The organic layer was separated, and the aqueous phase was extracted once more with DCM (50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. The crude mixture was purified by flash column chromatography on silica gel (0-35% gradient of AcOEt in heptane) to give Intermediate 89 (2.5 g, 44%).

[0317] Synthesis of intermediate 90: [ka] Intermediate 89 (2.5 g, 6.8 mmol), Zn (3.5 g, 54 mmol), and ammonia (2.5 mL, 34 mmol) were added to EtOH (60 mL). The mixture was refluxed (80 °C) overnight, cooled to RT, filtered through a pad of Celite, and the cake was washed with EtOH. The crude mixture was purified by flash column chromatography on silica gel (0-25% gradient of AcOEt in heptane) to give Intermediate 90 (1.9 g, 81%).

[0318] Synthesis of intermediate 91: [ka] 3-Chloroperbenzoic acid (3.3 g, 14.9 mmol) was added portionwise to a solution of Intermediate 90 (1.7 g, 5 mmol) in DCM (70 mL). The reaction was allowed to stir at RT for 7 h. 1 M Na2CO3 (40 mL) was added to the mixture with stirring. DCM (30 mL) was added, and the organic layer was separated and washed once more with 1 M Na2CO3 (20 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. Chromatography on silica gel (0-40% MeOH in DCM gradient) afforded Intermediate 91 as a colorless oil (1.4 g, 71%).

[0319] Synthesis of intermediate 92: [ka] Intermediate 91 (1.3 g, 3.6 mmol) and triethylamine (126 μL, 0.9 mmol) were added to MeOH (60 mL), and the mixture was reduced over Pd / C 10% (142 mg, 0.1 mmol) under 1 atmosphere of H for 1 h. The catalyst was filtered through a short pad of Celite. The filtrate was then concentrated to dryness. Crude intermediate 92 (865 mg, 96%) was obtained as a yellow sticky solid, which was used directly in the next synthetic step without further purification.

[0320] Synthesis of intermediate 93: [ka] Intermediate 93 (147 mg, 18%) was prepared starting from intermediate 92 by the same reaction protocol as for intermediate 11.

[0321] Synthesis of intermediate 94: [ka] To a solution of 4-azaspiro[2.5]octane-4-carboxylic acid, 6-oxo, 1,1-dimethylethyl ester (1.4 g, 6.4 mmol) in toluene (21 mL) was added tert-butoxybis(dimethylamino)methane (1.6 mL, 7.7 mmol) at room temperature. The reaction mixture was stirred for 20 hours and concentrated to dryness. The crude intermediate 94 was dried under high vacuum at room temperature and used directly in the next synthetic step (1.8 g, 100%).

[0322] Synthesis of intermediate 95: [ka] 2-Methyl-2-thiopseudourea hemisulfate (1.8 g, 12.9 mmol) and Intermediate 94 (1.8 g, 6.4 mmol) were added to EtOH (51 mL). Sodium ethoxide (6 mL, 16 mmol) was added, and the resulting mixture was heated at 85 °C for 12 h. The reaction mixture was added to AcOEt (50 mL), and HO (50 mL) was added. The organic layer was separated, and the aqueous phase was extracted with additional AcOEt (2 × 20 mL). The combined organic layers were dried over MgSO, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane). The desired fractions were collected and evaporated in vacuo to give Intermediate 95 (1.1 g, 58%) as a brown foam.

[0323] Synthesis of intermediate 96: [ka] 3-Chloroperbenzoic acid (2.5 g, 11.1 mmol) was added portionwise to a solution of intermediate 95 in DCM (35 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with DCM (40 mL) and washed with 1 M Na2CO3 (30 mL). The organic layer was separated and washed once more with saturated NaCl (20 mL). The organic layer was dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; AcOEt in heptane 0 / 100 to 60 / 40). The desired fractions were collected and evaporated in vacuo to give intermediate 96 (1 g, 83%) as a colorless foam.

[0324] Synthesis of intermediate 97: [ka] Intermediate 96 (1 g, 3.1 mmol) was added to DCM (35 mL) and treated with trifluoroacetic acid (3.4 mL, 46.2 mmol) at room temperature. The reaction mixture was stirred overnight. The reaction mixture was evaporated in vacuo and then co-evaporated with toluene (10 mL). The residue was added to DCM (40 mL) and 1 M Na2CO3 (20 mL) was added. The organic layer was separated and the aqueous phase was extracted with additional DCM (2 × 10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; DCM / MeOH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). The desired fractions were collected and concentrated in vacuo to give Intermediate 97 (0.6 g, 87%).

[0325] Synthesis of intermediate 98: [ka] Intermediate 97 (0.5 g, 2.2 mmol), Intermediate 8 (0.6 g, 2.2 mmol), 2-chloro-1-methylpyridin-1-ium iodide (1.1 g, 4.5 mmol), and triethylamine (1.9 mL, 11.3 mmol) were added to THF (26 mL) while bubbling a stream of nitrogen through the solution. The vial was sealed, and the resulting solution was stirred at 55 °C for 20 h. AcOEt (80 mL) and 1 M Na2CO3 (60 mL) were added. The phases were separated. The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; DCM / MeOH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). Fractions containing the desired product were collected together and evaporated in vacuo to give Intermediate 98 (0.8 g, 84%).

[0326] Synthesis of intermediate 99: [ka] tert-Butyl 4-amino-3,3-dimethylbutanoate (3.7 g, 19.9 mmol) and triethylamine (6.1 mL, 43.8 mmol) were added to DCM (40 mL) with stirring. Next, 2-nitrobenzenesulfonyl chloride (5.3 g, 23.9 mmol) in DCM (30 mL) was added dropwise over 15 min with ice cooling. The mixture was then warmed to room temperature. Stirring was maintained for 4 h. Water (100 mL) was added to the mixture. The organics were extracted with DCM (50 mL). The organic layer was washed with saturated sodium hydroxide, NaHCO3 (100 mL), dried over MgSO4, filtered, and concentrated to give the crude product. Chromatography on silica gel (0-50% gradient of AcOEt in heptane) gave intermediate 99 (7.9 g, 99%) as a yellowish solid.

[0327] Synthesis of Intermediate 100: [ka] Intermediate 99 (7.4 g, 19.9 mmol) and ethyl bromoacetate (8.8 mL, 79.4 mmol) were added to DMF (100 mL). Potassium carbonate (8.2 g, 59.6 mmol) was added at room temperature, and the reaction was stirred overnight. The reaction mixture was diluted with AcOEt (200 mL) and water (500 mL). The organic layer was separated, washed with brine (100 mL), dried over MgSO4, filtered, and concentrated to give the crude product. Chromatography on silica gel (0-30% gradient of AcOEt in heptane) gave Intermediate 100 as a viscous colorless oil (7.6 g, 82%).

[0328] Synthesis of intermediate 101: [ka] Thiophenol (1.5 g, 14.5 mmol) was added to a mixture of Intermediate 100 (6 g, 13.1 mmol) and cesium carbonate (8.6 g, 26.3 mmol) in DMF (60 mL). The reaction was monitored by TLC (heptane / EA, 2 / 1, v / v) and appeared to be complete within 45–60 min. The mixture was diluted with diethyl ether (200 mL) and water (200 mL). The organic layer was separated and washed once more with water (70 mL) and then brine (50 mL). Drying over MgSO4, filtration, and removal of the solvent afforded the crude mixture. Chromatography on silica gel (0–30% gradient of AcOEt in heptane) afforded Intermediate 101 as a clear oil (3.6 g, 52%).

[0329] Synthesis of intermediate 102: [ka] Benzyl chloroformate (3.9 mL, 27.8 mmol) was added to a solution of intermediate 101 (1.9 g, 6.9 mmol) in saturated NaHCO (20 mL) and DCM (25 mL) at 0 °C. The mixture was allowed to reach room temperature and stirred overnight. The mixture was diluted with DCM (100 mL) and 25% NH OH (25 mL) was added with stirring. After 15 min, the organic layer was separated, dried over MgSO , filtered, and concentrated to dryness. Chromatography on silica gel (0-30% gradient of AcOEt in heptane) afforded intermediate 102 as a clear oil (2.6 g, 92%).

[0330] Synthesis of intermediates 103a and 103b: [ka] To a solution of intermediate 102 (2.6 g, 6.4 mmol) in THF (50 mL) was added potassium tert-butoxide (1 g, 9.6 mmol). TLC (heptane / AcOEt, 2 / 1, v / v) after 2 h showed complete conversion. The reaction was diluted with AcOEt (100 mL) and water (25 mL). Sat. NH4Cl (20 mL) was added with stirring. The organic layer was separated, and the aqueous phase was extracted once more with AcOEt (50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0-15% gradient of AcOEt in heptane) afforded intermediates 103a (272 mg, 11%) and 103b (1.2 g, 54%).

[0331] Synthesis of intermediate 104: [ka] Intermediate 103b (750 mg, 2.2 mmol) and N,N-dimethylformamide dimethyl acetal (1 mL, 7.5 mmol) were stirred at 90 °C for 2 h. The reaction mixture was concentrated to dryness. Crude intermediate 104 was dried under high vacuum at room temperature and finally used directly in the next step (901 mg, >100%).

[0332] Synthesis of intermediate 105: [ka] Intermediate 104 (0.8 g, 2.2 mmol) and 1-(tetrahydro-2H-pyran-4-yl)guanidine (483 mg, 3.4 mmol) were added to DMF (15 mL). Sodium acetate (369 mg, 4.5 mmol) was added, and the resulting mixture was heated to 90 °C for 45 min. The mixture was cooled to room temperature and concentrated to dryness. The residue was added to AcOEt (50 mL) and washed with water (50 mL), 0.5 M HCl (50 mL), and brine (15 mL). The organic layer was dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0-5% MeOH in DCM gradient) afforded Intermediate 105 as a yellowish oil (122 mg, 11%).

[0333] Synthesis of intermediate 106: [ka] To a solution of intermediate 105 (122 mg, 0.26 mmol) in THF (2 mL) was added 1 M sodium hydroxide (2 mL, 2 mmol). The mixture was stirred at room temperature for 6 h. 1 M sulfuric acid (1.1 mL, 1.1 mmol) was added to the mixture, which was then heated to 80 °C for 1 h. The mixture was cooled to room temperature and diluted with AcOEt (20 mL) and brine (20 mL). The organic layer was separated, dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0-5% MeOH in DCM gradient) gave intermediate 106 (92 mg, 85%).

[0334] Synthesis of intermediate 107: [ka] Hydrogenolysis of intermediate 106 (92 mg, 0.23 mmol) in MeOH (10 mL) over Pd / C 10% (61 mg, 0.06 mmol) was carried out at room temperature under atmospheric pressure of H for 45 min. The catalyst was filtered through a short pad of Celite and further washed with MeOH (3 × 10 mL). The filtrate was concentrated to dryness to give intermediate 107 (51 mg, 80%).

[0335] Synthesis of intermediate 108: [ka] Triethylamine (22.6 mL, 162 mmol) was added to a cooled (ice bath) solution of tert-butyl 4-amino-3-methylbutanoate (23.5 g, 135.5 mmol) and DCM (300 mL). Then, 2-nitrobenzenesulfonyl chloride (36 g, 162.5 mmol) in DCM (100 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature, and stirring was maintained overnight. Sat. NaHCO (100 mL) was added to the mixture. The phases were separated, and the organic layer was dried over MgSO, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 108 (27.5 g, 57%), which was used directly in the next step.

[0336] Synthesis of intermediate 109: [ka] Intermediate 108 (27.5 g, 76.7 mmol) and bromoacetic acid (34 mL, 307 mmol) were added to DMF (385 mL). Potassium carbonate (21.2 g, 153 mmol) was added at room temperature, and the reaction mixture was continued overnight. The mixture was diluted with AcOEt (300 mL) and washed with water (900 mL). The aqueous layer was washed twice more with AcOEt (2 × 200 mL). The combined organic layers were washed with saturated NaCl (100 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 109 (28.6 g, 83%).

[0337] Synthesis of intermediate 110: [ka] Thiophenol (9.9 mL, 96 mmol) was added to a mixture of intermediate 109 (28.6 g, 64.3 mmol) and cesium carbonate (41.9 g, 128.7 mmol) in DMF (350 mL). The reaction mixture was stirred at room temperature for 24 h. The mixture was diluted with AcOEt (200 mL) and water (500 mL). The aqueous layer was extracted with AcOEt (3 × 200 mL and 2 × 100 mL). The combined organic layers were washed with saturated NaCl (100 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 1 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 110 (12.3 g, 73%).

[0338] Synthesis of intermediate 111: [ka] To a solution of intermediate 110 (12.3 g, 47.4 mmol) in sodium bicarbonate (120 mL) and DCM (160 mL) at 0 °C was added benzyl chloroformate (17.3 mL, 121.3 mmol). The mixture was allowed to reach room temperature and stirred overnight. The mixture was diluted with DCM (60 mL). The organic layer was dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 111 (17.9 g, 96%).

[0339] Synthesis of intermediate 112: [ka] To a solution of intermediate 111 (17.9 g, 45.4 mmol) in THF (136 mL) under a nitrogen atmosphere was added potassium tert-butoxide (7.6 g, 68.2 mmol). The reaction was diluted with DCM (30 mL) and water (20 mL). Sat. NH4Cl (50 mL) was added with stirring. The organic layer was separated and the aqueous phase was extracted once more with DCM (20 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 112 (9 g, 57%).

[0340] Synthesis of intermediate 113: [ka] Trifluoroacetic acid (38.5 mL, 518.1 mmol) was added to a solution of intermediate 112 (9 g, 25.9 mmol) in DCM (90 mL). The mixture was stirred for 3 h to complete the tert-butyl ester cleavage. The mixture was concentrated to dryness to a residue, which was added to MeOH / HO (175 mL / 70 mL) and refluxed overnight. The mixture was cooled to room temperature, and MeOH was removed in vacuo. DCM (50 mL) and 1 M NaCO (50 mL) were added with stirring. The organic layer was separated, dried over MgSO, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; heptane / AcOEt, 2 / 1, v / v 0 / 100 to 100 / 0 in heptane) to give intermediate 113 (5.2 g, 81%).

[0341] Synthesis of intermediate 114: [ka] tert-Butoxybis(dimethylamino)methane (1 mL, 4.8 mmol) was added to a solution of intermediate 113 (1 g, 4 mmol) in toluene (10 mL) at room temperature. The mixture was stirred for 20 hours. The reaction mixture was concentrated to dryness. The crude intermediate 114 was dried under high vacuum at room temperature and used directly in the next synthetic step (1.2 g, 100%).

[0342] Synthesis of intermediate 115: [ka] N-(1-methyl-1H-pyrazol-4-yl)guanidine (0.7 g, 4.8 mmol) and Intermediate 114 (1.2 g, 4 mmol) were added to EtOH (31 mL). Sodium ethoxide (3 mL, 8.1 mmol) was added, and the resulting mixture was heated at 45 °C overnight. The reaction mixture was diluted with DCM (50 mL), and the organics were washed with water (20 mL). The organic layer was dried over MgSO, filtered, and concentrated to dryness. The residue was purified by flash column chromatography (silica; AcOEt in heptane 0 / 100 to 100 / 0) to give Intermediate 115 (0.3 g, 69% purity).

[0343] Synthesis of intermediate 116: [ka] Hydrogenolysis of intermediate 115 (0.3 g, 0.8 mmol) in MeOH (5 mL) over Pd / C 10% (0.2 g, 0.2 mmol) was carried out overnight at room temperature under an atmosphere of H. The catalyst was filtered through a short pad of Celite and washed with MeOH (3 × 10 mL). The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography (silica; DCM / MeOH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM) to give intermediate 116 (0.019 g, 9%).

[0344] Synthesis of intermediate 117: [ka] NaH (60% dispersion in mineral oil) (195 mg, 4.9 mmol) was added portionwise to a solution of intermediate 3a (800 mg, 2.4 mmol) and iodomethane (456 μL, 7.3 mmol) in DMF (8.8 mL, 113.7 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 min. The reaction mixture was quenched with aqueous NH4Cl and extracted three times with AcOEt. The organic layer was washed with brine, dried over MgSO4, filtered, and the solvent was evaporated. The residue was purified by chromatography on silica gel (SiO2, Grace, 40 g; eluent: 90% heptane, 10% EtOAc to 40% heptane, 60% AcOEt). Pure fractions were collected and the solvent was evaporated to give intermediate 117 (410 mg, 49%).

[0345] Synthesis of intermediate 118: [ka] Intermediate 117 (410 mg, 1.2 mmol) and tetrahydro-2H-pyran-4-amine (0.75 g, 7.2 mmol) were stirred at 110 °C for 5 h. The crude mixture was purified by chromatography on silica gel (SiO, Grace, 40 g; eluent: 90% heptane, 10% AcOEt to 40% heptane, 50% AcOEt, 10% MeOH (2% NHOH)). Pure fractions were collected and the solvent was evaporated to give intermediate 118 (310 mg, 71% yield).

[0346] Synthesis of intermediate 119: [ka] HCl 4M in dioxane (2.1 mL, 4 M, 8.4 mmol) was added to a solution of intermediate 118 (310 mg, 0.86 mmol) in 1,4-dioxane (3.1 mL, 37.2 mmol) and MeOH (1 mL, 26 mmol) at room temperature. The reaction was stirred for 3 h. The volatiles were evaporated, the residue was taken up in water, basified with KCO, and the aqueous phase was extracted with DCM. The organic layer was dried over MgSO, filtered, and evaporated to dryness to give intermediate 119 (180 mg, 80% yield).

[0347] Synthesis of intermediates 120a and 120b: [ka] A mixture of 1 M diethylzinc in hexanes (165.8 mL, 165.8 mmol) and DCM (160 mL) was cooled to 0 °C under a nitrogen atmosphere. Next, trifluoroacetic acid (12.7 mL, 165.8 mmol) in DCM (70 mL) was added dropwise over approximately 30 min. After an additional 30 min, a solution of diiodomethane (13.3 mL, 165.8 mmol) in DCM (70 mL) was added dropwise to the white suspension over approximately 15 min. After an additional 10 min, the resulting mixture was treated with a solution of ethyl N-Boc-L-prolin-4-ene (20 g, 82.8 mmol) in DCM (50 mL) (slow addition over 30 min). The reaction was maintained at 0 °C for 5 min, then allowed to warm to room temperature and stirred for an additional 2.5 h. Finally, the mixture was cooled again to 0 °C, and triethylamine (28.9 mL, 207.2 mmol) was slowly added. The mixture was allowed to warm to room temperature and the reaction was continued overnight at room temperature. The insoluble material was filtered through a plug of Celite and washed with additional DCM (3 × 100 mL). The organic layer was separated, and the aqueous phase was extracted once more with DCM (250 mL). The combined organic layers were dried over MgSO4 and filtered. To overcome partial Boc cleavage, di-tert-butyl dicarbonate (9 g, 41.4 mmol) was added to the solution, and the mixture was stirred for 3 h. The mixture was concentrated to dryness. Chromatography on silica gel (0–15% gradient of AcOEt in heptane) afforded the pure diastereoisomers 120a (15 g, 71%) and 120b (749 mg, 3.5%).

[0348] Synthesis of intermediate 121: [ka] Intermediate 120a (15 g, 58.7 mmol) was added to AcOEt (150 mL) and treated with 4 N HCl in dioxane (100 mL, 400 mmol) at room temperature. The mixture was stirred for 5 h. The mixture was concentrated to give the crude product, which was further dried under high vacuum at 60 °C. Intermediate 121 (15.2 g, >100%) was used directly in the next step.

[0349] Synthesis of intermediate 122: [ka] Intermediate 121 (11.3 g, 58.7 mmol), benzyl bromide (8.4 mL, 70.5 mmol), and potassium carbonate (12.1 g, 88.1 mmol) were added to DMF (200 mL) and stirred at room temperature for 6 hours. The mixture was diluted with AcOEt (250 mL), and water (50 mL) and brine (50 mL) were added. The organic layer was separated, washed once more with water (100 mL), dried over MgSO4, and filtered. Removal of the solvent gave a crude oil. Flash chromatography on silica gel (0-25% gradient of AcOEt in heptane) gave Intermediate 122 as a clear oil (11.6 g, 80%).

[0350] Synthesis of intermediate 123: [ka] A solution of intermediate 122 (11.6 g, 47.3 mmol) in THF (100 mL) was added dropwise to a suspension of LiAlH (2.7 g, 70.9 mmol) in THF (50 mL) under a stream of nitrogen. The mixture was stirred at 0 °C for 2 h. The reaction was quenched with water (15 mL) at 0 °C. The mixture was diluted with DCM (100 mL) and the insoluble material was filtered through a pad of Celite, which was further washed with DCM (3 × 50 mL). The filtrate was transferred to a separatory funnel and washed with brine (50 mL). The organic layer was dried over MgSO, filtered, and concentrated to dryness to give intermediate 123 (8.3 g, 85%).

[0351] Synthesis of intermediate 124: [ka] Trifluoroacetic anhydride (11.5 mL, 82.6 mmol) was added to a solution of intermediate 123 (11.2 g, 55.1 mmol) in THF (100 mL) at −78 °C. After stirring the mixture at the same temperature for 3 h, triethylamine (15.3 mL, 110.2 mmol) was added dropwise, and the reaction was continued at −78 °C for 15 min, then allowed to warm to room temperature, and finally refluxed overnight. 2.5 M sodium hydroxide (220.4 mL, 551 mmol) was added, and the mixture was stirred at room temperature for 3 h. After that, most of the organic solvent was removed in vacuo. DCM (200 mL) and brine were added to the residue. The organic layer was separated, and the aqueous phase was extracted once more with DCM (100 mL). The combined DCM extracts were dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (0-80% gradient of AcOEt in heptane) gave intermediate 124 (9.8 g, 87%).

[0352] Synthesis of intermediate 125: [ka] Intermediate 124 (9.8 g, 48 mmol) and 4 N HCl in dioxane (13.2 mL, 52.8 mmol) were stirred in EtOH (165 mL). 10% Pd / C (2.1 g, 2 mmol) was added and the reaction was placed under an atmosphere of H (H-filled balloon). The mixture was stirred at room temperature for 5 h. The catalyst was filtered through a pad of Celite and washed with MeOH (2 × 20 mL). The filtrate was concentrated to dryness to give Intermediate 125 as a crude solid (8.3 g, >100%).

[0353] Synthesis of intermediate 126: [ka] Intermediate 125 (8.3 g, 38.6 mmol) was added to DCM (125 mL). 1 M sodium hydroxide (126.3 mL, 126.3 mmol) was added with stirring. Then, di-tert-butyl dicarbonate (10.1 g, 46.3 mmol) in DCM (75 mL) was added slowly. The cloudy mixture was vigorously stirred overnight. The mixture was diluted with DCM (20 mL) and a saturated solution of NaHCO3 was added. The organic layer was separated and dried over MgSO4. Filtration and removal of the solvent afforded the crude product. Chromatography on silica gel (0-50% gradient of AcOEt in heptane) afforded Intermediate 126 (4.3 g, 52%).

[0354] Synthesis of intermediate 127: [ka] Dess-Martin periodinane (12.4 g, 29.4 mmol) was added to a solution of intermediate 126 (4.2 g, 19.6 mmol) in DCM (300 mL) at room temperature. The mixture was stirred for 3 h. 1 M Na2CO3 (200 mL) and a saturated solution of Na2SO3 (10 mL) were added with vigorous stirring. After 10 min, DCM (100 mL) was added and the organic layer was separated. The crude product was obtained by drying over MgSO4, filtration, and removal of the solvent. Chromatography on a silica gel column (0-50% gradient of AcOEt in heptane) gave a colorless oil that crystallized on standing to give intermediate 127 (3.6 g, 87%).

[0355] Synthesis of intermediate 128: [ka] tert-Butoxybis(dimethylamino)methane (2.9 mL, 14.2 mmol) was added to a solution of intermediate 127 (1.5 g, 7.1 mmol) in toluene (50 mL) at room temperature. The mixture was stirred overnight. The reaction mixture was concentrated to dryness. The crude residue was dried under high vacuum at room temperature to give intermediate 128 (2.3 g, >100%), which was used directly in the next step.

[0356] Synthesis of intermediate 129: [ka] Intermediate 128 (517 mg, 1.9 mmol) and N-[(1-methyl-1H-pyrazol-3-yl)methyl]guanidine (0.6 g, 3.9 mmol) were added in EtOH (20 mL). Sodium ethoxide (1.4 mL, 3.9 mmol) was added, and the resulting mixture was heated to 70 °C for 18 h. The mixture was cooled to room temperature, and DCM (100 mL) was added, followed by water (20 mL) and brine (20 mL). The organic layer was separated, dried over MgSO, filtered, and concentrated to dryness. Chromatography on silica gel (0-5% MeOH in DCM gradient) gave intermediate 129 (527 mg, 75%) as yellow rods.

[0357] Synthesis of intermediate 130: [ka] Trifluoroacetic acid (3.2 mL, 42 mmol) was added to a solution of intermediate 129 (522 mg, 1.4 mmol) in DCM (10 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated to dryness. The residue was taken up in DCM (30 mL) and washed with 1 M Na2CO3 (15 mL). The aqueous phase was exhaustively extracted with DCM / MeOH (9 / 1, v / v). The combined organic layers were dried over MgSO4, filtered, and concentrated to give the crude product. Chromatography on silica gel (mixture DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1, v / v / v) gradient 0-50% in DCM) gave intermediate 130 (347 mg, 91%) as a sticky solid.

[0358] Synthesis of intermediate 131: [ka] A mixture of intermediate 27 (0.88 g, 3.5 mmol), triethylamine (0.62 mL, 4.4 mmol) and DCM (12 mL) was added to a cold (ice bath) solution of diphosgene (0.52 mL, 4.3 mmol) in DCM (10 mL). The reaction mixture was stirred at 0° C. for 90 min. HO and DCM were added, the RM was extracted, and the organic layer was separated, dried over MgSO, filtered and evaporated to give intermediate 131, which was used directly in the next step.

[0359] Synthesis of intermediates 132a and 132b: [ka] 1-Methyl-3-phenylpiperazine (13.3 g, 75.7 mmol) was separated by chiral SFC (stationary phase: CHIRALPAK AD-H 5 μm 250*30 mm, mobile phase: 92% CO2, 8% MeOH / iPrOH mixture 50 / 50 v / v (+ 3.0% iPrNH2)) to give intermediate 132a (5.9 g, 33.3 mmol) [α] d=49.1°(589nm, c 0.33w / v%, CHCl3, 20℃) ((S) enantiomer) and intermediate 132b (6.4g, 36.1mmol) [α] d = -56.9° (589 nm, c 0.32 w / v%, CHCl3, 20°C) ((R) enantiomer).

[0360] Synthesis of intermediate 133: [ka] A mixture of intermediate 66 (850 mg, 3.4 mmol), triethylamine (504 μl, 3.6 mmol) and DCM (10 mL) was added to a cold (ice bath) solution of diphosgene (437 μl, 3.6 mmol) in DCM (5 mL). The reaction mixture was stirred at 0° C. for 90 min. Water and DCM were added, the RM was extracted, and the organic layer was separated, dried over MgSO, filtered and evaporated to give intermediate 133, which was used directly in the next step.

[0361] Synthesis of intermediate 134: [ka] A mixture of intermediate 9 (0.5 g, 1.9 mmol), triethylamine (0.7 mL, 5 mmol) and DCM (10 mL) was added to a cold (ice bath) solution of diphosgene (0.27 mL, 2.2 mmol) in DCM (5 mL). The reaction mixture was stirred at 0° C. for 90 min. Water and DCM were added to extract the RM, and the organic layer was separated, dried over MgSO, filtered, evaporated and used directly in the next step.

[0362] Synthesis of intermediate 135: [ka] Intermediate 134 (549 mg, 1.9 mmol), Intermediate 132a (434 mg, 2.5 mmol), and triethylamine (0.34 mL, 2.4 mmol) in DCM (5 mL) were stirred at rt for 2 days. Water and DCM were added to extract the RM, and the organic layer was separated, dried over MgSO4, filtered, and evaporated. Purification was carried out by preparative LC (stationary phase: irregular SiOH 35-40 μm 24 g Buchi, mobile phase: DCM 100% to 95 / 5 / 0.1 CMA). Pure fractions were collected and evaporated to dryness, yielding 589 mg (72%) of Intermediate 135 [α]. d =+28.3°(589nm, c0.36w / v%, DMF, 20℃).

[0363] Synthesis of intermediate 136: [ka] Intermediate 135 (500 mg, 1.16 mmol) and 4-amino-1-Boc-piperidine (1.6 g, 8 mmol) were stirred in a sealed tube at 110 °C overnight. The residue was purified by preparative LC (stationary phase: irregular SiOH 35-40 μm 40 g Buchi, gradient 100% DCM to 90% DCM 10% CHOH 0.1% NHOH) to give intermediate 136 (575 mg, 90% yield) [α]. d =+68.4°(589nm, c0.22w / v%, DMF, 20℃).

[0364] Synthesis of intermediate 137: [ka] Intermediate 136 (575 mg, 1 mmol) and trifluoroacetic acid (1.2 mL, 15.7 mmol) in DCM (20 mL) were stirred at rt for 15 h. Water was added and the mixture was basified with K2CO3. The organic layer was extracted, and the aqueous layer was saturated with K2CO3 and extracted with AcOEt. Both organic layers were combined, dried over MgSO4, filtered, and evaporated to dryness to give intermediate 137 (429 mg, 91%).

[0365] Synthesis of intermediate 138: [ka] A mixture of intermediate 132a (150 mg, 0.85 mmol), triethylamine (142 μl, 1 mmol), and DCM (3.5 mL) was added to a cold solution (ice EtOH) of triphosgene (303 mg, 1 mmol) in DCM (2.5 mL). The temperature was allowed to rise to rt, and the reaction was stirred for 1 h. Water and DCM were added, the RM was extracted, and the organic layer was separated, dried over MgSO, filtered, and evaporated. The crude intermediate 138 was used directly in the next step.

[0366] Synthesis of intermediate 139: [ka] Intermediate 3a (580 mg, 1.77 mmol) and 1,1-dioxo-tetrahydrothiopyran-4-amine (2 g, 13.4 mmol) in a sealed tube were heated at 110 °C for 6 h. DCM and water were added, and the organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. The residue was purified by preparative LC (SiOH 35-40 μm Buchi, gradient 100% DCM to 90% DCM 10% CHOH 0.1% NHOH). Fractions were collected and evaporated to dryness to give Intermediate 139 (350 mg, 50%).

[0367] Synthesis of intermediate 140: [ka] Trifluoroacetic acid (2.2 mL, 8.8 mmol) was added dropwise to a solution of intermediate 139 (350 mg, 0.88 mmol) in dioxane (3.5 mL) and MeOH (1 mL) at room temperature. The reaction was stirred for 2 days, poured into water, basified with KCO, and extracted with DCM. The organic layer was dried over MgSO, filtered, and evaporated to dryness to give intermediate 140 (249 mg, 95%).

[0368] Synthesis of intermediate 141: [ka] A mixture of intermediate 140 (249 mg, 0.84 mmol), pyridine (0.102 mL, 1.26 mmol) and DCM (3 mL) was added to a solution of diphosgene (0.12 mL, 1 mmol) in DCM (3 mL) at −5° C. The reaction mixture was stirred at 0° C. for 90 min. Water and DCM were added, the mixture was extracted, and the organic layer was separated, dried over MgSO, filtered and evaporated to give intermediate 141, which was used directly in the next step.

[0369] Synthesis of Compound 1: [ka] A mixture of intermediate 5 (5.2 g, 20.1 mmol), intermediate 8 (7.7 g, 30.1 mmol), HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (15.5 g, 40.9 mmol), and diisopropylethylamine (20 mL, 0.121 mol) in DMF (140 mL) was stirred at room temperature for 20 h. The solvent was removed, and the residue was added to DCM and HO. The organic layer was extracted, dried over MgSO, filtered, and evaporated. The crude mixture was purified by flash chromatography (DCM / MeOH gradient 100:0 to 80:20) followed by achiral SFC (stationary phase: 2-ethylpyridine 5 μm 150*30 mm, mobile phase: 90% CO, 10% MeOH (0.6% iPrNH)). The pure fractions were collected and evaporated to give compound 1, which was crystallized in diethyl ether, filtered and dried to give 4.24 g (44%) [α] d : +59.4°C (589 nm, c 0.18 w / v%, DMF, 20°C). mp = 178°C (DSC).

[0370] The compounds shown in the table below were prepared by similar reaction protocols.

[0371] Table 1

[0372] Table 2

[0373] Table 3

[0374] Table 4

[0375] Table 5

[0376] Table 6

[0377] Table 7

[0378] Table 8

[0379] Table 9

[0380] Table 10

[0381] [Table 11]

[0382] Synthesis of Compound 1: [ka] Second Synthesis (1-Methyl-1H-pyrazol-3-yl)methylamine (1 g, 9 mmol) was heated to 110 °C in a sealed tube, Intermediate 11 (425 mg, 0.99 mmol) was added, and the reaction mixture was heated at 110 °C for 5 h. The residue was dissolved in DCM and purified by flash chromatography (DCM / MeOH / NH OH gradient 100:0:0 to 90:10:0.2). Pure fractions were collected, evaporated, crystallized in Et O, filtered, and dried to give compound 1 (177 mg, 39%). mp = 178 °C (DSC).

[0383] The compounds shown in the table below were prepared by similar reaction protocols.

[0384] [Table 12]

[0385] [Table 13]

[0386] [Table 14]

[0387] [Table 15]

[0388] [Table 16]

[0389] [Table 17]

[0390] [Table 18]

[0391] Synthesis of compound 91: [ka] A mixture of intermediate 18 (250 mg, 1 mmol), intermediate 8 (400 mg, 1.6 mmol), HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethylurea hexafluorophosphate) (590 mg, 1.6 mmol), and diisopropylethylamine (1.1 mL, 6.6 mmol) in DMF (10 mL) was stirred at room temperature for 15 h. The solvent was removed by evaporation, and the residue was added to DCM and HO. The organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. This fraction was purified by flash chromatography (DCM / MeOH / NHOH gradient 100:0:0 to 90:10:0.2). Pure fractions were collected and evaporated to dryness. The residue was washed with an aqueous solution of KCO, and CHCl was added. After stirring the mixture for 20 minutes, the organic layer was extracted, dried over MgSO4, filtered, and evaporated to dryness to give compound 91 (190 mg, 41%). This fraction was lyophilized with acetonitrile / water 20 / 80 to give compound 91 (177 mg, 39%). d :67.7°(589nm, c0.08w / v, MeOH, 23℃).

[0392] The compounds shown in the table below were prepared by similar reaction protocols.

[0393] [Table 19]

[0394] [Table 20]

[0395] [Table 21]

[0396] [Table 22]

[0397] [Table 23]

[0398] Synthesis of compounds 92a and 92b: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.6 g, 1.6 mmol) was added to a solution of intermediate 25 (0.44 g, 1.6 mmol), 27 (0.36 g, 1.4 mmol), and diisopropylethylamine (1 mL, 5.8 mmol) in DMF (20 mL). The reaction was stirred at room temperature overnight. 1 M Na2CO3 (10 mL) and DCM (25 mL) were added. The phases were separated. The aqueous layer was extracted with additional DCM (5 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; DCM / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). The desired fractions were collected and concentrated in vacuo to give a residue that was purified by reverse-phase chromatography [start (90% HO-10% ACN:MeOH 1:1)-finish (54% HO-46% ACN:MeOH 1:1)]-[65 mM NHOAc + ACN (90:10)]. The desired fractions were collected and concentrated in vacuo to give Compound 92a (180 mg, 26%) and Compound 92b (152 mg, 22%).

[0399] The compounds shown in the table below were prepared by similar reaction protocols.

[0400] [Table 24]

[0401] [Table 25]

[0402] [Table 26]

[0403] [Table 27]

[0404] [Table 28]

[0405] [Table 29]

[0406] [Table 30]

[0407] Synthesis of compounds 122a and 122b: [ka] Intermediate 31 (0.38 g, 0.78 mmol) was added to THF (10 mL) and treated with 37% aqueous formaldehyde (116 μL, 1.6 mmol) at room temperature. After 15 min, sodium triacetoxyborohydride (0.33 g, 1.6 mmol) was added. The reaction was stirred overnight at room temperature. NaCO was added, and the reaction was extracted with DCM (2 × 20 mL). The combined organic layers were dried over MgSO, filtered, and concentrated. Chromatography on silica gel (gradient: DCM / MeOH / NHOH (9.0 / 0.9 / 0.1)) afforded a mixture of diastereoisomers. This mixture was purified by reverse-phase chromatography [start (81% HO-19% MeCN-MeOH) - end (45% HO-55% MeCN-MeOH)] - [65 mM NHOAc + ACN (90:10)]. The desired fractions were combined, and the pH was lowered to 8 with 1M Na2CO3. The compound was extracted with DCM (2 × 15 mL), dried over MgSO4, filtered, and concentrated to give 89 mg of the first diastereoisomer and 71 mg of the second diastereoisomer. The first diastereoisomer was purified by reverse-phase chromatography [start (90% HO-10% MeCN-MeOH)-end (54% HO-46% MeCN-MeOH)]-[25 mM NH4HCO3]. The desired fractions were concentrated in vacuo at 60 °C and dried under vacuum to give compound 122a (30 mg, 8%) as a white solid. The second diastereoisomer was purified by reverse-phase chromatography [start (90% HO-10% MeCN-MeOH)-end (54% HO-46% MeCN-MeOH)]-[25 mM NH4HCO3]. The desired fractions were concentrated in vacuo at 60° C. and dried under vacuum to give compound 122b as a white solid (29 mg, 7%).

[0408] The compounds shown in the table below were prepared by similar reaction protocols.

[0409] [Table 31]

[0410] [Table 32]

[0411] [Table 33]

[0412] [Table 34]

[0413] [Table 35]

[0414] [Table 36]

[0415] Synthesis of compound 140a: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (1.2 g, 3.2 mmol) was added to a solution of Intermediate 47 (0.8 g, 3.2 mmol), Intermediate 27 (0.7 g, 2.9 mmol), and diisopropylethylamine (1.9 mL, 11.7 mmol) in DMF (20 mL). The reaction was stirred overnight at room temperature for 8 hours. Na2CO3 (50 mL, 1 M) was added, and the reaction was extracted with ACOEt (3 × 20 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash column chromatography (silica; DCM / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). The desired fractions were collected and concentrated in vacuo. The product was purified by reverse-phase chromatography [start (90% water - 10% MeCN-MeOH) - end (54% water - 46% MeCN-MeOH)] - [65 mM NHOAc + MeCN (90:10)]. DCM was added, the phases were separated, and the organic layer was dried over MgSO, filtered, and concentrated to dryness. The product was triturated to give a mixture of compounds 140a and 140b (600 mg, 46%). The mixture was subjected to chiral separation. Method: AMYLOSE_1Q_M6: [75% [n-heptane + 0.1% DEA] - 25% [2-propanol + 0.1% DEA] - 0% [n-heptane + 0.1% DEA] - 100% [2-propanol + 0.1% DEA]]. The product was concentrated to dryness to give compound 140b (205 mg, 15%), [α] d :+114.3°(589nm, c0.13w / v, MeOH, 23℃) and compound 140a (143mg, 11%), [α] d : +80.1° (589 nm, c0.13 w / v, MeOH, 23°C).

[0416] The compounds shown in the table below were prepared by similar reaction protocols.

[0417] [Table 37]

[0418] [Table 38]

[0419] Synthesis of compound 166: [ka] Intermediate 38 (156 mg, 0.347 mmol) was added to dichloroethane and treated with acetone (0.139 mL, 0.694 mmol) and acetic acid (0.020 mL, 0.347 mmol) at room temperature. After 15 minutes, triacetoxyborohydride (0.147 g, 0.694 mmol) was added. The reaction was allowed to proceed overnight. The reaction was diluted with DCM (300 mL) and washed with 1 M Na2CO3 (150 mL). The aqueous phase was extracted once more with DCM (100 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. Silica gel chromatography (DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1) gradient 0-50% in DCM) gave a mixture that was purified twice again by prep LC: MMP4-AC: 19-55% ACN / MeOH (1 / 1, v / v) gradient in 25 mM ammonium acetate), followed by a second prep LC: MMP5-NH4OH-ACN: 28%-64% ACN gradient in 0.4% ammonia water). Pure fractions were collected, and the compound was extracted with DCM (100 mL), dried over MgSO4, filtered, and concentrated to give colorless rods, which were triturated with pentane (2 mL) to give compound 166 as a white solid (35 mg, 20%).

[0420] The compounds shown in the table below were prepared by similar reaction protocols.

[0421] [Table 39]

[0422] [Table 40]

[0423] [Table 41]

[0424] [Table 42]

[0425] Synthesis of compound 167: [ka] Intermediate 52 (0.276 g, 1.11 mmol), Intermediate 27 (0.14 g, 0.55 mmol), and diisopropylethylamine (0.18 mL, 1.1 mmol) were dissolved in DMF (2 mL). The mixture was stirred at room temperature for 20 minutes, and then HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.25 g, 0.7 mmol) was added. The mixture was stirred overnight at room temperature. The reaction was diluted with DCM (25 mL) and washed with 1 M Na2CO3 (10 mL). The phases were separated, and the aqueous layer was extracted once more with DCM (10 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; DCM / MeOH, 5 / 1, v / v 0 / 100 to 100 / 0 in DCM). The desired fractions were collected and concentrated in vacuo. Compound 167 (0.073 g, 27%) was obtained purely by reverse-phase chromatography [start (72% HO-28% CHCN-CHOH)-finish (36% HO-64% CHCN-CHOH)]-[HO:25 mM NHHCO]. d :+104.1°(589nm, c0.13w / v, MeOH, 23℃).

[0426] The compounds shown in the table below were prepared by similar reaction protocols.

[0427] [Table 43]

[0428] Synthesis of compounds 169a and 169b: [ka] Intermediate 27 (0.5 g, 2 mmol), trans-3-pyrrolidinecarboxylic acid, 1-methyl-4-phenyl-, hydrochloride (0.6 g, 2.4 mmol), and diisopropylethylamine (1 mL, 6 mmol) were dissolved in DMF (10 mL). The mixture was stirred at room temperature for 20 minutes, and then HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.9 g, 2.4 mmol) was added. The resulting mixture was stirred at room temperature for an additional hour. The reaction was diluted with DCM (5 mL) and washed with 1 M Na2CO3 (40 mL). The phases were separated, and the aqueous layer was extracted once more with DCM (25 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; DCM / MeOH / NH3 (25% in water), 9 / 0.95 / 0.05, v / v 0 / 100 to 100 / 0 in DCM).

[0429] Compounds 169a and 169b were separated by reverse phase chromatography [start (90% water-10% CHCN)-finish (54% water-46% CHCN)]-[water:65 mM NH4OAc+ACN (90:10)] to give compound 169b (0.2 g, 23%) [α] d :+73.9°(589nm, c0.18w / v, MeOH, 23℃) and compound 169a (0.24g, 27%) [α] d : +131.8° (589 nm, c 0.16 w / v, MeOH, 23°C).

[0430] Synthesis of compounds 170a and 170b: [ka] Intermediate 59 (0.24 g, 0.5 mmol) was added to MeOH (15 mL) and treated with 37% aqueous formaldehyde (81 μL, 1.1 mmol) at room temperature. After 15 minutes, sodium triacetoxyborohydride (172 mg, 0.8 mmol) was added. The reaction was stirred overnight. NaCO was added, and the mixture was extracted with DCM (2 × 35 mL). The combined organic layers were dried over MgSO, filtered, and concentrated. The residue was purified by reverse-phase chromatography [start (81% water - 19% ACN:MeOH 1:1) - finish (45% water - 55% ACN:MeOH 1:1)] - [65 mM NHOAc + ACN (90:10)]. The desired fractions were collected and extracted with DCM (2 × 35 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to give compound 170a (52 mg, 20%) [α] d :+70.9°(589nm, c0.12w / v, MeOH, 23℃) and compound 170b (61mg, 24%) [α] d : +87° (589 nm, c 0.069 w / v, MeOH, 23°C).

[0431] Synthesis of compounds 171a and 171b: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.8 g, 2 mmol) was added to a solution of intermediate 66 (463 mg, 1.8 mol), intermediate 8 (526 mg, 2 mmol) and dihydropropylethylamine (1.3 mL, 7.5 mmol) in DMF (25 mL) at room temperature. The reaction was continued for 36 h. The mixture was diluted with AcOEt (200 mL) and washed with 1 M Na2CO3 (150 mL). The aqueous phase was extracted with AcOEt (3 × 100 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO4, filtered and concentrated. Chromatography on silica gel (mixture DCM / MeOH / NH4OH gradient 9.0 / 0.9 / 0.1, v / v, 0-50% in DCM) gave a mixture of compounds 171a and 171b, which was separated by chiral separation (Column Amylose-1, Q-M5: gradient of (2-propanol / ethanol 9 / 1, v / v + 0.1% DEA) in (n-heptane + 0.1% DEA) from 5 to 70%) to give compound 171a (268 mg, 31%) [α] d : +34.5° (589 nm, c 0.13 w / v, methanol, 23.0°C), compound 171b (220 mg, 26%) [α] d : -51.5° (589 nm, c 0.12 w / v, methanol, 23.0°C).

[0432] The compounds shown in the table below were prepared by similar reaction protocols.

[0433] [Table 44]

[0434] Synthesis of compound 174: [ka] While bubbling nitrogen through the reaction tube, Intermediate 69 (300 mg, 0.8 mmol), (1-methyl-1H-pyrazol-3-yl)methanamine (0.2 g, 1.6 mmol), RuPhos Pd G3 (33 mg, 0.04 mmol), and sodium tert-butoxide (0.15 g, 1.6 mmol) were added to toluene (15 mL). Degassing was continued for 5 min, and the reaction vessel was sealed with a screw cap. The mixture was heated to 120 °C for 4 h. The mixture was cooled to room temperature, diluted with DCM / MeOH (100 mL, 5 / 1, v / v), and washed once with water (20 mL). The organic layer was dried over MgSO4, filtered, and concentrated. Chromatography on silica gel (DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1, v / v / v) gradient 0-50% in DCM) gave an oily residue which crystallized on standing to give compound 174 (0.140 g, 39%) [α] d : +43.7° (589 nm, c 0.17 w / v, methanol, 23.0°C).

[0435] The compounds in the table below were prepared by similar reaction protocols.

[0436] [Table 45]

[0437] Synthesis of compound 176: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.4 g, 1 mmol) was added to a solution of Intermediate 71 (0.2 g, 0.8 mmol), Intermediate 8 (0.26 g, 1 mmol), and diisopropylethylamine (0.4 mL, 2.6 mmol) in DMF (20 mL). The reaction was stirred at room temperature for 2 days. 1 M Na2CO3 (10 mL) and DCM (25 mL) were added. The aqueous layer was extracted with DCM (5 mL). The combined organic layers were dried over MgSO4, filtered, and evaporated in vacuo. The residue was purified by flash column chromatography (silica; DCM / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM).

[0438] The desired fractions were collected and concentrated in vacuo. The residue was purified by reverse-phase chromatography [start (81% HO-19% ACN:MeOH 1:1)-end (45% HO-55% ACN:MeOH 1:1)]-[25 mM NH4HCO3] and repurified by reverse-phase chromatography [start (90% HO-10% MeCN:MeOH)-end (54% HO-46% MeCN:MeOH)]-[65 mM NH4OAc + MeCN (90:10)]. The desired fractions were collected and concentrated in vacuo. The residue was triturated with diethyl ether to give compound 176 (82 mg, 21%) as an off-white solid [α]. d :+8.2°(589nm, c0.07w / v, MeOH, 23℃).

[0439] Synthesis of compounds 177a, 177b, and 177c: [ka] Intermediate 74 (0.49 g, 1 mmol) was added to MeOH (15 mL) and treated with 37% aqueous formaldehyde (0.115 mL, 1.5 mmol) at room temperature. Triacetoxyborohydride (0.3 g, 1.5 mmol) was then added after 15 min. The reaction mixture was stirred overnight. The reaction was diluted with DCM (60 mL) and washed with 1 M Na2CO3 (20 mL). The aqueous phase was extracted once more with DCM (50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to give a crude oil. The residue was purified by flash column chromatography (silica; DCM / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). The product was obtained as an oil. The impure product was purified by reverse-phase chromatography [start (90% HO-10% MeCN-MeOH)-end (54% HO-46% MeCN-MeOH)]-[25 mM NH4HCO3]. The desired fractions were collected, concentrated at 60 °C, and dried under high vacuum. The product was triturated with diethyl ether to give compound 177a (343 mg, 67%). Chiral separation by SFC (Lux-Amylose-1 SFC isocratic mode 20% propanol) gave compound 177b (116 mg, 23%) [α]. d :+65.2°(589nm, c0.11w / v, MeOH, 23℃) and compound 177c (72mg, 14%) [α] d : +27.3° (589 nm, c 0.14 w / v, MeOH, 23°C).

[0440] The compounds shown in the table below were prepared by similar reaction protocols.

[0441] [Table 46]

[0442] Synthesis of compounds 180a and 180b: [ka] Intermediate 84a (0.3 g, 1.2 mmol), Intermediate 8 (0.37 g, 1.44 mmol), and diisopropylamine (0.8 mL, 4.8 mmol) were added to DMF (15 mL) at room temperature. HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.55 g, 1.44 mmol) was added, and the mixture was stirred overnight. 1 M Na2CO3 (30 mL) and DCM (35 mL) were added. The organic layer was separated, and the aqueous phase was extracted once more with DCM (30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (silica; DCM / CH3OH, 9 / 1, v / v 0 / 100 to 100 / 0 in DCM). The desired fractions were collected and concentrated in vacuo. The product was purified by reverse-phase chromatography [start (72% HO-28% MeCN-MeOH)-finish (36% HO-64% MeCN-MeOH)]-[65 mM NHOAc + MeCN (90:10)] and triturated with diethyl ether to give a mixture of trans diester isomers as a foam (222 mg, 39%). The residue was purified by chiral SFC (Lux-Amylose-1 SFC isocratic mode 30% EtOH) to give compound 180a (0.061 g, 11%) [α]. d :+100.8°(589nm, c0.21w / v, MeOH, 23℃) and compound 180b (0.052g, 9%) [α] d : -80.7° (589 nm, c 0.15 w / v, MeOH, 23°C).

[0443] The compounds shown in the table below were prepared by similar reaction protocols.

[0444] [Table 47]

[0445] [Table 48]

[0446] [Table 49]

[0447] Synthesis of compound 190: [ka] (4-Methoxycyclohexyl)amine (334 μl, 2.4 mmol) was added to the reaction tube with intermediate 93 (147 mg, 0.3 mmol) at 80 °C. The reaction mixture was then heated at 100 °C for 15 min. HO and DCM were added, and the organics were separated, dried over MgSO, filtered, and concentrated. The crude material was purified by chromatography on silica gel (0-100% MeOH in DCM gradient) and reverse-phase chromatography [start (70% HO - 30% ACN:MeOH 1:1) - end (27% HO - 73% ACN:MeOH 1:1)] - HO = [25 mM NHHCO, pH = 8]. The residue was triturated with diethyl ether to give compound 190 (43 mg, 26%) as a yellow solid [α]. d :-41.6°(589nm, c0.08w / v, MeOH, 23℃).

[0448] The compounds shown in the table below were prepared by similar reaction protocols.

[0449] [Table 50]

[0450] Synthesis of compound 192: [ka] Compound 192 (0.12g, 47%) [α] d : +32.9° (589 nm, c 0.18 w / v, MeOH, 23° C.) is prepared by a reaction protocol similar to that for compound 190 starting from intermediate 98.

[0451] Synthesis of compound 193: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (81 mg, 0.21 mmol) was added to a solution of intermediate 107 (51 mg, 0.2 mmol), intermediate 8 (55 mg, 0.2 mmol) and diisopropylethylamine (132 μl, 0.8 mmol) in DMF (5 mL) at room temperature. The reaction was continued for 20 h. The mixture was diluted with AcOEt (20 mL) and washed with 1 M Na2CO3 (15 mL). The aqueous phase was extracted with AcOEt (10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO4, filtered and concentrated to dryness to give the crude product. Chromatography on silica gel (DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1, v / v / v) 0–50% in DCM) gave compound 193 (49 mg, 54%) [α] d : -55.5° (589 nm, c 0.15 w / v, methanol, 23°C) was obtained.

[0452] Synthesis of compound 194: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (37 mg, 1 mmol) was added to a solution of intermediate 116 (0.022 g, 0.09 mmol), intermediate 8 (25 mg, 1 mmol), and diisopropylethylamine (61 μL, 0.36 mmol) in DMF (5 mL) at room temperature. The reaction was continued for 20 h. The mixture was diluted with DCM (50 mL) and washed with 1 M Na2CO3 (40 mL). The aqueous phase was extracted with DCM (50 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated to dryness. Chromatography on silica gel (DCM / MeOH / NH4OH (9.0 / 0.9 / 0.1, v / v / v) gradient 0 to 50% in DCM) gave compound 194 (0.01 g, 23%).

[0453] Synthesis of compounds 195a and 195b: [ka] To a solution of intermediate 8 (526 mg, 2 mmol) in DCM (4 mL) was added oxalyl chloride (179 μL, 2 mmol) at rt. One drop of DMF was added and the reaction was stirred for 1 h. Intermediate 119 (180 mg, 0.7 mmol) was added, followed by triethylamine (572 μL, 4.1 mmol). The reaction was stirred at rt for 14 h. The reaction mixture was quenched with an aqueous solution of NH4Cl and extracted with EtOAc (3 times). The organic layer was washed with brine, dried over MgSO4, filtered, and the solvent was evaporated. The residue was purified by chromatography on silica gel (SiO2, Grace, 24 g; eluent: 100% DCM to 85% DCM, 15% MeOH (2% NH4OH)). The pure fractions were collected and the solvent evaporated to give two fractions, which were combined and purified by reversed phase (stationary phase: YMC-actus Triart C18 10 μm 30 × 150 mm, mobile phase: gradient 50% NH4HCO3 0.2%, 50% MeOH to 15% NH4HCO3 0.2%, 85% MeOH) followed by chiral SFC (stationary phase: Lux Cellulose-2 5 μm 250 × 21.2 mm, mobile phase: 50% CO2, 50% EtOH (0.3% iPrNH2)): the two fractions were lyophilized to give compound 195a (6 mg, 2%) and compound 195b (24 mg, 7%).

[0454] The compounds shown in the table below were prepared by similar reaction protocols.

[0455] [Table 51]

[0456] Synthesis of compound 198: [ka] HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (545 mg, 1.4 mmol) was added to a solution of intermediate 130 (335 mg, 1.3 mmol), intermediate 8 (367 mg, 1.4 mmol) and diisopropylethylamine (889 μl, 5.2 mmol) in DMF (30 mL) at room temperature. The reaction was continued for 20 h. The mixture was diluted with AcOEt (150 mL) and washed with 1 M Na2CO3 (100 mL). The aqueous phase was extracted with AcOEt (5 × 50 mL). The combined organic layers were dried over MgSO4, filtered and concentrated to dryness. Chromatography on silica gel (DCM / MeOH / NHOH (9.0 / 0.9 / 0.1, v / v / v) 0-50% in DCM) gave an amorphous solid (451 mg), which was crystallized from ACN (5 mL) to give compound 198 as a white solid (136 mg, 22%). d : +95.8° (589 nm, c 0.12 w / v, methanol, 23° C.). The mother liquor was purified to give an additional batch of 160 mg (27%).

[0457] The compounds shown in the table below were prepared by similar reaction protocols.

[0458] [Table 52]

[0459] [Table 53]

[0460] Initial synthesis of compound 204: [ka] Intermediate 131 (1.1 g, 3.5 mmol), Intermediate 132a (0.8 g, 4.5 mmol), and triethylamine (0.7 mL, 5 mmol) in DCM (12 mL) were stirred overnight at rt. Water and DCM were added, the mixture was extracted, and the organic layer was separated, dried over MgSO, filtered, and evaporated to dryness. Purification was carried out by preparative LC (stationary phase: SiOH 35-40 μm 40 g Buchi, mobile phase: DCM 100% to 90 / 10 / 0.1 CMA). Fractions were collected and evaporated to dryness. A second purification by preparative LC (24 g SiOH 15 μm Interchim, gradient 100% DCM to 90% DCM 10% CH3OH 0.2% NH4OH) followed by purification by achiral SFC (stationary phase: 2-ethylpyridine 5 μm 150*30 mm, mobile phase: 88% CO2, 12% MeOH) gave compound 204 (476 mg, 30%). [α] d :=+93.3°(589nm, c0.21w / v%, DMF, 20℃).

[0461] Second synthesis of compound 204a: [ka] Intermediate 133 (1.06 g, 3.4 mmol), intermediate 132a (842 mg, 4.8 mmol), and triethylamine (664 μl, 4.8 mmol) in DCM (10 mL) were stirred overnight at rt. Water and DCM were added, the mixture was extracted, and the organic layer was separated, dried over MgSO, filtered, and evaporated. Purification by preparative LC (stationary phase: irregular SiOH 40 μm 40 g, mobile phase: DCM 100% to 95 / 5 / 1 CMA) gave a mixture of diastereoisomers, which was separated by chiral SFC (stationary phase: CHIRALPAK AD-H 5 μm 250 × 30 mm, mobile phase: 65% CO, 35% MeOH (0.3% iPrNH)) to give compound 204b (255 mg) (crystallized in diethyl ether (90 mg, 6%)) [α]. d : -115.7° (589 nm, c 0.35 w / v%, DMF, 20°C) and compound 204a (263 mg) (crystallized in diethyl ether (70 mg, 4%)) [α]d : +89.4° (589 nm, c 0.32 w / v%, DMF, 20°C).

[0462] The compounds shown in the table below were prepared by similar reaction protocols.

[0463] [Table 54]

[0464] Synthesis of compound 209: [ka] To a solution of intermediate 137 (150 mg, 0.334 mmol), triethylamine (0.14 mL, 1 mmol) in DCM (2 mL) was added methanesulfonyl chloride (52 μL, 0.67 mmol) dropwise at 0° C. The reaction was stirred at room temperature for 15 hours. Water was added, and the organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. The residue was purified by preparative LC (12 g SiOH 30 μm Interchim, gradient 100% DCM to 80% DCM 20% CHOH 0.1% NHOH). The fractions were collected and evaporated to dryness. Crystallization in DIPE, filtration, and drying gave compound 209 (96 mg, 54%). [α] d :=+78.1°(589nm, c 0.26w / v%, DMF, 20℃).

[0465] The compounds shown in the table below were prepared by similar reaction protocols.

[0466] [Table 55]

[0467] Synthesis of compound 213: [ka] Intermediate 5 (130 mg, 0.503 mmol), Intermediate 138 (144 mg, 0.6 mmol), and triethylamine (0.105 mL, 0.755 mmol) were stirred in DCM (8.7 mL) at rt for 8 h. Water and DCM were added, the mixture was extracted, and the organic layer was separated, dried over MgSO, filtered, and evaporated. Purification by preparative LC (stationary phase: irregular SiOH 40 μm 12 g, mobile phase: 97 / 3 / 1 to 90 / 10 / 1 CMA) gave compound 213 (70 mg, 30% yield).

[0468] Synthesis of compound 214: [ka] A mixture of intermediate 141 (252 mg, 0.7 mmol), intermediate 132a (140 mg, 0.79 mmol), and triethylamine (0.15 mL, 1.1 mmol) in DCM (3.5 mL) was stirred at room temperature for 15 hours. The solvent was removed, and the residue was added to DCM and water. The organic layer was extracted, dried over MgSO, filtered, and evaporated to dryness. The residue was purified by preparative LC (24 g of SiOH 35-40 μm Buchi, gradient 100% DCM to 90% DCM 10% CHOH 0.1% NHOH). Fractions were collected, evaporated to dryness, and purified by preparative LC (12 g of SiOH 15 μm Interchim, gradient 100% DCM to 90% DCM 10% CHOH 0.1% NHOH). The residue was crystallized in DIPE, filtered, and dried to give compound 214 (96 mg, 27%). d :=+87.4°(589nm, c 0.23w / v%, DMF, 20℃).

[0469] Example B: Analytical Characterization of Intermediates and Compounds Optical rotation (OR) Optical rotations were measured at λ=589 nm (i.e., sodium D line) on a Perkin Elmer 341 digital polarimeter at 20° C. or 23° C. using a 0.2 mL cell (l=1 dm) and are reported as [α]D (g / concentration in 100 mL solvent).

[0470] Melting point For some compounds, melting points (mp) were measured using a Mettler Toledo aDSC 1 STARe System. Melting points were measured at a temperature ramp rate of 10°C / min up to 350°C. Values ​​are reported as peak values.

[0471] LCMS basic procedure High-performance liquid chromatography (HPLC) measurements were performed using an LC pump, diode array detector (DAD) or UV detector, and column as specified in each method. Additional detectors were included as needed (see methods table below). The flow from the column was introduced into a mass spectrometer (MS) equipped with an atmospheric pressure ion source. It is within the knowledge of one skilled in the art to set tuning parameters (e.g., scan range, dwell time, etc.) to obtain ions capable of identifying the nominal monoisotopic molecular weight (MW) of the compound. Data collection was performed using appropriate software. Compounds were analyzed based on their experimental retention times (R t ) and ions. Unless otherwise specified in the data tables, the reported molecular ions are [M+H] + (protonated molecule) and / or [MH] - (deprotonated molecule). If the compound cannot be directly ionized, specify the type of adduct (i.e., [M+NH4] + , [M+HCOO] - For molecules with multiple isotopic patterns (Br, Cl, etc.), the reported values ​​are those obtained for the lowest isotopic mass. All results were obtained with experimental uncertainties typically associated with the methods used.

[0472] In the following, "MSD" is a mass selective detector and "DAD" is a diode array detector.

[0473] [Table 56]

[0474] Table 57

[0475] Table 58

[0476] Table 59

[0477] Table 60

[0478] Table 61

[0479] Table 62

[0480] Table 63

[0481] Table 64

[0482] NMR Some NMR experiments were performed on a Bruker Avance 500 spectrometer equipped with a Bruker 5 mm BBFO probehead with z-gradients, operating at 500 MHz for protons and 125 MHz for carbon. Chemical shifts (d) are reported in parts per million (ppm). J values ​​are in Hz. Some NMR experiments were performed at ambient temperature (298.6 K) on a Bruker Avance III 400 spectrometer equipped with an inverted double-resonance (H, C, SEI) probehead with z-gradients, operating at 400 MHz for protons, using an internal deuterium lock. Chemical shifts (d) are reported in parts per million (ppm). J values ​​are in Hz.

[0483] [Table 65]

[0484] [Table 66]

[0485] [Table 67]

[0486] Example C: Pharmacological Assays Expression and purification of the trimeric complex of CDK7, cyclin H, and MAT1 Human CDK7 (amino acids 1–346), human MAT1 (amino acids 1–309), and human cyclin H (amino acids 1–323) carrying an N-terminal His6 tag followed by a tobacco etch virus (TEV) protease cleavage site were coexpressed in the baculovirus-SF9 insect cell expression system to generate trimers. Cell pellets were harvested 72 hours postinfection and resuspended using a Dounce homogenizer in 20 mM Hepes-NaOH (pH 8.0), 300 mM NaCl, 10% glycerol, 2 mM dithiothreitol (DTT), and 20 mM imidazole supplemented with cOmplete™ Protease Inhibitor Cocktail (Roche) and 25 U / mL Benzonase® Nuclease HC, according to the manufacturer's instructions. Cells were lysed by three passes through a Microfluidics M110Y Microfluidizer at 600 kPa followed by centrifugation at 38,000 × g for 1 h at 4°C. The supernatant was loaded onto a pre-equilibrated HisTrap HP column and eluted in 20 mM Hepes-NaOH (pH 8.0), 50 mM NaCl, 10% glycerol, 2 mM DTT, and 400 mM imidazole. The eluate was further purified by gel filtration on a Superdex S200 16 / 60 column and eluted with 20 mM Hepes-NaOH (pH 7.5), 50 mM NaCl, 10% glycerol, and 2 mM DTT. Fractions containing a 1:1:1 ratio of the trimeric complex of CDK7, cyclin H, and MAT1 were pooled, concentrated to 3 mg / mL with a 10 kDa MWCO concentrator, and diluted to a final concentration of 1.6 mg / mL with 11.1 mM Hepes-NaOH (pH 8.0), 27.8 mM NaCl, 1.1 mM DTT, and 50% glycerol.

[0487] In vitro CDK7 assay and potency determination of reversible inhibitors The inhibitory potency of compounds was investigated using the absorbance kinetic assay described below. Compounds with potencies approaching the detection limit of the assay (IC50 < 10 nM) were further evaluated in the more sensitive fluorescent endpoint assay.

[0488] Absorbance kinetic assay (20 nM CDK7 / cyclin H / MAT-1 complex) The CDK7 complex catalyzes the ATP-dependent phosphorylation of the peptide substrate CDK7 / 9-tide derived from RNA Pol II, generating a phosphopeptide and ADP. The kinase reaction product ADP is converted to lactate and NAD in the presence of phosphoenolpyruvate (PEP), NADH, and the coupling enzymes lactate dehydrogenase (LDH) and pyruvate kinase (PK). + The catalytic activity of the CDK7 complex was measured by continuously tracking the absorbance intensity at 340 nm, which corresponds to the depletion of NADH.

[0489] Compound potency was determined by the addition of 300 μM CDK7 / 9 tide (K) in a buffer containing 20 mM Tris, pH 7.4, 10 mM MgCl2, and 0.004% Triton X-100. M peptide =140.5±18.5μM), 500μM ATP(K M ATP The assay conditions were: 500 μM PEP, 100 μM NADH, 0.6–1 unit PK / 0.9–1.4 units PK, and 20 nM CDK7 / cyclin H / MAT-1 complex. Absorbance at 340 nm was monitored dynamically for 8 hours at 2-minute intervals.

[0490] Assays were performed in 384-well plates pre-spotted with nanoliter amounts of compound using a LabCyte Echo 555, using a 100 μl reaction volume per well. Compound dilution plates were diluted 2-fold (this could be adjusted as needed) with DMSO to 11 concentrations, and a non-inhibitory DMSO control was also included. A 2x mixture of substrate and coupling reagent was added to the assay plate, followed by an equal volume of 40 nM CDK7 / cyclin H / MAT-1 complex. After mixing, the assay plate was spun at 2000 rpm for 3 minutes and then transferred to a plate reader for data collection.

[0491] For reversible inhibitors, the absorbance reaction progress curve was linear. The steady-state rate was derived from the slope of the linear curve. The following equation was applied to determine the percent inhibition:

number

[0492] I C 50 The value is calculated by the following formula:

number

[0493] Flint assay (5 nM CDK7 / cyclin H / MAT-1 complex) The continuous absorbance assay was converted to an endpoint fluorescence assay by following the decrease in the NADH fluorescence signal at excitation and emission wavelengths of 340 nm and 440 nm, respectively.

[0494] The fluorescence assay was performed using the same concentrations of substrate and coupling reagent as used in the absorbance assay, but with a reduced concentration of CDK7 / cyclin H / MAT-1 complex of 5 nM (final concentration), and the reaction time was 24 h. The percent inhibition was calculated using the following formula: Inhibition rate = (sample - NC) / (PC - NC)*100 where NC means negative control (reaction without inhibitor) and PC means positive control (reaction with complete inhibition).

[0495] The dose curve was fitted using the following equation, and the IC 50 asked for. Y = bottom + (top - bottom) / (1 + 10^((logIC 50 -X)*Hill slope)) where X = log of compound concentration 10;The top and bottom can be defined by PC and NC, respectively.

[0496] Imaging-based intracellular RNA PolII Ser5 phosphorylation assay To assess inhibition of CDK7 kinase activity, we used a 384-well automated imaging assay. This assay detects phosphorylation of serine 5 on a unique heptapeptide sequence in the C-terminal domain of the Rpb1 subunit of RNA polymerase II, a downstream substrate of CDK7. This heptapeptide sequence is repeated up to 52 times in the CTD of Rpb1.

[0497] material A549 adenocarcinoma human alveolar basal epithelial cells (ATCC, CCL-185), rabbit phospho-Rpb1 CTD (Ser5) antibody (D9N51 (Cell Signaling Technology)), DMEM (Sigma), fetal bovine serum (Biowest), L-glutamine (Sigma), penicillin / streptomycin (Life Technologies), sodium pyruvate (Sigma), Hepes (Sigma), poly-D-lysine-coated μ-Clear 384 black plates (Greiner), formaldehyde (PolySciences), D-PBS (Sigma), methanol (Sigma), Alexa Fluor 488 goat anti-rabbit IgG secondary antibody (Life Technologies), HCS CellMask™ Deep Red stain (Life Technologies), Hoechst 33258 (Invitrogen).

[0498] RNA polymerase II serine 5 phosphorylation was detected using a specific rabbit phospho-Rpb1 CTD (Ser5) antibody. A549 adenocarcinoma human alveolar epithelial cells were seeded at 1000 cells / well in 20 μl of medium (DMEM supplemented with 1% Fetal Bovine Serum (heat-inactivated 30 min at 56°C), 2 mM L-glutamine, 50 U / ml penicillin, 50 μg / ml streptomycin, 1 mM sodium pyruvate, and 50 mM Heps) and cultured for 20 h at 37°C and 5% CO in poly-D-lysine-coated μClear 384 black plates.

[0499] After incubation, the cells were challenged with the compounds for 3 hours at 37°C and 5% CO2. DMSO was used as a high control, and 10 μM of the LDC4297 reference compound was used as a low control. 40 nl of the test compounds and controls were spotted onto the cell plate using an Echo Liquid Handler (Echo 550, Labcyte). After incubation, the cells were fixed with 20 μl of 10% formaldehyde for 20 minutes at room temperature. The medium / formaldehyde solution was removed, and the plate was resuspended in 30 μl of D-PBS (Ca). 2+ and Ma 2+ The cells were washed three times with PBS (no buffer) and permeabilized by adding 20 μl of ice-cold methanol for 20 minutes. The cells were washed three times with 30 μl of D-PBS and then left for 1 hour with 20 μl of blocking buffer (25 ml fetal bovine serum in 500 ml D-PBS).

[0500] After removing the blocking buffer, 20 μl of 1 / 1000 primary rabbit phospho-Rpb1 CTD (Ser5) antibody was added. This antibody binds to the phosphorylated serine 5 of the heptapeptide sequence within the CTD of Rpb1. After removing the primary antibody and washing the plate three times with 30 μl D-PBS, 20 μl of 1 / 2000 Alexa Fluor 488 goat anti-rabbit IgG secondary antibody was added for final detection of phospho-Rpb1 CTD (Ser5), along with 1 / 5000 HCS CellMask™ Deep Red stain for membrane staining and 1 / 5000 Hoechst 33258 for nuclear staining. Finally, the plate was washed twice with 30 μl D-PBS, and the wells were filled with 40 μl D-PBS. The plate was sealed (with thermowell sealing tape) and stored at 4°C until reading. Plates were read using an Opera Phenix (Perkin Elmer) with a 10x air objective, and data were calculated and analyzed in Phaedra.

[0501] I C 50 The values ​​were calculated using the following formula: LC = mean low control value = Cells treated with 10 μM LDC4297 HC = mean of high control values = Cells treated with 0.2% DMSO

[0502] The mean values ​​of total HC and total LC are used for normalization. % efficiency = 100 - (sample - LC) / (HC - LC) x 100 % Control = (Sample / HC) x 100

[0503] A best-fit curve was generated using least squares to plot % control versus compound concentration, which gave the IC 50 An estimate of the slope of the plot can also be obtained by the Hill coefficient.

[0504] [Table 68]

[0505] [Table 69]

[0506] [Table 70]

[0507] [Table 71]

[0508] [Table 72]

[0509] [Table 73]

[0510] [Table 74]

[0511] Example D: Prospective Formulations "Active ingredient" (ai) as used throughout these examples refers to a compound of formula (I) or a pharmaceutically acceptable addition salt or solvate thereof, including any tautomeric or stereoisomeric form; in particular to any one of the exemplified compounds.

[0512] A typical example of a formulation for the present invention is as follows:

[0513] 1. Tablets Active ingredient 5~50mg Dicalcium phosphate 20mg Lactose 30mg Talcum 10mg Magnesium stearate 5mg Potato starch until the total reaches 200mg

[0514] 2. Suspension agents Aqueous suspensions for oral administration are prepared so that each milliliter contains 1 to 5 mg of the active ingredient, 50 mg of sodium carboxymethylcellulose, 1 mg of sodium benzoate, 500 mg of sorbitol, and 1 ml or less of water.

[0515] 3. Injections The parenteral composition is prepared by stirring 1.5% (weight / volume) of the active ingredient in 0.9% aqueous NaCl solution or 10% (by volume) aqueous propylene glycol solution.

[0516] 4. Ointments Active ingredient: 5-1000mg Stearyl alcohol 3g 5g lanolin 15g Vaseline Water until the total reaches 100g

[0517] In this embodiment, the active ingredient may be replaced by an equivalent amount of any of the compounds according to the invention, in particular by an equivalent amount of any of the exemplified compounds. The present invention includes the following embodiments. [Claim 1] Formula (I), including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof: [ka] (In the formula, A 1 is CR 1a R 1b or NR 2 and; A 2 is CR 3a R 3b or NR4 and; A 3 and A 4 each independently represents CH or N; A 5 is -CH 2 - or -CH(CH 3 )-and; m is 0 or 1; Each R 1a and R 1b are independently hydrogen, C 1~6 Alkyl or -N(C 1~4 alkyl) 2 and; R 2 is hydrogen; haloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; -C(=O)-NH 2 ;-C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl) 2 ;C 3~6 Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C 1~6 Alkoxy, Cyano, C 3~6 C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S 1~6 is alkyl; Each R 3a and R 3b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 Alkyl; C 1~6 Alkoxy;C 1~6 Alkyloxycarbonyl; C 2~6 Alkenyl; C 2~6 Alkynyl; Cyano C 1~6 Alkyl; Hydroxy C 1~6 Alkyl; -C(=O)-NH 2 ;-C(=O)-NH(C 1~4 alkyl);-C(=O)-N(C 1~4 alkyl) 2 ;-N(C 1~4 alkyl) 2 ;C 3~6 Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently represent one or more of halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 optionally substituted with alkyl; R 4 is C 1~6 Alkyl; or halo, hydroxy, mercapto, carboxyl, haloC 1~6 Alkyl, mono- or di(C 1~6 alkyl)amino, mono- or di(C 1~6 alkyl)aminocarbonyl, C 1~6 Alkyl carbonyl, C 1~6 Alkylcarbonylamino, C 1~6 Alkoxy, C 1~6 Alkoxycarbonyl, C 1~6 Alkylthio, cyano, nitro, haloC 1~6 Alkoxy, aminocarbonyl, C 3~6 Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C 1~6 Alkyl)amino, C 1~6 Alkylcarbonylamino, [(mono- or di-C 1~6 Alkyl)amino-C 1~6 alkyl]carbonylamino or C 1~6 C optionally substituted with alkylsulfonylamino 1~6 phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from alkyl; Each R 5a 、R 5b 、R 6a 、R 6b 、R 7a and R 7b are independently hydrogen; C 1~6 Alkyl; HaloC 1~6 alkyl; or R 5a and R 5b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 6a and R 6b C along with the carbon atoms to which they are attached 3~6 can form a cycloalkyl; or R 5b and R 6a may form a cyclopropyl group together with the carbon atom to which they are attached; provided that R 5a 、R 5b 、R 6a 、R 6b 、R 7a and R 7b is not hydrogen; R 8 is a direct bond, hydroxy, halo, deuterium or C 1~4 C optionally substituted with alkoxy 1~4 Alkanediyl;-CH 2 -C(=O)-; spiro-C 3~6 cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C 3~6 cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R 9 is C 3~6 C optionally substituted with cycloalkyl 1~6 Alkyl, Cyano, Halo, HaloC 1~6 Alkyl, C 3~6 C optionally substituted with cycloalkyl 1~6 Alkoxy, HaloC 1~6 Alkoxy, Hydroxyl, Hydroxy C 1~6 Alkyl, oxo, -SO 2 -C 1~4 Alkyl, -SO 2 -C 3~6 Cycloalkyl, -SO 2 -NH 2 , -SO 2 -NH(C 1~4 alkyl), -SO 2 -N(C 1~4 alkyl) 2 , -NH-C(=O)-C 2~6 Alkenyl, -C(=O)-C 1~6 Alkyl, -C(=O)-C 1~6 Alkyl-C 3~6 Cycloalkyl, -C(=O)-C 3~6 Cycloalkyl, -C(=O)-C 2~6 Alkenyl, C 3~6 Cycloalkyl, spiro-C 3~6 cycloalkyl, phenyl, a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5 Compound. [Claim 2] Formula (II), including any tautomers and stereochemical isomers, isotopically labeled derivatives, or pharmaceutically acceptable salts or solvates thereof:

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. Formula (I): 【Chemistry 1】 (In the formula, A １ is CR １ａ R １ｂ or NR ２ and A ２ is CR ３ａ R ３ｂ or NR ４ and A ３ and A ４ each independently represents CH or N; A ５ is -CH ２ - or -CH(CH ３ )- and; m is 0 or 1; Each R １ａ and R １ｂ are independently hydrogen, C １～６ Alkyl or -N(C １～４ alkyl) ２ and R ２ is hydrogen; haloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C １～６ Alkoxy, cyano, C ３～６ C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; Each R ３ａ and R ３ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; Cyano C １～６ Alkyl; Hydroxy C １～６ Alkyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; -N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently have one or more of halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ optionally substituted with alkyl; R ４ is C １～６ Alkyl; or halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ６ａ and R ６ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; provided that R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ is not hydrogen; R ８ is a direct bond, hydroxy, halo, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl, cyano, halo, haloC １～６ Alkyl, C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy, HaloC １～６ Alkoxy, hydroxyl, hydroxy C １～６ Alkyl, oxo, -SO ２ -C １～４ Alkyl, —SO ２ -C ３～６ Cycloalkyl, —SO ２ -NH ２ , -SO ２ -NH(C １～４ alkyl), -SO ２ -N(C １～４ alkyl) ２ , -NH-C(=O)-C ２～６ Alkenyl, —C(═O)—C １～６ Alkyl, —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl, —C(═O)—C ３～６ Cycloalkyl, —C(═O)—C ２～６ Alkenyl, C ３～６ Cycloalkyl, spiro-C ３～６ cycloalkyl, phenyl, a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5. or a pharmaceutically acceptable salt or solvate thereof.

2. Formula (II): including any tautomers and stereochemical isomers, and isotopically labeled derivatives. 【Chemistry 2】 (In the formula, A ３ is CH or N; A ４ is CH or N; R ２ is hydrogen; haloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C １～６ Alkoxy, cyano, C ３～６ C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; Each R ３ａ and R ３ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; Cyano C １～６ Alkyl; Hydroxy C １～６ Alkyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; -N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently have one or more of halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ optionally substituted with alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ６ａ and R ６ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; provided that R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ is not hydrogen; R ８ is a direct bond, hydroxy, halo, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl; Cyano, Halo; HaloC １～６ Alkyl; C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy; HaloC １～６ Alkoxy; Hydroxyl; Hydroxy C １～６ Alkyl; oxo; -SO ２ -C １～４ Alkyl; -SO ２ -C ３～６ Cycloalkyl; —SO ２ -NH ２ , -SO ２ -NH(C １～４ alkyl); -SO ２ -N(C １～４ alkyl) ２ ;-NH-C(=O)-C ２～６ Alkenyl; —C(═O)—C １～６ Alkyl; —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl; —C(═O)—C ３～６ Cycloalkyl; —C(═O)—C ２～６ Alkenyl; C ３～６ Cycloalkyl; spiro-C ３～６ cycloalkyl; phenyl; a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, which is:

3. including any tautomeric and stereochemical isomeric forms, and isotopically labeled derivatives, A ３ is CH; A ４ is CH or N; R ２ is hydrogen; or deuterium, hydroxyl, C １～６ C optionally substituted with alkoxy or a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; Each R ３ａ and R ３ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ Alkyl; N(C １～４ alkyl) ２ ; C ３～６ cycloalkyl; phenyl; 5-6 membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl and heteroaryl each independently contain one or more of halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ optionally substituted with alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen or C １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; R ８ is a direct bond, hydroxy, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl; Halo; HaloC １～６ Alkyl; C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy; HaloC １～６ Alkoxy; Hydroxyl; Hydroxy C １～６ Alkyl; oxo; -SO ２ -C ３～６ Cycloalkyl; —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl; —C(═O)—C ３～６ Cycloalkyl; C ３～６ Cycloalkyl; spiro-C ３～６ cycloalkyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and 3. The compound according to claim 1, wherein n is 0, 1, 2, 3, or 4, or a pharmaceutically acceptable salt or solvate thereof.

4. Formula (IIIa) or (IIIb), including any tautomers and stereochemical isomers, and isotopically labeled derivatives: 【Transformation 3】 (In the formula, A ４ is CH or N; R ２ is hydrogen; haloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C １～６ Alkoxy, cyano, C ３～６ C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; R ３ａ is C １～６ Alkyl; HaloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; Cyano C １～６ Alkyl; Hydroxy C １～６ Alkyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; -N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; aryl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; 5- to 6-membered monocyclic heteroaryl containing at least one heteroatom selected from N, O, or S, wherein the aryl, heterocyclyl, and heteroaryl each independently have one or more of halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ optionally substituted with alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ６ａ and R ６ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; R ８ is a direct bond, hydroxy, halo, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 4-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl; Cyano, Halo; HaloC １～６ Alkyl; C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy; HaloC １～６ Alkoxy; Hydroxyl; Hydroxy C １～６ Alkyl; oxo; -SO ２ -C １～４ Alkyl; -SO ２ -C ３～６ Cycloalkyl; —SO ２ -NH ２ , -SO ２ -NH(C １～４ alkyl); -SO ２ -N(C １～４ alkyl) ２ ;-NH-C(=O)-C ２～６ Alkenyl; —C(═O)—C １～６ Alkyl; —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl; —C(═O)—C ３～６ Cycloalkyl; —C(═O)—C ２～６ Alkenyl; C ３～６ Cycloalkyl; spiro-C ３～６ cycloalkyl; phenyl; a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; and n is 0, 1, 2, 3, 4 or 5.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt or solvate thereof, which is

5. Formula (IVa) or (IVb), including any tautomers and stereochemical isomers, and isotopically labeled derivatives: 【Chemistry 4】 (In the formula, A ４ , R ２ , R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ , R ７ｂ , R ８ , A, R ９ and n are each independently as defined in any one of claims 1 to 4; R １０ is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ is alkyl; and p is 0, 1, 2, 3, 4 or 5.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, which is

6. Formula (Va) or (Vb), including any tautomers and stereochemical isomers, and isotopically labeled derivatives: 【Transformation 5】 (In the formula, R ２ is hydrogen; haloC １～６ Alkyl; C １～６ Alkoxy; C １～６ Alkyloxycarbonyl; C ２～６ Alkenyl; C ２～６ Alkynyl; —C(═O)—NH ２ ;-C(=O)-NH(C １～４ alkyl); -C(=O)-N(C １～４ alkyl) ２ ; C ３～６ Cycloalkyl; phenyl; 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or deuterium, hydroxyl, C １～６ Alkoxy, cyano, C ３～６ C optionally substituted with cycloalkyl, phenyl, or 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ６ａ and R ６ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; R ８ is a direct bond, hydroxy, halo, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; or 3-12 membered heterocyclyl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl; Cyano, Halo; HaloC １～６ Alkyl; C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy; HaloC １～６ Alkoxy; Hydroxyl; Hydroxy C １～６ Alkyl; oxo; -SO ２ -C １～４ Alkyl; -SO ２ -C ３～６ Cycloalkyl; —SO ２ -NH ２ , -SO ２ -NH(C １～４ alkyl); -SO ２ -N(C １～４ alkyl) ２ ;-NH-C(=O)-C ２～６ Alkenyl; —C(═O)—C １～６ Alkyl; —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl; —C(═O)—C ３～６ Cycloalkyl; —C(═O)—C ２～６ Alkenyl; C ３～６ Cycloalkyl; spiro-C ３～６ cycloalkyl; phenyl; a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; n is 0, 1, 2, 3, 4 or 5; R １０ is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ is alkyl; and p is 0, 1, 2, 3, 4 or 5.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, which is

7. including any tautomeric and stereochemical isomeric forms, and isotopically labeled derivatives, R ２ is hydrogen; or deuterium, hydroxyl, C １～６ C optionally substituted with alkoxy or a 4- to 7-membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S １～６ is alkyl; Each R ５ａ , R ５ｂ , R ６ａ , R ６ｂ , R ７ａ and R ７ｂ are independently hydrogen; C １～６ Alkyl; HaloC １～６ alkyl; or R ５ａ and R ５ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ６ａ and R ６ｂ C together with the carbon atom to which they are attached ３～６ can form a cycloalkyl; or R ５ｂ and R ６ａ together with the carbon atom to which they are attached can form a cyclopropyl; R ８ is a direct bond, hydroxy, deuterium or C １～４ C optionally substituted with alkoxy １～４ Alkanediyl; -CH ２ -C(=O)-; spiro-C ３～６ cycloalkyl; or a 4- to 7-membered spiro monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; A is C ３～６ cycloalkyl; aryl; 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R ９ is C ３～６ C optionally substituted with cycloalkyl １～６ Alkyl; Halo; HaloC １～６ Alkyl; C ３～６ C optionally substituted with cycloalkyl １～６ Alkoxy; HaloC １～６ Alkoxy; Hydroxyl; Hydroxy C １～６ Alkyl; oxo; -SO ２ -C ３～６ Cycloalkyl; —C(═O)—C １～６ Alkyl-C ３～６ Cycloalkyl; —C(═O)—C ３～６ Cycloalkyl; C ３～６ Cycloalkyl; spiro-C ３～６ cycloalkyl; 4-7 membered monocyclic heterocyclyl containing at least one heteroatom selected from N, O, or S; n is 0, 1, 2, 3 or 4; R １０ is hydrogen, halo, hydroxy, mercapto, carboxyl, haloC １～６ Alkyl, mono- or di(C １～６ alkyl)amino, mono- or di(C １～６ alkyl)aminocarbonyl, C １～６ Alkylcarbonyl, C １～６ Alkylcarbonylamino, C １～６ Alkoxy, C １～６ Alkoxycarbonyl, C １～６ Alkylthio, cyano, nitro, halo C １～６ Alkoxy, aminocarbonyl, C ３～６ Cycloalkyl or deuterium, amino, hydroxy, mono- or di(C １～６ alkyl)amino, C １～６ Alkylcarbonylamino, [(mono- or di-C １～６ alkyl)amino-C １～６ alkyl]carbonylamino or C １～６ C optionally substituted with alkylsulfonylamino １～６ is alkyl; and 7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein p is 0, 1, 2, or 3.

8. Any tautomers and stereochemical isomers, including isotopically labeled derivatives, １ is N, and R ２ is C optionally substituted with deuterium １～６ The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt or solvate thereof, wherein R is alkyl.

9. R ５ａ is C １～６ alkyl; or R ５ａ and R ５ｂ may form a cyclopropyl group together with the carbon atom to which they are attached; or R ６ａ and R ６ｂ may form a cyclopropyl group together with the carbon atom to which they are attached; or R ５ｂ and R ６ａ may form cyclopropyl together with the carbon atom to which they are attached, or a pharmaceutically acceptable salt or solvate thereof.

10. including any tautomeric and stereochemical isomeric forms, and isotopically labeled derivatives, R ８ is C optionally substituted with hydroxy or deuterium １～４ alkanediyl; A is a 5-12 membered heteroaryl containing at least one heteroatom selected from N, O, or S; R ９ is C １～６ is alkyl; and The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt or solvate thereof, wherein n is 1.

11. including any tautomeric and stereochemical isomeric forms, and isotopically labeled derivatives, 【Transformation 6】 【Transformation 7】 【Transformation 8】 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 【Chemistry 17】 [Chemistry 18] 【Chemistry 19】 【Chemistry 20】 or a pharmaceutically acceptable salt or solvate thereof, selected from:

12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.

13. A compound according to any one of claims 1 to 11 for use in therapy.

14. A compound according to any one of claims 1 to 11 for use in the prevention and / or treatment of a disease state or condition mediated by cyclin dependent kinase 7 (CDK7).

15. 15. The compound for use according to claim 14, wherein the disease state or condition is a proliferative disease.

16. 16. The compound for use according to claim 15, wherein the proliferative disorder is cancer, leukemia, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, multiple myeloma, bone cancer, osteosarcoma, Ewing's sarcoma, triple-negative breast cancer (TNBC), brain tumor, neuroblastoma, lung cancer, small cell lung cancer (SCLC), large cell lung cancer, benign neoplasm, angiogenesis, inflammatory disease, rheumatoid arthritis, autoinflammatory disease, autoimmune disease or infectious disease.

17. Use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for the prevention or treatment of cancer.

18. 18. The use of a compound according to claim 17 for the treatment of cancer.

19. A pharmaceutical composition for preventing or treating a disease state or condition mediated by CDK7 in a subject in need thereof, comprising a compound according to any one of claims 1 to 11.

20. 20. The pharmaceutical composition of claim 19, wherein the disease or condition is selected from a proliferative disease, cancer, leukemia, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, multiple myeloma, bone cancer, osteosarcoma, Ewing's sarcoma, triple-negative breast cancer (TNBC), brain tumor, neuroblastoma, lung cancer, small cell lung cancer (SCLC), large cell lung cancer, benign neoplasm, angiogenesis, inflammatory disease, rheumatoid arthritis, autoinflammatory disease, autoimmune disease, or infectious disease.

21. 21. The pharmaceutical composition of claim 19 or 20, wherein the subject is a mammal.

22. 12. An in vitro method of modulating CDK7 activity, comprising contacting a CDK7 protein or a portion thereof with a compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or solvate thereof.

Images